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Chapter 1  : Introduction
1
Worldwide, colorectal cancer (CRC) is the third most common cancer in men and the 
second most common cancer among women. Yearly, 1.36 million people are diagnosed 
with this cancer, and the incidence is still rising. Each year, it is associated with 694,000 
deaths from widespread metastatic disease1. Surgery alone can cure a large group of 
CRC patients who present without distant metastases, and even without adjuvant ther-
apy, up to 50% of these patients will remain disease free2-4. In spite of optimal surgical 
treatment, however, between 30–50% of patients with stage II and III CRC will develop 
metastatic disease2-4. Postoperative adjuvant chemotherapy may significantly reduce 
this risk, but there are some drawbacks. At present, identification of those patients at 
risk for developing recurrent disease is not possible, and all such patients should be 
treated, only a selected group of stage II and III patients may benefit from the adjuvant 
treatment. In addition, the response rate to chemotherapy for individual patients is 
unknown, and with the lack of predictive markers, many patients may be exposed to the 
toxicity of chemotherapy without having any benefit, even developing a recurrence in 
spite of chemo treatment. In patients with stage II CRC, only 15% respond to adjuvant 
chemotherapy, with an improved survival of less than 5% at 5 years5-7. For this reason, 
the decision to offer adjuvant chemotherapy should be balanced against the possible 
risks of treatment-related toxicity. Better tools are needed to help clinicians identify the 
group of patients at a high risk for disease relapse.
PrognoSiS anD PreDiCtion 
Prognostic factors are characteristics that provide information about the likely outcome 
of a disease. Such prognostic markers are helpful for identifying patients with cancer 
who are at high risk for developing distant metastases and are therefore potential 
candidates for adjuvant chemotherapy. Predictive factors are characteristics that pro-
vide information about the likely benefit from treatment. Such predictive factors can 
be used to identify subpopulations of patients who are most likely to benefit from a 
given therapy. In stage II and III colon cancer, both prognostic and predictive factors are 
needed to refine the selection of patients for adjuvant chemotherapy. 
CLiniCaLLy uSeD PrognoStiC anD PreDiCtive MarkerS
tnM classification
The TNM (tumor, node, metastases) staging system developed by the AJCC (American 
Joint Committee on Cancer) and the IUCC (International Union for Cancer Control) re-
mains the most important indicator for prognosis, long-term survival stratification, and 
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treatment guidelines in CRC8. Unfortunately, the system has several limitations, such as 
a reliance on surgical resection, which is not applicable to inoperable candidates; its 
inability to incorporate data on resection margins as well as molecular data (MSI and 
KRAS-status); and its inability to predict heterogeneous outcomes and responses to 
therapy with same-stage tumors. 
In addition, other histopathologic features have been correlated with prognosis. 
These including the following: 
•	 Lymphovascular	 invasion:	 associated	with	 a	 higher	 risk	 of	 local	 recurrence,	 nodal	
disease, development of liver metastases9-11 
•	 Tumor	grade:	higher	grade	associated	with	increased	nodal	 involvement,	metasta-
ses, recurrence after excision, and worse long-term prognosis10,12-14
•	 Histologic	 subtype:	 medullary	 type	 associated	 with	 reduced	 nodal	 involvement	
and better survival15; signet ring and small cell morphology associated with poor 
prognosis16,17, as is undifferentiated type 18.
Microsatellite instability
Microsatellite instability (MSI), a form of genetic instability underlying about 15% of 
sporadic CRCs, is most commonly caused by loss of function of the DNA mismatch repair 
system (MMR)19. There are five human MMR genes – MLH1, MSH2, MSH6, PMS1, and 
PMS2 – that can be inactivated due to deletions, point mutations, or epigenetic silenc-
ing. MSH2 and MLH1 are the most common MMRs associated with Lynch syndrome, 
accounting for 2–3% of all CRC cases20-22. MSI tumors can be divided into high (MSI-H) 
and low/stable (MSI-L/S) subtypes based on the degree of instability observed. 
MSI, regardless of subtype, is associated with better survival and lower recurrence 
risk after colon resection23 and has also been correlated with chemotherapy response. 
MSI tumors with a N0/N1 lymph node status and proximal location are associated with 
improved survival with adjuvant FOLFOX chemotherapy24. They also show a higher 
response rate to bevacizumab chemotherapy whereas MSI stable disease shows no 
survival benefit25. MSI-H tumors exhibit a unique clinicopathologic pattern including 
proximal location, poor differentiation, histologic heterogeneity, increased lymphocytic 
response and inflammatory reaction, mucin production, and exophytic growth pat-
tern26-28. MSI-H lesions are also associated with a lower risk of metastases and improved 
prognosis29,30
KRAS
Half of colorectal tumors are initiated by mutations in the KRAS oncogene. The ras 
family of proteins (H-, K-, and N-Ras) is associated with functions including cell growth, 
proliferation, and differentiation31,32. KRAS-positive mutation status is associated with 
decreased survival in patients undergoing bevacizumab chemotherapy31. The same ef-
13
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fect has been seen in patients with a positive NRAS mutation (present in approximately 
3% of CRCs)33. The National Comprehensive Cancer Network recommends screening 
for both KRAS and NRAS mutations before treatment with anti-EGFR (epidermal growth 
factor receptor) therapy34. 
gene expression profiles 
Gene expression profiling (GEP) is an emerging tool. This methodology attempts to 
identify differentially expressed subsets of genes (gene signatures) in groups of patients 
with distinct clinical outcomes.
The Oncotype DX Colon Cancer Test is a commercially available gene expression profile 
derived from real-time polymerase chain reaction. Gene expression data from 1851 
patients were used to build the assay. The final panel consists of seven genes associated 
with recurrence for a recurrence score and six genes predictive of fluorouracil/folonic 
acid treatment benefit to provide a treatment score35,36. In several validation studies, 
the prognostic aspect of the test was confirmed. The predictive GEP, however, failed to 
significantly predict treatment response37-39.
Another GEP assay is the ColoPrint, an 18-gene signature developed by Agendia. It was 
developed using a set of 188 fresh-frozen tumors from stage I through IV colon cancer. 
The selected gene set is associated with prognosis. In a study by Maak et al., the Coloprint 
was evaluated in a group of stage II CRC patients. On multivariate analysis, Coloprint was 
the only significant parameter to predict development of metastatic disease (high-risk 
hazard ratio=4.28, confidence interval 1.36–13.50, p= 0.013)40,41. Nevertheless, these 
gene profiles do not give sufficient information for treatment strategies in individual 
patients. 
FoLLow-uP
The main cause of death from CRC is metastatic disease. As mentioned, in spite of op-
timal surgical treatment, between 30 and 50% of patients with stage II and III CRC will 
develop metastatic disease2-4. Unfortunately, we lack the instruments to identify these 
patients, and all CRC patients therefore are followed for at least 5 years after colon sur-
gery to detect recurrence. During follow-up, blood level carcinoembryogenic antigen 
(CEA) measurements and radiological imaging of the liver (CT imaging or ultrasound) 
are performed42,43. It is still not clear which follow-up schedule and components will 
provide the best surveillance strategy44,45. The follow-up visits of patients with CRC are 
labor intensive and expensive because of the administrative and logistic work as well as 
the numerous diagnostic tests. 
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CoLoreCtaL Liver MetaStaSeS
The first presentation of colorectal metastases is most often in the liver. 
Liver resection is considered to be the optimal treatment for colorectal liver metastases 
(CLM) with 5-year survival rates up to 67% in highly selected patients46. At presentation, 
only a minor portion of patients are eligible for resection because of widespread meta-
static disease or predicted insufficient liver remnant after metastasectomy. Therefore, 
early detection of CLM is necessary. As a result of improvements in surgical technique, 
the introduction of more effective systemic chemotherapy47-49, and the use of portal 
vein embolization50,51, radiofrequency ablation52,53, and stereotactic body radiation54, the 
indications for liver resection have expanded over the past decade. Despite the good 
outcomes for many patients undergoing this procedure, a substantial portion will still 
experience early recurrence with one-year recurrence rates of CLM after liver resection 
up to 50%55. 
The identification of patients at high risk of disease recurrence after surgery for resect-
able CLM might lead to better selection of patients for this procedure. These patients 
should either be spared an often high-risk operation or should be treated by additional 
and more intensified therapy to minimize the risk of early recurrence.
outLine oF the theSiS 
MatCh study 
To achieve identification of CRC subtypes, related prognostic markers, and treatment 
outcome, a multicenter cohort study including patients with CRC undergoing curative 
surgery was initiated in 2007 (MATCH study). The project was a collaboration among 
Erasmus MC University Medical Center and seven teaching hospitals, including Francis-
cus Gasthuis, Elisabeth Hospital, IJsselland Hospital, Ikazia Hospital, Maasstad Hospital, 
Reinier de Graaf Gasthuis, and Tweesteden Hospital. Tissue samples, including normal 
colon tissue and tumor tissue, and clinical data were stored using standard operating 
procedures and case record forms.
One of the vital items in the data collection is the pathology report. As discussed ear-
lier, the TNM classification is the most important factor in determining the therapeutic 
approach. In stage II CRC, adjuvant chemotherapy is not recommended56,57. However, 
the American Society of Clinical Oncology (ASCO) guidelines suggest a subdivision of 
stage II patients into low- and high-risk groups. In high-risk patients, adjuvant chemo-
therapy can be considered, but it has no place in low-risk patients56,58. This subdivision 
is based on five factors: T-stage (T4), tumor differentiation grade (poor), lymphovascular 
invasion (present), tumor perforation (present), and lymph node metastasis status (Nx; 
15
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less than 10 lymph nodes in the resection specimen)56. Because of their importance and 
clinical implications, the pathology reports of colon cancer specimens should include a 
statement regarding these five factors. The Netherlands Society of Pathology introduced 
the guideline “Protocol Colonrectum” in 200859, summarizing which factors should be 
included in a pathology report. Until 2012, the reporting of the five risk factors was 
voluntary; later on, it became mandatory59.
In chapter 2, we review the pathology reports of stage II patients from the MATCH 
cohort to determine the accuracy and completeness regarding the five high-risk factors 
and their impact on overall survival.  
One of the key elements of the MATCH study is the collection of fresh-frozen tissue 
samples with the intention of using them for molecular biomarker research. Today’s 
state-of-the-art techniques require high-quality tissue samples60-62, and 10% of fresh-
frozen samples are unsuitable for molecular analyses. In our multicenter study, tissue 
samples were obtained, processed, and stored following standard operating procedures 
in both the university hospital (a center with experience in fresh-frozen tissue sampling 
with dedicated personnel) and the non-university teaching hospitals (not used to or 
equipped/staffed for routine fresh-frozen tissue sampling). To evaluate the quality of the 
fresh-frozen tissue samples from the different hospitals, we performed a random check. 
The RNA Integrity Number (RIN), a common standard used to assess tissue quality, was 
measured63,64. In chapter 3, we discuss the results of this quality control procedure. 
Colorectal liver metastases
With annual 1.36 million new CRC cases worldwide, the frequent follow-up visits in an 
outpatient clinic are time consuming and expensive. Nevertheless, after tumor resec-
tion, follow-up is of great importance to detect liver metastases at an early stage. With 
early diagnosis, the prognosis of patients can be improved.
In a quest for new tools to identify early disease recurrence, we sought a marker with 
high sensitivity, low cost, and application outside the hospital. 
A promising source for biomarker research is the urine proteome, which provides 
detailed information for monitoring changes in human physiology65,66. Urine collection 
is non-invasive and always available in large amounts, and the natural occurring peptide 
(NOP) in urine has the advantage of being easily accessible without labor-intensive 
sample preparation. To prove this principle in patients with CLM, we conducted a pilot 
study. Urine from patients with CLM and from healthy persons and patients with benign 
liver lesions (hepatocellular adenoma) and malignant liver lesions (hepatocellular carci-
noma) was collected and analyzed by mass spectrometry. We identified peptides that 
could differentiate among the different liver tumors and healthy persons (unpublished 
work, poster presentation ESMO 2010). In chapter 4, we describe the in-depth identifi-
cation and validation of these NOPs. The practical aspects, such as sample preparation 
16
and sample measurements by mass spectrometry, are explained, and the building of a 
prognostic peptide model is discussed that enables discrimination between patients 
with CLM and healthy persons. 
In chapter 5, we investigate the possibility of a combined test with our urine peptide 
AGP and blood level CEA to increase sensitivity for detection of CLM. Alongside better 
sensitivity, the test would be less expensive than liver imaging and could be performed 
outside the hospital, by a general practitioner, for instance. For this study, we compared 
the AGP urine levels and CEA blood levels between patients with CLM and healthy 
persons. 
Over the years, the number of patients eligible for liver surgery has increased because 
of better imaging modalities, the introduction of effective chemotherapy, and the 
availability of more surgical techniques, including extensive resections with or without 
portal vein embolization and additional treatment with radiofrequency ablation and 
stereotactic body radiation48-54. Thus, the indications for liver resection have expanded, 
and the only remaining limitations are unresectable extrahepatic disease and insuf-
ficient liver remnant. 
As a result of these developments, the surgical approach has shifted towards an 
increase in nonanatomical resections. By this approach, the amount of residual liver 
parenchyma can be optimized, thus reducing the risk for progressive liver failure and 
postoperative complications67,68. When intrahepatic recurrence occurs, repetitive local 
treatment may be offered69.
Although it has been reported that anatomical resection improves (disease-free) sur-
vival in patients with hepatocellular carcinoma70-72, the literature about CLM is inconsis-
tent. In chapter 6, we use a clinical database to investigate whether a difference can be 
found in surgical and oncological morbidity and overall survival comparing anatomical 
resections with nonanatomical resections for CLM. 
A significant number of patients will not benefit from liver metastasis surgery because 
early recurrence will occur. As noted, the one-year recurrence rate after liver surgery for 
CLM can be as high as 50%55. Identification of patients at high risk for disease recurrence 
after liver resection is important because these patients could be spared an operation 
and might be offered chemotherapy to prevent extension of disseminated disease. To 
focus on this topic, we studied the feasibility of detecting circulating cells as a biomarker 
for recurrence.
Circulating tumor cells (CTCs) shed into the vasculature from a tumor and can be 
detected in the majority of patients with metastatic cancer73. One of the techniques for 
isolating these cells is the CellSearch Technique (Veridex LLC, Raritan NJ, USA). Using this 
method, the presence of CTCs in peripheral blood of patients has strong prognostic value 
in various malignancies including CRC74-78. Most research has been done in patients with 
17
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irresectable metastatic disease and treated with chemotherapy. Little is known about 
the prognostic value of CTC in patients with isolated CLM. 
In chapter 7, we discuss the results of a pilot study to evaluate the best protocol for 
blood sample collection and preparation using the CellSearch System. The sampling 
procedure must be optimized to allow detection of small numbers of CTCs in limited 
disease. Subsequently, in chapter 8, we investigate whether the detection of CTCs by 
the CellSearch System can identify the high-risk patients who will develop disease recur-
rence within one year after liver surgery. 
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abStraCt 
introduction: The completeness of the pathological examination of resected colon 
cancer specimens is important for further clinical management. We reviewed the patho-
logical reports of 356 patients regarding the five factors (pT-stage, tumor differentiation 
grade, lymphovascular invasion, tumor perforation and, lymph node metastasis status) 
that are used to identify high-risk stage II colon cancers, as well as their impact on overall 
survival (OS).
Methods: All patients with stage II colon cancer who were included in the first five years 
of the MATCH study (July 1 2007 –July 1 2012) were selected (n=356). The hazard ratios 
of relevant risk factors were calculated using Cox Proportional Hazards analyses.
results: In as many as 69.1% of the pathology reports, the desired information on one 
or more risk factors was considered incomplete. In multivariable analysis, age (HR: 1.07, 
95%CI 1.04-1.10, p<0.001), moderately- (HR: 0.35, 95%CI 0.18-0.70, p=0.003) and well 
(HR 0.11, 95% CI 0.01-0.89, p=0.038) differentiated tumors were significantly associated 
with OS.
Conclusion: Pathology reports should better describe the five high-risk factors, in order 
to enable proper patient selection for further treatment. Chemotherapy may be offered 
to stage II patients only in select instances, yet a definitive indication is still unavailable.
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introDuCtion 
Colorectal cancer is currently the second most common malignancy in the Western 
world1. Overall, 50-60% of the patients diagnosed with colorectal cancer will develop 
metastases2-6. Τhe risk of developing metastases as well as survival can be estimated 
more accurately for the individual patient by taking into consideration the American 
Joint Committee on Cancer (AJCC) TNM classification7. The pathological TNM classifica-
tion is the most important factor to determine the therapeutic approach8. 
For colon cancer, curatively resectable tumors are divided into AJCC stage I to III, with 
stage III necessitating adjuvant chemotherapy in addition to watchful waiting strategies. 
Patients with stage II colon carcinoma are thought not to require adjuvant chemotherapy 
in most cases9,10. However, the American Society of Clinical Oncology (ASCO) guidelines 
propose a subdivision of stage II patients into low and high-risk. This subdivision is based 
on five high-risk factors: T-stage, tumor differentiation grade, lymphovascular invasion 
(LVI), tumor perforation and, most importantly, lymph node metastasis status9. In high-
risk patients, adjuvant chemotherapy can be considered, while adjuvant chemotherapy 
has no place in the treatment of low risk stage II colon cancer patients9,11. 
Because of their importance and clinical implications, the pathology reports of colon 
cancer specimens should include a statement regarding the five aforementioned fac-
tors. In addition to the five high-risk factors, molecular subtypes of cancer have been 
previously reported to have an effect on overall survival (OS) as well12. In particular, pa-
tients with microsatellite instability (MSI) are reported to have higher OS12. To optimize 
the accuracy of pathology reports on colorectal cancer specimens, the Dutch federation 
for pathology in 2008 drew up the guideline ‘Protocol Colonrectum’, summarizing which 
factors should be included in a pathology report and how13. The reporting of the five 
high-risk factors was facultative until early 2012, when the reporting of the factor LVI 
became mandatory13.
In this study a cohort of 356 patients was reviewed to determine the accuracy and 
completeness regarding the five factors used to identify high-risk stage II colon cancers. 
We performed a detailed analysis of nodal status, which is considered the most impor-
tant risk factor6. 
MethoDS 
Patient selection
Patients were selected from the MATCH study (MEC-2007-088), an ongoing prospective 
registration cohort including all patients who undergo curative surgery for primary 
colorectal cancer in seven hospitals in the Rotterdam region. All patients with stage II 
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colon cancer who were included in the first five years of the MATCH study (July 1 2007 
–July 1 2012) were selected. All patients gave written informed consent.
Scoring pathology report
Pathology reports were examined for the existence of a statement on the five factors 
used to identify high-risk stage II patients: pathological T-stage (pT-stage), N-stage, 
tumor differentiation grade, LVI and tumor perforation. For the T-stage, tumor differ-
entiation grade and LVI the presence or absence of a statement regarding these tumor 
characteristics was scored. For the N-stage, patients with more than 10 harvested lymph 
nodes were considered to have an N0 stage, while patients with less than 10 harvested 
lymph nodes were considered to have an Nx stage. In Nx patients, the presence or 
absence of a specific comment regarding the low total lymph node yield was scored. 
Tumor perforation was planned only to be scored present or absent in case of a clinical 
suspicion for perforation. As no patients had a clinical suspicion of tumor perforation, 
this factor was not scored. Data on MSI were not routinely scored. However, since MSI 
is highly correlated with right-sidedness of the tumor, we used this as a dummy vari-
able12. Pathological risk factors associated with lower survival in stage II patients were 
individually examined in our patient cohort for both differences in clinicopathologic 
characteristics of patients, as well as survival analyses.  
Statistical analysis
Summary statistics were provided as percentages of categorical variables and medians 
with interquartile ranges of continuous variables. Comparison of categorical variables 
was performed using the Pearson c2 test, while continuous variables were compared 
using the Kruskal-Wallis test. OS estimates and figures were created using the Kaplan-
Meier method. Patients who expired within 3 months postoperatively were excluded 
from the survival analysis. Differences in survival amongst the different risk factors were 
assessed using the Log-Rank test. The hazard ratios of relevant risk factors, along with 
their 95% CIs, were calculated using Cox Proportional Hazards analyses. Conditional 
backwards selection with all relevant risk factors was conducted, based on the prob-
ability of the likelihood-ratio statistic based on conditional parameter estimates. All 
analyses were carried out with SPSS 22 (IBM, New York). All tests were 2-sided and p< .05 
was considered statistically significant.
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reSuLtS 
Pathology reports
As shown in Figure 1, in 69.1% of the pathology reports the information on one or more 
risk factors was considered incomplete (61.2% 1 factor, 7.9% 2 factors). T-stage and N-
stage were reported in all cases. However, in the 44 Nx patients, the pathology report 
did not comment on this total yield as being a risk factor. In 62.8% of all cases no state-
ment regarding presence or absence of LVI was recorded; tumor differentiation grade 
was not reported in 2%. As mentioned in the introduction, the reporting of LVI became 
mandatory in 2012. LVI, regardless whether present or absent, was reported significantly 
more after mandating the reporting of this risk factor (33.5% vs. 87.5%; p<0.001). 
Complete
30,90%
1	Missing
61,24%
2	Missing
7,87%
Overall	Reporting
Figure 1a Overall reporting of high-risk factors (N-
stage, T-Stage, Lymphovascular Invasion, and Tu-
mor Differentiation) in the pathology report
Appropriate
87,60%
Inappropriate
12,40%
N	- Stage
Figure 1b N-Stage Pathology Report Scoring
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Figure 1D Lymphovascular Invasion Pathology Re-
port Scoring
Clinicopathological Characteristics
Total baseline and other characteristics compared by N-stage are shown in table 1. Just 
over half (n=193, 54.2%) of the patients were male. The median age was 71 years (IQR 64-
79 years). A diagnostic colonoscopy was performed in 327 (96.2%) of the patients and 320 
(89.9%) patients underwent staging CT imaging. A small subgroup of patients received 
additional abdominal ultrasound (n=104, 29.2%), MRI (n=8, 2.2%), or PET-scan (n=1, 0.3%). 
More than two thirds of patients had an American Society of Anesthesiologists (ASA) clas-
sification score of 2 (n=195, 70.1%). At the time of surgery half of the patients underwent 
Appropriate
100,00%
Inappropriate
0,00%
T	- Stage
Figure 1C T-Stage Pathology Report Scoring
Appropriate
97,70%
Inappropriate
2%
Tumor	Differentiation
Figure 1e Tumor Differentiation Pathology Report 
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laparoscopic surgery (n=174, 49.0%) and most patients underwent a right (n=172, 49.0%) 
or left sided hemicolectomy (n=169, 48.1%). The majority of patients had a T3 (n=324, 
91.0%), whereas a small minority had a T4 tumor (n=32, 9.0%). Of our 356 patients, 312 
(87.6 %) patients did not have lymph node metastases and had more than 10 nodes, 
while 44 (12.4%) did not have the required minimum of 10 nodes. Over three quarters of 
the patients had a moderately differentiated tumor (n=298, 83.9%). A small subgroup of 
patients (n=21, 5.9%) received adjuvant therapy. 13 patients (4.1%) expired within 90 days 
and were therefore excluded in survival analyses.
table 1: Clinicopathological Characteristics, Stratified by Nodal Status
Characteristic n0 (n = 312) nx (n = 44) P-value total (n = 356)
Gender  
Female 139 (44.6) 24 (54.5) 163 (45.8)
Male 173 (55.4) 20 (45.5) 0.213 193 (54.2)
Age, years (IQR) 71 (63-78) 75 (66-82) 0.029 71 (64-79)
Diabetes 51 (16.9) 2 (4.7) 0.037 53 (15.4)
Colonoscopy 285 (96.3) 42 (95.5) 0.789 327 (96.2)
Abdominal Ultrasound 94 (30.1) 10 (22.7) 0.312 104 (29.2)
CT-Abdomen 279 (89.4) 41 (93.2) 0.439 320 (89.9)
MRI Abdomen 7 (2.2) 1 (2.3) 0.990 8 (2.2)
PET-scan 1 (0.3) 0 (0.0) 0.707 1 (0.3)
ASA Class  
1 31 (12.9) 1 (2.7) 32 (11.5)
2 167 (69.3) 28 (75.7) 195 (70.1)
3 43 (17.8) 8 (21.6) 51 (18.3)
4 0 (0.0) 0 (0.0) 0.191 0 (0.0)
Type of Operation  
Open Resection 153 (49.5) 25 (58.1) 178 (50.6)
Laparoscopic Resection 156 (50.5) 18 (41.9) 0.289 174 (49.4)
Type of Resection  
Left-Sided Resection 144 (46.8) 25 (58.1) 169 (48.1)
Right-Sided Resection 154 (50.0) 18 (41.9) 172 (49.0)
(Sub)total Colectomy 10 (3.2) 0 (0.0) 0.232 10 (2.8)
AJCC T-Stage  
T3 283 (90.7) 41 (93.2) 324 (91.0)
T4 29 (9.3) 3 (6.8) 0.591 32 (9.0)
Tumor Differentation  
Poor 32 (10.3) 4 (9.1) 36 (10.1)
Moderate 260 (83.6) 38 (86.4) 298 (83.9)
Well 12 (3.9) 1 (2.3) 13 (3.7)
Unknown 7 (2.3) 1 (2.3) 0.949 8 (2.3)
Lymphovascular Invasion  
No 91 (29.3) 12 (27.3) 103 (29.0)
Yes 23 (7.4) 6 (13.6) 29 (8.2)
Unknown 197 (63.3) 26 (59.1) 0.368 223 (62.8)
Adjuvant Therapy 18 (5.8) 3 (6.8) 0.782 21 (5.9)
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Differences between the patients with and without high-risk factors were more closely 
evaluated (table 1, supplementary table 1-3). Between the Nx and N0 group a significant 
difference was observed in median age, with the Nx group being significantly older 
(71 vs. 75 years, p=0.037). T4 patients as opposed to T3 patients received adjuvant che-
motherapy (37.5% vs. 2.8%, p<0.001) more often, and had an unknown (not reported) 
differentiation grade of their tumor relatively more frequently (9.4% vs. 1.5%, p=0.021). 
No clinical differences were observed between patients with demonstrated LVI, patients 
without LVI, and patients in whom this factor was not recorded in the pathology report. 
Finally, there was a trend towards administering chemotherapy in patients with worse 
tumor differentiation (p=0.086).
overall Survival per high-risk Factor
Median follow-up in our cohort was 72.4 months (IQR 62.8-80.8). The 1-, 3- and 5-year 
survival was 98.0 %, 89.1, and 80.4% respectively. When examining high-risk factors more 
closely in our cohort of stage II patients we found that these risk factors did not seem to 
have a significant impact on survival (figure 2). In our study, we did not find a significant 
association between the failure to report any of the five factors and overall survival. No 
difference was found between left-sided colorectal cancer, right-sided colorectal cancer, 
and colorectal cancer on both sides. As depicted in the Kaplan Meier graphs, no trend 
towards a difference was visible for any of the risk factors either. Age (HR: 1.06, 95% CI 
1.03-1.08, p<0.001) and ASA Class 3 (HR: 3.52, 95% CI 1.19-10.42, p=0.023) were signifi-
cantly associated with OS in univariable analysis. In multivariable analysis age (HR: 1.07, 
95% CI 1.04-1.10, p<0.001), moderately- (HR: 0.35, 95% CI 0.18-0.70, p=0.003) and well 
(HR 0.11, 95% CI 0.01-0.89, p=0.038) differentiated tumors were significantly associated 
with OS, after conditional backwards selection of associated variables (Table 2).
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table 2. Survival Analysis of Stage II Colon Cancer Patients
 
Characteristic
univariable analysis Multivariable analysis
hr 95% Ci p value hr 95% Ci p value
Age, years (IQR) 1.06 1.03-1.08 <0.001 1.07 1.04-1.10 <0.001
AJCC T-Stage  
T3 Ref - -  
T4 0.84 0.36-1.93 0.677  
N-Stage  
N0 Ref - -  
Nx 1.29 0.70-2.39 0.414  
Tumor Differentiation  
Poor Ref - - Ref - -
Moderate 0.57 0.29-1.11 0.097 0.35 0.18-0.70 0.003
Well 0.58 0.16-2.11 0.409 0.11 0.01-0.89 0.038
Lymphovascular Invasion  
No Ref - -  
Yes 1.31 0.58-2.97 0.522  
Unknown 1.14 0.68-1.93 0.617  
Diabetes  
No Ref - -  
Yes 1.25 0.71-2.20 0.446  
Colonoscopy  
No Ref - -  
Yes 1.33 0.32-5.42 0.694  
ASA Class  
1 Ref - -
2 1.60 0.57-4.46 0.371
3 3.52 1.19-10.42 0.023
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DiSCuSSion 
Colorectal cancer is currently one of the most common malignancies in the Western 
world1. For colon cancer, tumors are divided into stage I to IV with a subdivision for 
stage II patients into low and high-risk patients, based on the factors pT-stage, tumor 
differentiation grade, LVI, tumor perforation and, most importantly, lymph node metas-
tasis status. In this study a set of 356 pathology reports was reviewed to determine the 
accuracy and completeness regarding the five factors used to identify high-risk stage II 
colon cancers and the impact on clinical management. 
In 2007 Quirke et al. suggested three main reasons for the incompleteness of pathol-
ogy: the ignorance of the importance of certain features for clinical management, the 
large number of possible prognostic features that could be reported, and the desire to 
hold on to free text reports14. While the first may be overcome by education and routine 
audit with feedback, the second and third reason requires a standardized minimum set 
of items that should be reported. Interestingly, in 1998 the Royal College of Pathologists 
already suggested such a set which included all five factors examined in the current 
study15. The use of proforma reporting for pathology reports on colorectal cancer speci-
mens has been described to increase the completeness of the reports up to 96%16,17. 
Synoptic reporting, in which a prespecified set of items have to be scored before the 
report can be finalized, has also been described to add to the completeness of pathol-
ogy reports18. The increase of LVI reporting in our data after synoptic reporting became 
mandatory substantiates these earlier observations.
In 2000, the college of American Pathologists published a statement summarizing 
and categorizing the pathologic prognostic factors and predictive factors in colorectal 
cancer.19 The pT category and pN category of the pTNM staging system as well as LVI 
were categorized in Category I, which included factors definitively proven to be of 
prognostic import based on evidence from multiple statistically and methodologically 
table 2. Survival Analysis of Stage II Colon Cancer Patients (continued)
 
Characteristic
univariable analysis Multivariable analysis
hr 95% Ci p value hr 95% Ci p value
Type of Operation  
Open Resection Ref - -  
Laparoscopic Resection 1.13 0.72-1.77 0.605  
Type of Resection  
Left-Sided Resection Ref - -  
Right-Sided Resection 1.03 0.65-1.61 0.913  
(Sub)total Colectomy 0.44 0.06-3.23 0.422  
Adjuvant Therapy 0.42 0.10-1.71 0.224      
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well executed published trials. Tumor grade fell into Category IIA, which included fac-
tors extensively studied clinically and/or biologically and repeatedly shown to have 
prognostic and/or predictive value, but has to be validated in statistically robust studies. 
The importance to mention these tumor characteristics was illustrated by Maughan et 
al., who reported an association between the failure to report either vascular invasion 
or peritoneal involvement and overall survival in a large retrospective study of close to 
6,000 patients20. 
In our cohort, reporting of most high-risk factors in stage II patients was absent in the 
majority of the pathology reports between 2007 and 2012. However, a difference in OS 
between patients in whom factors indicating worse prognosis were not reported and 
those in whom they were absent was not found. Poorly differentiated tumors, performed 
worse than moderately and well differentiated tumors when corrected for age at the 
time of surgery. Age itself was an independent risk factor as well. The reasons for the lack 
of predictive value of the other four recognized high-risk factors in our cohort is likely 
multifactorial. Firstly, this was a prospectively included cohort in which all variables were 
scored before the individual disease course of patients was known, eliminating potential 
bias in the scoring of variables. All patients were demographically similar, as they were 
treated in the same region in the Netherlands. This also limited differences in the quality 
of health care potentially correlating with the quality of diagnosis.
The use of adjuvant chemotherapy in stage II colon cancer patients remains open for 
discussion. Current literature does not support the use of adjuvant chemotherapy for all 
stage II colon cancer patients since it does not improve disease-free or overall survival 
as illustrated in the MOSAIC trial21. However, the indirect evidence of the beneficial role 
of adjuvant chemotherapy in stage III colon cancer patients and the identification of 
high-risk stage II colon cancer patients using the currently available risk factors justifies 
the consideration of the adjuvant chemotherapy as stated by the American Society of 
Clinical Oncology9. In our study the use of adjuvant chemotherapy was not a significant 
predictor of better overall survival (HR: 0.42, 95% CI: 0.10-1.71, p = 0.224).
Although it is, to our knowledge, the first study into the completeness of prognostic 
factor reporting in type II colon cancer patients, this study has a number of limitations. 
First of all, our number of patients is comparatively low. Because our study is based on 
primary data of patients with stage II colon cancer, however, this is one of the larger 
studies of its kind6,14-16. A direct consequence of cohort size is a relatively low number 
of patients within some subgroups of the survival analysis. Since selection bias is highly 
unlikely due to the prospective inclusion of this cohort, we have no reason to question 
the accuracy of our data. An increase in patient numbers, therefore, would only lead to 
improved precision (i.e. smaller confidence intervals) and would not change the trends 
in survival depicted by our data. We therefore believe that an increase of the number 
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of patients in the subgroups would still not lead us to conclude clinically significant 
differences over these subgroups, with regard to overall survival. 
We conclude that pathology reports should better describe the five high-risk factors 
in stage II colon cancer, in order to enable proper patient selection for further treatment. 
Of the five factors only the tumor differentiation grade was observed to be prognostic in 
multivariable survival analysis. Chemotherapy may be offered to patients only in select 
instances, when a certain set of prognostic markers is present. Further research into 
these prognostic markers is warranted, as a definitive set is still unavailable.
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Supplementary table 1: Clinicopathological Characteristics, Stratified by T Stage
Characteristic t3 (n = 324) t4 (n = 32) P-value total (n = 356)
Gender  
Female 149 (46.0) 14 (43.8) 163 (45.8)
Male 175 (54.0) 18 (56.2) 0.808 193 (54.2)
Age, years (IQR) 72 (63-79) 71 (65-76) 0.587 71 (64-79)
Diabetes 50 (16.0) 3 (9.4) 0.324 53 (15.4)
Colonoscopy 297 (96.1) 30 (96.8) 0.856 327 (96.2)
Abdominal Ultrasound 92 (28.4) 12 (37.5) 0.280 104 (29.2)
CT-Abdomen 289 (89.2) 31 (96.9) 0.169 320 (89.9)
MRI Abdomen 8 (2.5) 0 (0.0) 0.369 8 (2.2)
PET-scan 1 (0.3) 0 (0.0) 0.753 1 (0.3)
ASA Class  
1 28 (11.1) 4 (15.4) 32 (11.5)
2 175 (69.4) 20 (76.9) 195 (70.1)
3 49 (19.4) 2 (7.7) 51 (18.3)
4 0 (0.0) 0 (0.0) 0.311 0 (0.0)
Type of Operation  
Open Resection 162 (50.3) 16 (53.3) 178 (50.6)
Laparoscopic Resection 160 (49.7) 14 (46.7) 0.751 174 (49.4)
Type of Resection  
Left-Sided Resection 157 (48.9) 12 (40.0) 169 (48.1)
Right-Sided Resection 156 (48.6) 16 (53.3) 172 (49.0)
(Sub)total Colectomy 8 (2.5) 2 (6.7) 0.324 10 (2.8)
Tumor Differentiation  
Poor 34 (10.5) 2 (6.2) 36 (10.1)
Moderate 271 (83.9) 27 (84.4) 298 (83.9)
Well 13 (4.0) 0 (0.0) 13 (3.7)
Unknown 5 (1.5) 3 (9.4) 0.021 8 (2.3)
Lymphovascular Invasion  
No 96 (29.7) 7 (21.9) 103 (29.0)
Yes 27 (8.4) 2 (6.2) 29 (8.2)
Unknown 200 (61.9) 23 (71.9) 0.539 223 (62.8)
N-Stage  
N0 283 (87.3) 29 (90.6) 312 (87.6)
Nx 41 (12.7) 3 (9.4) 0.591 44 (12.4)
Adjuvant Therapy 9 (2.8) 12 (37.5) <0.001 21 (5.9)
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Supplementary table 2: Clinicopathological Characteristics, Stratified by Lymphovascular Invasion
Characteristic
no 
Lymphovascular 
invasion (n = 103)
Lymphovascular 
invasion (n = 29)
unknown  
(n = 223) P-value
total 
(n = 356)
Gender  
Female 48 (46.6) 13 (44.8) 102 (45.7) 163 (45.8)
Male 55 (53.4) 16 (55.2) 121 (54.3) 0.982 193 (54.2)
Age, years (IQR) 69 (61-76) 71 (62-79) 72 (65-80) 0.049 71 (64-79)
Diabetes 16 (16.2) 3 (10.3) 33 (15.3) 0.740 53 (15.4)
Colonoscopy 90 (91.8) 29 (100.0) 207 (97.6) 0.025 327 (96.2)
Abdominal Ultrasound 24 (23.3) 7 (24.1) 73 (32.7) 0.180 104 (29.2)
CT-Abdomen 94 (91.3) 25 (86.2) 200 (89.7) 0.721 320 (89.9)
MRI Abdomen 1 (1.0) 1 (3.4) 6 (2.7) 0.563 8 (2.2)
PET-scan 0 (0.0) 0 (0.0) 1 (0.4) 0.743 1 (0.3)
ASA Class  
1 11 (13.8) 2 (9.1) 19 (10.9) 32 (11.5)
2 57 (71.2) 16 (72.7) 121 (69.1) 195 (70.1)
3 12 (15.0) 4 (18.2) 35 (20.0) 51 (18.3)
4 0 (0.0) 0 (0.0) 0 (0.0) 0.856 0 (0.0)
Type of Operation  
Open Resection 56 (56.0) 18 (62.1) 103 (46.4) 178 (50.6)
Laparoscopic Resection 44 (44.0) 11 (37.9) 119 (53.6) 0.119 174 (49.4)
Type of Resection  
Left-Sided Resection 42 (42.0) 12 (41.4) 115 (52.0) 169 (48.1)
Right-Sided Resection 52 (52.0) 17 (58.6) 102 (42.6) 172 (49.0)
(Sub)total Colectomy 6 (6.0) 0 (0.0) 4 (1.8) 0.092 10 (2.8)
AJCC T-Stage  
T3 96 (93.2) 27 (93.1) 200 (89.7) 324 (91.0)
T4 7 (6.8) 2 (6.9) 23 (10.3) 0.539 32 (9.0)
Tumor Differentiation  
Poor 10 (9.7) 7 (24.1) 19 (8.6) 36 (10.1)
Moderate 86 (83.5) 20 (69.0) 192 (86.5) 298 (83.9)
Well 3 (2.9) 1 (3.4) 8 (3.6) 13 (3.7)
Unknown 4 (3.9) 1 (3.4) 3 (1.4) 0.153 8 (2.3)
N-Stage  
N0 91 (88.3) 23 (79.3) 197 (88.3) 312 (87.6)
Nx 12 (11.7) 6 (20.7) 26 (11.7) 0.368 44 (12.4)
Adjuvant Therapy 5 (4.9) 4 (13.8) 12 (5.4) 0.169 21 (5.9)
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Characteristic
Poor 
(n = 36)
Moderate 
(n = 298)
well 
(n = 13)
unknown 
(n= 8) P-value
total 
(n = 356)
Gender  
Female 17 (47.2) 136 (45.6) 7 (53.8) 2 (25.0) 163 (45.8)
Male 19 (52.8) 162 (54.4) 6 (46.2) 6 (75.0) 0.623 193 (54.2)
Age, years (IQR) 69 (58-76) 64 (72-79) 70 (68-77) 65 (55-77) 0.257 71 (64-79)
Diabetes 3 (8.3) 44 (15.3) 6 (46.2) 0 (0.0) 0.007 53 (15.4)
Colonoscopy 35 (100.0) 270 (95.4) 13 (100.0) 8 (100.0) 0.444 327 (96.2)
Abdominal Ultrasound 12 (33.3) 85 (28.5) 5 (38.5) 2 (25.0) 0.809 104 (29.2)
CT-Abdomen 29 (80.6) 272 (91.3) 10 (76.9) 8 (100.0) 0.061 320 (89.9)
MRI Abdomen 2 (5.6) 5 (1.7) 1 (7.7) 0 (0.0) 0.245 8 (2.2)
PET-scan 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 0.979 1 (0.3)
ASA Class  
1 6 (18.8) 23 (10.2) 1 (8.3) 2 (28.6) 32 (11.5)
2 17 (53.1) 164 (72.6) 9 (75.0) 4 (57.1) 195 (70.1)
3 9 (28.1) 39 (17.3) 2 (16.7) 1 (14.3) 51 (18.3)
4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.296 0 (0.0)
Type of Operation  
Open Resection 22 (61.1) 144 (49.0) 6 (46.2) 6 (75.0) 178 (50.6)
Laparoscopic 
Resection 14 (38.9) 150 (51.0) 7 (53.8) 2 (25.0) 0.272 174 (49.4)
Type of Resection  
Left-Sided Resection 12 (33.3) 150 (51.2) 4 (30.8) 2 (25.0) 169 (48.1)
Right-Sided Resection 24 (66.7) 135 (46.1) 8 (61.5) 5 (62.5) 172 (49.0)
(Sub)total Colectomy 0 (0.0) 8 (2.7) 1 (7.70 1 (12.5) 0.059 10 (2.8)
AJCC T-Stage  
T3 34 (94.4) 271 (90.9) 13 (100.0) 5 (62.5) 324 (91.0)
T4 2 (5.6) 27 (9.1) 0 (0.0) 3 (37.5) 0.021 32 (9.0)
Lymphovascular Invasion  
No 10 (27.8) 86 (28.9) 3 (25.0) 4 (50.0) 103 (29.0)
Yes 7 (19.4) 20 (6.7) 1 (8.3) 1 (12.5) 29 (8.2)
Unknown 19 (52.8) 192 (64.4) 8 (66.7) 3 (37.5) 0.153 223 (62.8)
N-Stage  
N0 32 (88.9) 260 (87.2) 12 (92.3) 7 (87.5) 312 (87.6)
Nx 4 (11.1) 38 (12.8) 1 (7.7) 1 (12.5) 0.949 44 (12.4)
Adjuvant Therapy 3 (8.3) 16 (5.4) 0 (0.0) 2 (25.0) 0.086 21 (5.9)
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abStraCt 
introduction: The growing interest in the molecular subclassification of colorectal 
cancers is more and more facilitated by large multicenter biobanking initiatives.1,2 The 
quality of tissue sampling is pivotal for successful translational research. This study 
shows the quality of fresh frozen tissue sampling within a multicenter cohort study for 
colorectal cancer (CRC) patients.
Material and Methods: Each of the seven participating hospitals randomly contributed 
ten tissue samples, which were collected following Standard Operating Procedures 
using established techniques. To indicate if the amount of intact RNA is sufficient for 
molecular discovery research and prove SOP compliance, the RNA integrity number 
(RIN) was determined. Samples with a RIN <6 were measured a second time and when 
consistently low a third time. The highest RIN was used for further analysis.
results: 91% of the tissue samples had a RIN ≥6 (91%). The remaining six samples had 
a RIN between 5-6 (4.5%) or lower than 5 (4.5%). The median overall RIN was 7.3 (range, 
2.9 to 9.0). The median RIN of samples in the university hospital homing the biobank was 
7.7 and the median RIN for the teaching hospitals was 7.3, ranging from 6.5 to 7.8. No 
differences were found in the outcome of different hospitals (p=0.39). 
Conclusion: This study shows that the collection of high quality fresh frozen samples 
of colorectal cancers is feasible in a multicenter design with complete SOP adherence. 
Thus, using basic sampling techniques large patient cohorts can be organized for pre-
dictive and prognostic (bio)marker research for CRC.
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introDuCtion 
Colorectal cancer (CRC) is the second most common malignancy in the Western World3. 
As in all cancer research, there is a strong trend towards molecular subclassification of 
CRC4. The studies conducted to identify these molecular and clinically relevant markers 
demand large numbers of patients with accurate long-term clinical data combined with 
high quality tissue samples to be able to use state of the art techniques1,5,6. Subsequently, 
the standard enclosed formalin-fixed paraffin-embedded tissue can be used to develop 
assays for daily clinical practice. Therefore, large multicenter biobanking initiatives are 
needed to facilitate these research efforts1,2. However, 10% of the fresh frozen tissue 
samples collected for research purposes are unsuitable for molecular analyses. This is 
due to multiple non-modifiable factors such as tissue type, intrinsic patient factors, 
warm ischemia time (extraction of the resection specimen after ligation of the large 
vessels) and modifiable factors such as cold ischemia time (tissue transport from the op-
erating theatre to the pathology lab), the conservation (fixation/stabilization) method, 
subsequent transport  and the storage of the tissue samples7,8. The RNA Integrity Num-
ber (RIN), first described in 2006, is currently a common standard used to assess tissue 
quality9. This method became well accepted to measure the SOP adherence of quality 
in tissue banking10.
In this cohort, fresh frozen tissue samples were obtained in both a university (a center 
with experience in tissue sampling and storage, and dedicated personnel)11 as well as six 
non-university teaching hospitals also referred to as peripheral hospitals (not used to, 
and equipped and staffed for routine fresh frozen tissue sampling) is assessed within the 
MATCH study, a multicenter cohort study in the region of Rotterdam, the Netherlands, 
including patients with CRC. 
MateriaLS anD MethoDS 
MatCh-study design 
The MATCH-study is an ongoing multicenter cohort study including adult patients with 
CRC undergoing curative surgery. The participating centers include one university hos-
pital (Erasmus MC Medical Center) and six non-university teaching hospitals (Elisabeth 
hospital, IJsselland hospital, Ikazia hospital, Maasstad hospital, Reinier de Graaf Gast-
huis, Franciscus Gasthuis). The MATCH study was approved by the Medical Ethical Board 
of the Erasmus MC Medical Center, Rotterdam, the Netherlands (MEC-2007-088). All 
patients provide written informed consent for the collection of long-term clinical data 
and storage of tissue samples. The study is of an integrated approach using clinical pa-
tient care in non-university hospitals with university-based facilities for tissue and data 
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storage. The rationale of this study was to identify subtypes of colorectal cancer, related 
prognostic markers and outcome of treatment. Liver metastases was defined as primary 
outcome defining a good or dismal outcome of disease progression as liver involvement 
has been demonstrated to be the main factor to determine long term outcome. 
Clinical data
Medical specialists of departments of Surgery, Pathology, Gastroenterology, Radiology 
and Medical oncology were consulted. Clinical data included reports of colonoscopy, 
radiology and pathology, as well as, surgical reports and postoperative complications. 
A standard case record was created in a web based multicenter access database. The 
follow-up of these patients was standardized in all hospitals following an intensive 
follow-up schedule according the national CRC guidelines12. 
tissue sampling
All tissue samples were handled following a Standard Operation Procedure (SOP) pro-
vided by the study team at the start of the study. In short, resection specimens were 
transported (at room temperature without any conservation fluids) from the operating 
theatre to the pathology department, immediately following removal of the specimen 
from the patient. At the pathology department the specimen was handled at room tem-
perature and within two hours after resection samples were snap-frozen as described 
below. When the two hour time limit was exceeded, no tissue samples were taken. 
Macroscopically, one to four tumor samples and one to two healthy colon tissue 
samples of 0.5-1 cm3 were taken by the pathologist. Tissue sampling for the MATCH 
study was not allowed to interfere with the standard pathology routine needed for 
clinical practice. Tumor and normal tissue were stored in labeled cryovials and snap 
frozen in liquid nitrogen or dry-ice11,13. Samples were then stored at low-temperature 
refrigerators (-80°C) in the hospital of primary surgery and in batches transported to the 
central tissue bank (-196°C liquid nitrogen Barrels) at the university hospital. Of all new 
tissue specimens stored in the central bank, on a yearly base 2% is tested for quality, by 
determining the RNA integrity10,14. 
tissue quality assessment 
To assess the tissue quality of the samples collected in the MATCH-study, we randomly 
selected 10 tissue samples per participating hospital, representing about 4% of the 
entire collection. Samples that were exposed to neoadjuvant chemotherapy and/or 
radiotherapy were excluded as this may damage tissue resulting in failure of analysis.
RNA quality was determined by measuring of the RIN9,15. For RNA isolation, 10-20 tis-
sue slides of 10µm were cut. One slide was colored by hematoxylin and eosin (H&E) stain 
for morphological conformation of the diagnosis. For RNA extraction, the slides were 
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put in a Qiazol Lysis buffer and shaken for ten seconds to homogenize the tissue. RNA 
was then extracted using the miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to 
the method suggested by the manufacturer. The integrity of RNA was measured by the 
Bioanalyser (Agilent Technologies, Santa Clara, CA, USA) using the lab-on-a-chip, RNA 
6000 nano assay. This is an automated system bases on electrophoretic separation. The 
RIN is directly calculated applying an algorithm on the ratio of 18S/28S ribosomal RNA 
bands. A tissue sample with a RIN of ≥6 is believed to be of good quality (Figure 1a)16. 
Samples with a RIN <6 (Figure 1b) were measured a second and when consistently low 
a third time. When the RIN was consistently low, the case was discussed with the techni-
cian to see if any deviation from protocol (e.g. during the freezing procedure or sample 
preparation) could explain the low RIN. When samples were measured multiple times, 
the highest RIN was used for further analysis.
Figure 1a Image intact RNA (RIN 9.0), ob-
tained from the electropherogram and 
virtual gel
Figure  1b Image partially degraded RNA 
(RIN 3.3), obtained from the electrophero-
gram and virtual gel
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Statistical analysis
Statistical analyses were performed by using SPSS (IBM Corp. Released 2012. IBM SPSS 
Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.). Categorical data were 
described as frequencies with percentages and continuous data as median with the 
range. The c2 test was used to compare categorical data, for continuous date the One-
way ANOVA test was used. A p-value less than 0.05 was considered to be statistically 
significant.
reSuLtS 
In total, 70 random samples were selected for analysis out of the 1700 samples collected 
in the study period 1st October 2007 – 1st January 2013. During the work-up and data 
quality check, three samples were excluded leaving a total sample size of n=67. Two 
tissue samples were exposed to neoadjuvant radiation therapy and one tissue sample 
was too small. 
Out of the 67 samples, two samples were analyzed two times (3.0%) and seven samples 
three times (10.4%). The median overall RIN of all samples was 7.3 (range, 2.9 to 9.0). The 
majority (n=61) of the tissue samples had a RIN ≥6 (91%). The remaining six samples 
had a RIN between 5-6 (4.5%) or lower than 5 (4.5%) (Figure 2 and 3). Three of the seven 
samples that were measured three times had a RIN < 5 and were discussed with the 
technician. However, the low RIN could not be attributed to protocol deviations. The me-
dian RIN for a center specialized in tissue sampling at the operation theatre (university 
hospital) was 7.7 and the median RIN for teaching hospitals without a wide experience 
in this field ranged from 6.5 to 7.8. The overall median RIN of the non-university teach-
ing hospitals (median RIN =7.3) did not differ significantly with the median RIN of the 
Figure  2  The RIN distribution in 67 samples
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university hospital (p=0.39) (Figure 4). When using the specialized university hospital as 
a reference, the median RIN of one non specialized teaching hospital (hospital 6) had a 
significantly lower median RIN than the university hospital (p=0.02). However, a median 
RIN of 6.5 is still well above the cut-off of 6. Interestingly, the range of RIN for the non-
university teaching hospitals tended to be larger than the range of RIN if the university 
hospital (Figure 3).
Figure 3 Box plot with the RIN per hospital
Figure 4 Box plot with the RIN for the university hospital and non-university hospitals
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DiSCuSSion 
This study shows that the collection of high quality fresh frozen samples of CRC is fea-
sible in a multicenter design including hospitals for which fresh frozen tissue sampling 
is not part of the daily routine. In our study, 91% had a RIN ≥6 and thus can be used for 
highly demanding gene array assays.
The RIN was developed and published in 2006 to meet the need for a reliable standard 
to estimate the integrity of RNA samples9. A comparison study comparing a subjective 
evaluation of the electropherogram, the 28S-18S peaks ratio and the RIN showed a su-
perior result for the manual and RIN method over the ratio method16. Nowadays, the RIN 
is widely used to quantify the RNA quality of samples and select samples for expression 
analyses. However, the cut-off used to select ‘high quality’ samples varies in literature, 
ranging from a RIN of 5 to 7. These cut-offs can be based on the recommendations in a 
manufacturer manual or on the experience of a lab17-20. At our hospital, we use a RIN of 
≥6 as the cut-off which qualified 91% of the samples as high quality samples21. When 
samples repeatedly have a RIN <6, they may be excluded to prevent a transcript spe-
cific bias, or analytical or bioinformatics steps specifically dealing with the low quality 
samples should be included in the methodology22,23. Furthermore, samples with a RIN < 
6 can still be used for RT-qPCR applications in which only short amplicons are analyzed.
The quality of RNA expression in tissue samples is dependent on multiple factors 
such as tissue type, intrinsic patient factors, warm and cold ischemia time, the fixation 
method and the storage of the tissue samples. While tissue type and intrinsic patient 
factors cannot be modified, other factors (i.e. ischemia time, fixation method and the 
storage of samples) can be influenced. The RIN can be used to determine large influ-
ences during the pre-analytical phase. Smaller differences can be assessed based on 
RNA expression analyses24. For fresh frozen samples, the most important factor appears 
to be the ischemia time and freeze thawing effects after freezing. A recent review spe-
cifically addressing the effect of cold ischemia on RNA stability concluded that in most 
studies included only minimal changes in the RIN were observed (≤10%) during a cold 
ischemia times of 1-6 hours25. One outlier reported a significantly decreased RIN of 44% 
in samples with a cold ischemia time of 1,5 hours compared to samples with a cold 
ischemia time of 10 minutes20. However, the 28S:18S ratios did not significantly differ20. 
Importantly, the definition of cold ischemia time differed between studies and often the 
cold ischemia time in the operating theatre was not taken into account. Furthermore, 
the effects of warm ischemia time are often ignored while they most likely interact with 
the effects of cold ischemia time. This may be explained by the fact that this factor is 
hard to reliably score and is considered to be a non-modifiable factor since attempts to 
minimize warm ischemia time may affect patient care. Such non-modifiable influences 
can only be documented to obtain a tool for determination of this influence26. Although 
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we did not specifically assessed the association between ischemia time and the RIN in 
our study, the maximum cold ischemia time was two hours since this was included in 
the SOP. Thus, the high percentage of high quality samples in our study is in line with 
the current literature. For the few samples with consistently low RIN values, no protocol 
deviations were found suggesting the low RIN was caused by non-modifiable factors. 
Our study shows that SOP compliance was positive in all the cooperating hospitals 
and high quality fresh frozen tissue sampling is possible in a multicenter setting includ-
ing both university and non-university hospitals. These findings support the feasibility 
of emerging large-scale ‘fit-for-purpose’ biobanks to facilitate the increasingly complex 
field of fundamental and translational cancer research1,2,27.
In conclusion, our study shows that the collection of high quality fresh frozen samples 
of CRC is feasible in a multicenter design and using basic sampling techniques. Thus, 
large patient cohorts can be organized for predictive and prognostic (bio)marker re-
search for CRC.
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abStraCt 
introduction: For both patients and the outpatient clinic the frequent follow-up visits 
after a resection of colorectal cancer (CRC) are time consuming and due to large patient 
numbers expensive. Therefore, it is important to develop an effective non-invasive test 
for the detection of colorectal liver metastasis (CLM) which could be used outside the 
hospital. 
The urine proteome is known to provide detailed information for monitoring changes 
in the physiology of humans. Urine collection is non-invasive and urine naturally occur-
ring peptides (NOPs) have the advantage of being easily accessible without labour-in-
tensive sample preparation. These advantages make it potentially useful for a quick and 
reliable application in clinical settings. In this study, we will focus on the identification 
and validation of urine NOPs to discriminate patients with CLM from healthy controls.
Materials and methods: Urine samples were collected from 24 patients with CLM and 
25 healthy controls. In the first part of the study, samples were measured with a nano 
liquid chromatography (LC) system (Thermo Fisher Scientific, Germaring, Germany) 
coupled on-line to a hybrid linear ion trap / Orbitrap mass spectrometer (LTQ-Orbitrap-
XL, Thermo Fisher Scientific, Bremen, Germany). A discovery set was used to construct 
the model and consecutively the validation set, being independent from the discovery 
set, to check the acquired model. From the peptides which were selected, multiple reac-
tion monitoring (MRM’s) were developed on a UPLC-MS/MS system. 
results: Seven peptides were selected and applied in a discriminant analysis a sensitiv-
ity of 84.6% and a specificity of 92.3% were established (Canonical correlation:0.797, 
Eigenvalue:1.744, F:4.49, p:0.005). The peptides AGPP(-OH)GEAGKP(-OH)GEQGVP(-OH)
GDLGA P(-OH)GP and KGNSGEP(-OH)GAPGSKGDTGAKGEP(-OH)GPVG were selected for 
further quantitative analysis which showed a sensitivity of 88% and a specificity of 88%.
Conclusion: Urine proteomic analysis revealed two very promising peptides, both 
part from collagen type 1, AGPP(-OH)GEAGKP(-OH)GEQGVP(-OH)GDLGAP(-OH)GP 
and KGNSGEP(-OH)GAPGSKGDTGAKGEP(-OH)GPVG which could detect CLM in a non-
invasive manner.
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introDuCtion 
Colorectal cancer (CRC) is the most common gastrointestinal malignancy worldwide 
and the 3rd leading cause of cancer-related deaths in the western world. More than one-
third of the patients develop colorectal liver metastases (CLM) during the course of the 
disease, which are responsible for at least two-thirds of the deaths1. 
For the follow-up after CRC, blood level Carcinoembryonic antigen (CEA) is used to 
detect CLM with a wide spread of sensitivity ranging from 58 to 89 percent2,3. Because 
of this suboptimal sensitivity, liver imaging with ultrasonography and computer tomog-
raphy are performed on a routine base. For both patients and the outpatient clinic the 
frequent follow-up visits are time consuming and due to large patient numbers expen-
sive. Therefore, it is important to develop an effective non-invasive test for the detection 
of CLM which could be used outside the hospital.
Proteomic patterns in body fluids present new opportunities for the development of 
novel, highly sensitive diagnostic tools for detection of cancer4,5. The urine proteome is 
known to provide detailed information for monitoring changes in the physiology of hu-
mans5,6. Urine collection is non-invasive and urine naturally occurring peptides (NOPs) 
have the advantage of being easily accessible without labour-intensive sample prepara-
tion7. These advantages make it potentially useful for a quick and reliable application in 
clinical settings. To prove the concept, it is possible to differentiate between different 
liver tumors (CLM, Hepatocellular Carcinoma (HCC), Hepatocellular Adenoma) and not 
only measure peptides involved in the process of general tumor growth in the liver, we 
conducted a pilot-study. In the current study we demonstrated we could discriminate 
between these liver tumors with the use of peptides found in urine (unpublished work, 
poster presentation ESMO 2010). In this study, we will focus on the identification and 
validation of urine NOPs to discriminate patients with CLM from healthy controls.
MateriaLS anD MethoDS 
ethics Statement
The use of patient materials was approved by the medical ethical committee of Erasmus 
University Medical Center and written informed consent was obtained for all patients.
Patient selection
We selected patients with Colorectal Liver metastasis (CLM) and healthy kidney donors 
as controls. Inclusion criteria were; female gender, age above 18 years and written in-
formed consent. The patients with CLM underwent liver resection and their diagnoses 
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were confirmed by the pathologist afterwards. Patients and controls were excluded if 
they were diagnosed with other malignancies or received prior chemotherapy. 
A discovery set was formed of 23 patients that contained 11 patients with CLM and 
12 controls. In addition, a validation set was formed with 26 patients, 13 with CLM, and 
13 controls.
Sample collection
From patients with CLM, 100 ml urine was collected (midstream morning urine of sober 
patients). Fifty ml of urine was sent to the chemical laboratory at room temperature for 
determination of standard parameters (e.g. creatinine, total urine protein). Aliquots of 
10 ml were made from the remaining 50 ml urine and stored within 4 hours from sample 
withdrawal at -80°C.
Sample preparation 
Preparation of samples for proteomic analysis was performed as described previously8 
with some minor modifications. In brief, urine samples were thawed at room temperature 
and placed in a water bath for 30’at 30°C with regular mixing to dissolve the precipitate. 
At room temperature, 1.4 ml urine was centrifuged to remove remaining precipitate for 
5’ at 2000g. A volume of 1.2 ml of urine was diluted with 0.6 ml 3 M urea, 15 mM NH4OH, 
0.03% (w/v) SDS solution. From this mixture, 1.5 ml high molecular weight components 
were discarded using Centrisart ultracentrifugation columns (Sartorius, Goettingen, 
Germany) with a molecular cut-off limit of 20 kDa at a centrifugal force of 2500g for 10’. 
From this filtered sample 1.2 ml was applied to a PD-10 desalting column (GE Health-
care) equilibrated with 25 ml 0.01% NH4OH and allowed to completely enter the filter 
bed. To improve the yield of natural occurring peptides (NOPs), 1.3 ml of equilibration 
buffer was applied to the filter bed as a first step and allowed to wash out by gravity 
flow. Subsequently, 2 ml of equilibration buffer was applied to the PD-10 column, the 
flow-through was collected, lyophilized, and stored at +4°C until further use. Prior to 
analysis by the nano-liquid chromatography/mass spectrometry (LC-MS), samples were 
suspended in 50 µl of HPLC-grade H2O.  For estimating the NOP content with the BCA 
assay (Pierce) 4 µL of sample was used. With the use of this information the sample was 
diluted to 0.8 µg peptide/µl to 0.1% trifluoroacetic acid/water for normalization. 
Qualitative Mass spectrometry analysis (orbitrap) 
In the first part of the study, samples were measured with a nano liquid chromatography 
(LC) system (Thermo Fisher Scientific, Germaring, Germany) coupled on-line to a hybrid 
linear ion trap / Orbitrap mass spectrometer (LTQ-Orbitrap-XL, Thermo Fisher Scientific, 
Bremen, Germany). Samples were loaded onto a trap column (PepMap C18, 300 μm ID 
5mm length, 5 μm particle size, 100 Å pore size; Thermo Fisher Scientific), washed and 
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desalted for 10 minutes using 0.1% trifluoroacetic acid (TFA) (in water) as loading solvent. 
Next, the trap column was switched in line with the analytical column (PepMap C18, 75 
μm ID x 250mm, 3 μm particle and 100 Å pore size; Thermo Fisher Scientific) and peptides 
were eluted with the following binary gradient: starting with 100% solvent A, then from 
0% to 25% solvent B in 60 min and from 25% to 50% solvent B in 30 min, where solvent 
A consisted of 2% acetonitrile and 0.1% formic acid (rest water), and solvent B consisted 
of 80% acetonitrile and 0.08% formic acid (rest water). All LC solvents were purchased 
at Biosolve, Valkenswaard, the Netherlands. Column flow rate was set at 300 nL/min. For 
electro-spray ionization (ESI), nano ESI emitters (New Objective, Woburn, MA, USA) were 
used and a spray voltage of 1.5 kV was applied. For Mass Spectrometry (MS) detection, 
a data-dependent acquisition method was used: high-resolution survey scan from 400 
– 1800 Th. was detected in the Orbitrap (target of automatic gain control = 10 E6, resolu-
tion = 30,000 at 400 m/z, lock mass set to 445.120025 Th (protonated (Si(CH3)2O))6)9). 
On the basis of this full scan the five most intensive ions were consecutively isolated 
(AGC target set to 104 ions) and fragmented by collisional activated dissociation (ap-
plying 35% normalized collision energy) and detected in the ion trap. Precursor masses 
within a tolerance range of +/- 5 ppm that were selected once for MS/MS were excluded 
for MS/MS fragmentation for 3 minutes or until the precursor intensity fell below an S/N 
of 1.5 for more than five scans (early expiration). Orbitrap full scan spectra and ion trap 
MS/MS fragmentation spectra were acquired partially simultaneously.
Data analysis 
The MS/MS data from the raw data files of each sample were converted into mgf files 
using Extract-MSN (part of XCalibur version 2.0.7, Thermo Fisher Scientific Inc.) and used 
to perform database searches using Mascot (version 2.2.06; Matrix Science Inc., London, 
UK) against the human subset of the Uniprot-Swissprot database (version 2011-3, hu-
man taxonomy, 20,287 entries). For database searches the following parameters were 
used: oxidation as a variable modification of methionine, hydroxylation as a variable 
modification of proline and lysine, maximal missed cleavage of 0, and “none” was se-
lected as enzyme. A peptide mass tolerance of 10  ppm and a MS/MS mass tolerance 
of 0.5 Da were accepted. An ion score of 25 was used as a cut-off value. Subsequently, 
the raw data files were loaded into the software package Progenesis LCMS (Version 2.5; 
Nonlineair Dynamics Ltd, New Castle, UK) and aligned for retention time. Only features 
with a charge state of +2 to+8 were included for further analyses. Next, the results of 
the Mascot database search were imported into Progenesis, and an export file was 
created in which for each individual sample the abundances of the detected features 
were displayed. Abundance levels of masses identified multiple times in one sample 
were summed into single abundance values prior to statistical analysis. To eliminate 
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sporadic findings, identified masses not present in at least 3 samples of one group were 
subsequently excluded from further analysis.
Statistical analysis
Statistical analyses on the patient characteristics were conducted in the Statistical 
Package for the Social Sciences (SPSS) version 20.0 (IBM Corp. Released 2011. IBM SPSS 
Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp). Categorical variables are 
presented as number (percentage). Continuous variables are presented as median 
(range), Categorical variables were compared, after testing for normality, with the c2 
test; continuous variables were compared with the Independent t-test. A p-value <0.05 
(two-sided) was considered significant. 
Statistical analysis of the observations as obtained from mass spectrometry was 
performed using STATA (version 10, StataCorp, Texas, US). After testing for normality, 
using Shapiro-Wilks, univariate comparison between individuals from the groups was 
performed using Mann-Whitney U-test (parameter free) or unpaired t-test (parametric). 
This yielded many features (in raw abundance format) with significant outcome between 
the evaluated combinations. Subsequently, the identified features were analyzed using 
stepwise regression to construct a model containing a combination of those features 
with the highest sensitivity and specificity to distinguish the respective groups. This was 
done in combination with canonical linear discriminant analysis10 to detect the various 
sensitivity and specificity details when the various models are applied.
Moreover, background evaluation was also performed in which models were applied 
with at random features and outcome to compare the acquired sensitivity and specific-
ity with those as obtained after statistical analysis.
The discovery set was used to construct the model, consecutively the validation set, 
being independent from the discovery set, to check the acquired model.
Throughout the study, applying two-sided testing, a significance level of 0.01 was 
considered to be statistically relevant.
The discovery set was subjected to a univariate analysis in order to identify masses 
significantly different (p<0.01) between CLM patients and healthy controls that ought 
to be present in both discovery and validation. From the peptides with p-values <0.01 a 
best fit model was made in the discovery set and subsequently tested in the validation 
set to determine sensitivity and specificity.
Quantitative mass spectrometry analysis (SrM)
For the peptides selected based on the statistical analysis heavy labeled stable isotopes 
were ordered (Pepscan, Lelystad, The Netherlands). A selective reaction monitoring 
(SRM) method for the selected peptides was developed and optimized on a UPLC which 
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was online connected to a Xevo TQS mass spectrometer (Waters, Milford Massachusetts, 
USA).
The sample was trapped on a Symmetry C18 nanoACQUITY column (5 µm x 180 µm 
20 mm) (Waters, Milford Massachusetts, USA) for 5 min and washed by a solution of 
99% A and 1% B, solvent A 0.1% formic acid in water and solvent B is 0.1% formic acid 
in acetonitrile, with a flow of 8.00 µl/min. Followed by separation on an BEH 300 C18 
column (1,7µm * 75µm * 200mm) (7 µm x 75 µm x 15 cm) with a flow of 0.3 µl/min 
and a gradient starting with 98.5 % A lowered in 30 min to 60 %. In 0.10 min it was 
further decreased to 20 % A and kept constant for 5 min following by an increase in 
0.10 min, back to 98.5 % for 20 min. Ions were produced by a Z-spray nanoflow source 
under atmospheric pressure using a capillary voltage of 3.00 kV, cone voltage of 50 V 
and a source offset of 50 V. The source temperature was maintained at 70 oC. For every 
peptide 3 transitions were chosen differing in collision energy (table 1). Fragmentation 
is induced by collision dissociation with argon gas which is inserted with a flow rate of 
0.15 ml/min. For the selection of the peptides for the final quantitative assay the fol-
lowing parameters were taken into account: No interference in used SRM transitions, 
co-elution of the peptide and internal standard (IS), linearity of response in measured 
concentration range, symmetry of peak shape and a signal intensity of at least 10 times 
the average observed background. 
table 1: The three transitions which have been developed for each peptide and the optimized collision 
energies.
Peptide Parent mass
(m/z)
Fragment
(m/z)
Collision energy
(v)
AGP P(-OH)GEAGK* P(-OH)GEQGV P(-OH)GDLGA 
P(-OH)GP 
1088.51 527.28 37
812.38 33
1364.64 33
1092.52 527.28 37
812.38 33
1372.66 33
K*GNSGEP(-OH)GAPGSK*GDTGAK*GEP(-OH)GPVG 786.04 442.23 29
814.37 29
957.94 25
794.05 442.23 29
822.38 29
969.96 25
For each stable isotope labeled amino acid an extra mass of 8 Da is included. 
m/z (mass-to-charge ratio); V (Voltage)
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The following parameters were taken into account for the selection of the peptides 
that were used for the SRM assay: no interference in used SRM transition, co-elution of 
the peptide and its internal standard (IS), linearity of response in measured concentra-
tion range and the peak intensity should be at least 10 times above the background 
level. The peak analysis was done with Skyline v1.3.0.3871 (MacCoss Lab, University 
of Washington, WA, United States of America). The results exported from Skyline were 
further analyzed with Microsoft Excel2007 (Redmond, WA, United States of America) 
and GraphPad Prism v5.00 (GraphPad Software, San Diego California USA) A ROC-curve 
was plotted by GraphPad Prism v5.00 (GraphPad Software, San Diego California USA). 
The cut-off value was chosen whereby both sensitivity and specificity were as high as 
possible.
reSuLtS 
Patient characteristics and clinical chemistry data of the urines are presented in Table 2. 
A significant difference in age (p=0.01) and Body Mass Index (BMI) (p=0.04) is observed. 
Kidney function and urine protein were comparable between both groups. 
table 2: Basic patient characteristics
Variable CLM
(n=24)
Healthy kidney donors
(n=25)
p- value
Age1,3 64 (43-81) 57 (34-75) 0.01
BMI1,3 23.6 (18-36) 27.3 (20-35) 0.04
No. of lesions1 2 (1-7) † - -
Size largest lesion (cm)1 3 (1-10) † - -
Serum creatinine
>115 µM2,4
1† (4%) 0 0.29
Urine protein >0.14 g/L2,4 3 (12.5%) 0 0.07
† 1 missing 
CLM, Colorectal Liver Metastasis; BMI, Body Mass Index 
1 Data are presented as median with the range between brackets. 
2 Data are presented as numbers with the percentage between brackets.
Data were analyzed using a 3Independent t-test or the 4 c2 test. 
Qualitative Mass spectrometry analysis (orbitrap)
Of the 28830 and 57276 masses detected in the discovery and validation set, respectively, 
2426 (8.6%) and 3424 (5.8%) unique peptide sequences were identified. These naturally 
occurring peptides belong to 189 and 445 proteins, respectively. Of the unique peptides 
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identified 1386 (55%) derived from 26 different collagen proteins in the discovery set and 
1303 (39%) from 34 in the validation set. Of all identified masses 80% of the abundant 
intensities is associated with collagen peptides. It occurred that same peptides were se-
quenced with one or more hydroxylated proline or lysine residues. Of all identified collagen 
peptides, 1702 peptides had 2 or more hydroxylations on either lysine or proline residues 
with a maximum of 11. These modified peptides are considered as unique peptides.
Statistical analysis and regression modeling
Univariate analysis of the discovery set revealed 40 collagen peptides that were signifi-
cantly different (p<0.01) between the healthy individuals and patients with CLM.
A Multivariate analysis, using stepwise regression was applied in the discovery set 
to construct a relevant model using all identified peptides, showing significance be-
tween healthy individuals and CLM patients.  To obtain a 100% sensitivity and 100% 
specificity a 17-collagen peptides model was identified (Canonical correlation:0.9911, 
Eigenvalue:55.64, F:16.37, p:0.003) (Table 3). 
table 3 : Sequences of the 17 Peptides used for the first model in the discovery set.
Mass (Da) Sequence Accesion 
code
2204.995 ADGQPGAKGEP(-OH)GDAGAKGDAGPP(-OH)GP COL1A1 
2175.011 agPP(-oh)geagkP(-oh)geQgvP(-oh)gDLgaP(-oh)gP CoL1a1 
1927.909 DP(-OH)GETGEQGDRGIP(-OH)GHRG COL1A1 
1778.855 GAAGEP(-OH)GKAGERGVP(-OH)GPP(-OH)GA COL1A1 
2628.235 GLPGP(-OH)AGP(-OH)P(-OH)GEAGKP(-OH)GEQGVP(-OH)GDLGAP(-OH)GP COL1A1 
2561.128 GPP(-OH)GADGQP(-OH)GAP(-OH)GEP(-OH)GDAGAKGDAGP(-OH)PGP COL1A1 
2632.164 GPP(-OH)GADGQP(-OH)GAP(-OH)GEP(-OH)GDAGAKGDAGP(-OH)PGPA COL1A1 
2786.247 GPP(-OH)GADGQP(-OH)GAKGEP(-OH)GDAGAP(-OH)GDAGP(-OH)PGPAGP COL1A1 
2516.165 GPP(-OH)GKNGDDGEAGKP(-OH)GRP(-OH)GERGP(-OH)PGP COL1A1 
1734.781 GPP(-OH)GPP(-OH)GKNGDDGEAGKPG COL1A1 
1408.664 GPPGP(-OH)P(-OH)GP(-OH)PGPPGPPS COL1A1 
2371.086 P(-OH)GNSGEP(-OH)GAP(-OH)GSKGDTGAKGEP(-OH)GPVG COL1A1 
2355.098 kgnSgeP(-oh)gaP(-oh)gSkgDtgakgeP(-oh)gPvg CoL1a1 
1522.732 KP(-OH)GEQGVP(-OH)GDLGAP(-OH)GP COL1A1 
2989.483 NVGAP(-OH)GAKGARGSAGP(-OH)P(-OH)GATGFP(-OH)GAAGRVGPPGP(-OH) COL1A1 
2973.485 NVGAPGAP(-OH)GARGSAGPP(-OH)GATGFP(-OH)GAAGRVGP(-OH)PGP COL1A1 
2670.203 ERGEAGIP(-OH)GVP(-OH)GAP(-OH)GEDGKDGSP(-OH)GEP(-OH)GA COL3A1 
The amino acids which are underscored are hydroxylated. The two peptides which are written in bold are 
the finally selected peptides. (COL1A1 Collagen, type I, alpha 1)
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Analysis of the samples from the validation set returned 58545 masses of which 3442 
unique peptides could be identified. Out of these 3442 peptides, 1304 belonged to 34 
different collagens.  
Within the validation set, of the original 40 peptides identified in the discovery set 
as having a significant difference in raw abundance between both groups, 7 peptides 
could be identified. It was decided to use all 7 peptides to model the outcome based on 
the results in the validation set. When these 7 peptides were applied in a discriminant 
analysis a sensitivity of 84.6% and a specificity of 92.3% were established (Canonical 
correlation:0.797, Eigenvalue:1.744, F:4.49, p:0.005). 
Figure 1 ROC-curves of the selected peptides AGPP(-OH)GEAGKP(-OH)GEQGVP(-OH)GDLGAP(-OH)GP (A) 
and KGNSGEP(-OH)GAP(-OH)GSKGDTGAKGEP(-OH)GPVG
Figure 1 ROC-curves of the selected peptides AGPP(-OH)GEAGKP(-OH)GEQGVP(-
OH)GDLGAP(-OH)GP (A) and KGNSGEP(-OH)GAP(-OH)GSKGDTGAKGEP(-
OH)GPVG 
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KGNSGEP(-OH)GAP(-OH)GSKGDTGAKGEP(-OH)GPVG 0.001011 88.24 87.50 0.8603 
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The peptides AGPP(-OH)GEAGK P(-OH)GEQGV P(-OH)GDLGA P(-OH)GP and KGNSGE 
P(-OH)GAPGSKGDTGAKGE P(-OH)GPVG were selected for further quantitative mass 
spectrometry analysis by selective reaction monitoring (SRM) based on a thorough 
evaluation on the criteria described in the materials and method section.  The quantita-
tive analysis resulted in a sensitivity of 88% and specificity of 89% (Figure 1).  
These two peptides have been retested in the Orbitrap data showing a sensitivity and 
specificity of 72.7% and 100% in the discovery set and 69.2% and 84.6% in the validation 
set. 
DiSCuSSion 
Patients
For this study healthy kidney donors have been selected as a control group. These con-
trols were selected because living kidney donors are examined intensively to exclude 
any disease. Because this specific control group was chosen, which were not matched 
with our CLM-patients, a difference in patient characteristics in BMI (p=0.04) and age 
(p=0.01) was found. Only women were selected because the first pilot study we have 
performed included different solid liver tumors including HCA, a benign liver tumor 
which occurs very rarely in men11. 
In this study, a collagen profile has been discovered and validated in patients who 
were diagnosed with colorectal liver metastasis at the time of sampling. To identify the 
prognostic value of our profile, we will continue sampling during the regular follow-up 
in patients who underwent surgery because of CRC.  Thereby patient variation presum-
ably can be diminished and an even better sensitivity and specificity can be expected. 
The short coming of this study is the small number of patients. However, we believe 
we describe a very innovative concept for the detection of colorectal liver metastasis. 
Furthermore, the detection of different amounts of hydroxylated collagen type 1 may 
proof to be very valuable for clinical use and, in addition, it could contribute to the 
understanding of the liver seeding and homing of colorectal metastasis.  Larger experi-
ments need to be performed to demonstrate the efficacy of this approach.
Peptide selection 
In this study, only two stable isotope labelled peptides were technically suitable in our 
final analysis (table 3). Mischak et al. already showed data generated by different pro-
teomics technologies are not always comparable12.  Although the result could possibly 
be improved by taking more significant different peptides, this study already shows the 
new possibilities to use urine proteomic analysis to detect CLM. 
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Collagen
The two peptides identified in this study are part of collagen type 1. Collagens are 
macromolecular molecules which are eliminated due to secretion by the kidney. Type I 
collagen is the most abundant in stroma which is composed of the extracellular matrix 
(ECM). In the adult liver the ECM is mostly composed of collagen type 1 and fibronec-
tin13-16.  The structure of the ECM is not static, it remodels constantly as a consequence of 
development and disease17.  This remodelling is a result of multiple processes that vary 
according to the initiating stimulus. The protein components of the ECM are cleaved 
by metalloproteinases (MMPs) and they seem to play a dominant role in this process 
of remodelling18. The remodelling of the ECM is an essential event before invasion of 
neoplastic cells into the stromal tissue and could explain our findings in the urine of 
patients with CLM. The different expressions of type 1 collagen were also described in 
the stromal composition of tissue samples from CRC and CLM19. The combination of 
these results provides evidence that type 1 collagen has a role in CLM. However further 
research is needed to support these findings. Previously our research group identified 
tumour specific collagen-like peptides which are located in the blood vessels of brain 
tumours. These proteins are expressed in tumour blood vessels, but not in blood vessels 
of healthy brain tissue20.  
hydroxylation
Hydroxylation of peptides provides further stabilization or, depending on the location 
of the hydroxylation, the opposite, namely instability. Normally the hydroxylation 
in collagen sequences happens at the terminal residue in Gly–Pro–Pro repeats21. The 
final classifier existed of two hydroxylated collagen peptides with a sensitivity of 88%, 
a specificity of 88%. We hypothesize that in the liver the post-translational modification 
related to hydroxylation in collagen is altered due to the cancer cell invasion. 
Although this study is based on relatively small numbers, urine proteomic analysis 
revealed two very promising peptides AGPP(-OH)GEAGK P(-OH)GEQGV P(-OH)GDLGA 
P(-OH)GP and KGNSGE P(-OH)GAPGSKGDTGAKGE P(-OH)GPVG, which are both part of 
collagen 1, to detect CLM in a non-invasive manner.
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abStraCt 
The clinical efficacy of carcinoembryonic antigen (CEA) as a marker of colorectal liver 
metastasis is limited, motivating a search for new biomarkers. Recently, urine proteomic 
analysis revealed AGPP(-OH)GEAGKP(-OH)GEQGVP(-OH)GDLGAP(-OH)GP (AGP), a 
promising peptide for this application. This study aimed to determine whether combin-
ing urine AGP testing with serum CEA analyses improves the sensitivity of detecting 
colorectal liver metastases. Urine samples from 100 patients with CLM were collected 
prospectively and compared to three control groups: healthy kidney donors, patients 
who were relapse-free for 24 months after curative CLM surgery, and primary colorectal 
cancer patients. A stable isotope labeled peptide standard was used to quantify the 
abundance of AGP in urine samples by selective reaction monitoring. Combined testing 
of urine AGP levels and serum CEA levels revealed a significantly increased sensitivity 
compared to CEA alone (85% vs. 68%, p<0.001; specificity 84% and 91%, respectively). 
No correlation was found between CEA and AGP-positive test results within individual 
patients (r2 = 0.08). Urine AGP testing was negative in the three control groups. These 
results indicate that collagen-derived urine AGP peptide with a specific hydroxylation 
pattern combined with serum CEA levels may significantly improve the detection of 
colorectal liver metastases in patients at risk. 
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introDuCtion 
Colorectal cancer (CRC) represents one of the most common malignant diseases, with 
1.2 million new cases a year worldwide1. Even after curative surgical resection of the 
primary tumor, 25–40% of CRC patients will develop colorectal liver metastases (CLM)2-5. 
Follow-up aims to detect metastases at an early stage, offering additional treatment 
and survival benefit6. Early detection of CLM leads to better results with the application 
of surgery or local ablation2. Although surgery may offer the best outcome, 80% of all 
patients with CLM are not considered candidates for resection due to advancement of 
the disease beyond curative treatment options7. Therefore, the ASCO guidelines recom-
mend an intensive follow-up every 2–3 months during the first 2 years after surgery8. 
Although follow-up protocols for patients who undergo curative resection for CRC dif-
fer worldwide, all advise ultrasound (US), computed tomography (CT), and/or carcino-
embryonic antigen (CEA) testing5. Ultrasound has a sensitivity of approximately 57% 
and a specificity of 91%. Computed tomography performs slightly better (sensitivity 
approximately 68% and specificity 96%)9. A positive CEA test has a sensitivity of ~64% 
for detecting CLM10. The low sensitivity of CEA is due to the fact that not all colorectal 
tumors and their metastases produce CEA, leading to false negatives10,11. However, CEA 
has a high specificity, as it is rarely elevated in the absence of CRC12. 
Recently, we performed urine proteome analysis and demonstrated two promising 
peptides to detect colorectal liver metastases, both being part of collagen type 1(I): 
AGPP(-OH)GEAGKP(-OH)GEQGVP(-OH)GDLGAP(-OH)GP (AGP) and KGNSGEP(-OH)
GAPGSKGDTGAKGEP(-OH)GPVG (KGN). These peptides had a sensitivity of approximately 
88% and a specificity of 88%. When AGP and KGN were combined, they had a sensitivity 
of 85% and a specificity of 92% in a discovery setting13. As AGP and KGN showed a strong 
correlation with a better performance for AGP we continued our studies with urine AGP 
analysis. 
In this study, we determined the additional value of urine AGP screening in addition to 
serum CEA levels to identify patients with CLM. 
MateriaLS anD MethoDS 
ethics Statement
The use of patient materials was approved by the medical ethics committee of Erasmus 
MC (MEC-2008-062). Written informed consent was obtained from all patients and con-
trols for our prospective observational case-control study.
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Sample vials were de-identified by numerical coding; only the people involved had 
access to patient information. 
Patient Selection
A total of 100 adult patients (age ≥18 years) with radiologically confirmed CLM who 
were planned to undergo surgical resection of metastatic liver lesion(s) (ICD 10 C18-C19) 
were prospectively selected. Patients with the primary tumor in situ or concomitant 
malignant diseases were excluded. All patients provided written informed consent. The 
diagnosis of CLM was confirmed by the pathologist in the resection specimens of all 
patients.
Three groups of control subjects were used. The first group of controls consisted 
of 100 healthy kidney donors (HKDs) who had a complete blood examination and 
abdominal CT imaging prior to donation and were considered healthy. The second 
group of controls consisted of 20 patients who underwent liver surgery for CLM and 
were relapse-free for at least 24 months (relapse-free controls, RFCs). The third group of 
controls included 18 patients with primary CRC in situ without CLM as demonstrated by 
CT –imaging (primary colorectal cancer controls, PCCs). For all patients, the diagnosis 
of CRC was confirmed by the pathologist. None of the patients received neoadjuvant 
chemotherapy or radiotherapy.
Study Design
Serum and urine samples were prospectively collected in three teaching hospitals in the 
city of Rotterdam, the Netherlands. Urine sampling was designed to mimic the clinical 
setting as much as possible. Urine was collected randomly during the day and the time 
to aliquoting and freezing the urine varied depending on the routine schedule of the 
hospital, but it was always within 4 hours of withdrawal. Clinical data were retrieved 
from (electronic) medical records, including, age, gender, body mass index (BMI), num-
ber of lesions, size of the largest lesion, and serum creatinine.
Specimen Characteristics
Midstream urine samples (50 ml) were collected from all patients and controls the day 
before surgery, or in case of the RFC group at the time of inclusion. Samples were stored 
as 10 ml aliquots in 15 ml BD Falcon tubes at -80°C within 4 hours of sample withdrawal. 
No additives were added prior to sample processing. Freeze-thaw cycles were kept 
to a minimum, with a maximum of two cycles per sample prior to sample processing. 
CEA measurements were part of the standard follow-up of patients with CRC and were 
extracted from the (electronic) patient files. 
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An additional serum sample was taken from the controls to determine serum CEA 
levels using the Elecsys CEA quantitative electrochemiluminescence immunoassay 
(Roche, Switzerland).
Chemicals
UHPLC solvents were obtained from Biosolve (Valkenswaard, the Netherlands) and all 
other chemicals from Sigma Aldrich (Zwijndrecht, the Netherlands). The stable isotope-
labeled peptide was obtained from Pepscan (Lelystad, the Netherlands). The hydrox-
ylation pattern of the stable isotope-labeled peptide on MS2 spectra was compared 
to that of AGP. Both spectra had a high overlap and similar hydroxylation pattern that 
confirmed the hydroxylation pattern of the identified human peptide (Figure 1).
Sample Preparation 
An automated sample preparation method that was cross-validated with the previous 
method published by Bröker et al. was applied (data not shown)13. Unless otherwise 
stated, samples were processed at room temperature. Prior to sample preparation the 
urine samples were thawed, first at room temperature for 1 h, and then in a 37°C water 
bath for 15 min. The samples were then vortexed for 5 s. Subsequently, 1.4 µl of a 5 
µM internal standard and 0.5 ml of urine were transferred to a 96 deep well plate. The 
Figure 1 The hydroxylation pattern of AGP was confirmed by MS2. The high resolution spectra of endog-
enous (top) and stable isotope-labeled peptides (bottom) were compared and found to be identical
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samples were frozen at -32°C, lyophilized overnight, and dissolved by adding 200 µl of 
10 M urea. Samples were shaken on a plate shaker (Eppendorf ) for 30 s at 800 rpm and 
then centrifuged for 5 min at 2500 g to precipitate insoluble particles. One hundred 
microliters of sample was transferred from each well to a 96-well plate, which was sealed 
with adhesive aluminum foil to prevent evaporation and contamination of the samples. 
The samples (40 µl) were separated on an mRP C-18 Hi-Recovery Protein Column (4.6 x 
50 mm) (Agilent, Amstelveen, the Netherlands) installed in an Ultimate 3000 (Dionex, 
Amsterdam, the Netherlands). Solvents A and B were 0.1% TFA in water and 0.1% TFA in 
acetonitrile, respectively, with a flow rate of 750 µl/min. The column was kept at a con-
stant temperature of 80°C. The gradient was started with 100% solvent A and reduced 
after 4 min in a 0.4 min step to 75% solvent A. At 6.0 min, solvent A was increased in 0.1 
min to 80% and then kept constant for 2.4 min, followed by a decrease in solvent A over 
24 s to 30%. It was then kept constant for 1.5 min. At 10.5 min, solvent A was further 
decreased over 15 s to 5%. Finally, at 13.3 min the column was equilibrated for 6.45 min 
with 100% solvent A. 
A portion of the flow was collected in a 96 deep well plate; the fractionation was 
started at 4.9 min and stopped at 6.5 min. The solvent was evaporated using a SpeedVac. 
The samples were then dissolved in 50 µl of 0.1% TFA. Each sample (5 µl) was injected 
and analyzed in a nanoAcquity Xevo-TQS mass spectrometer (Waters, Milford, Massa-
chusetts, USA). The samples were measured in a randomized order. Urine AGP levels 
were expressed as the analyte/internal standard (IS) ratio. 
Quantitative Mass Spectrometry
The liquid chromatography and mass spectrometry settings were similar to those pub-
lished by Bröker et al.13.
A selective reaction monitoring (SRM) method was developed and optimized on a 
Waters nanoAcquity Ultra Performance LC connected online to a Xevo TQS mass spec-
trometer (Waters, Milford, Massachusetts, USA). The sample was trapped on a Symmetry 
C18 nanoAcquity column (5 mm × 180 µm × 20 mm) (Waters, Milford,  Massachusetts, 
USA) for 5 min and washed with a solution of 99% A and 1% B (solvent A, 0.1% formic 
acid in water; solvent B, 0.1% formic acid in acetonitrile) at a flow rate of 8.00 ml/min, 
followed by separation on an Acclaim PepMap100 C18 3 µm column (75 µm × 150 mm) 
at a flow rate of 0.3 ml/min and gradient starting with 98.5% solvent A reduced over 30 
min to 60%. In 0.10 min it was further decreased to 20% solvent A and kept constant 
for 5 min, followed by an increase over 0.10 min to 98.5% and kept constant for 20 min. 
Ions were produced by a Z-spray nanoflow source under atmospheric pressure using a 
capillary voltage of 3.00 kV, cone voltage of 50 V, and a source offset of 50 V. The source 
temperature was maintained at 70°C. For AGP and the stable isotope-labeled peptide, 
three transitions with different collision energies were chosen (Table 1). Fragmentation 
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was induced by collision dissociation with argon gas inserted with a flow rate of 0.15 
ml/min. The following parameters were taken into account for the selection of AGP for 
the final quantitative assay: no interference in SRM transitions, co-elution of the peptide 
and IS, linearity of response in measured concentration range, symmetry of peak shape, 
and a signal intensity at least 10-times the average observed background. A chromato-
gram of a sample with the lowest AGP level (ratio = 0.170) is shown in Fig. 2a; peaks are 
measured properly with a high signal to noise ratio and a symmetrical peak shape. The 
selected transitions were relatively free of interference.
Power Calculation
In a previous pilot study we demonstrated a sensitivity of 85% and specificity of 92% for 
the combination of two collagen urine peptides, AGP and KGN, in urine13. With the avail-
ability of urine samples from 100 patients with CLM followed over a 3-year period, the 
95% confidence interval (CI) and estimated the sensitivity and specificity was calculated. 
The CIs for the estimated sensitivity and specificity of 70, 80, and 90% were 60–79%, 
71–87%, and 82–95%, respectively. We judged these CIs to be sufficiently small and used 
a control group of 100 normal subjects (healthy living kidney donors; HKDs).
Quality Controls 
One quality control (QC) was inserted per row of the 96-well plates. A total of 18 QC 
samples were measured with an average ratio of 0.232 and 14.6% CV. The QC AGP level 
was in the lower region of the measured concentrations, which are generally more re-
ceptive to variation; therefore, the CV indicated good reproducibility.
table 1: The three transitions and collision energies used for detection of AGP and corresponding stable 
isotope-labeled internal standard. *, stable isotope-labeled lysine (K) (+8Da).
Peptide Parent mass 
(m/z)
Fragment 
(m/z)
Collision energy 
(v)
AGP P(-OH)GEAGK P(-OH)
GEQGV P(-OH)GDL (z=+2)
1088.51 527.28 (y6) 37
812.38 (y9) 33
1364.64 (b15) 33
AGP P(-OH)GEAGK* 
P(-OH)GEQGV P(-OH)
GDL(z=+2)
1092.52 527.28 (y6) 37
812.38 (y9) 33
1372.66  (b15) 33
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Statistical analysis 
The peak analysis was performed using Skyline v1.4.0.4421 (MacCoss Lab, University 
of Washington, WA, USA). Skyline is an open source, freely available application which 
can be used to refine targeted methods for large-scale quantative mass spectrometry 
studies in life sciences. Next, ROC-curves were used to generate cut-off values and to 
determine sensitivity and specifity. These analyses were performed using Microsoft 
Excel 2007 (Redmond, WA, USA) and GraphPad Prism v5.00 (GraphPad Software, San 
Diego, CA, USA). 
Differences in the basic patient characteristics and treatment outcomes were assessed 
using the unpaired t-test and c2 test. Correlations between markers were assessed using 
the Pearson correlation coefficient. A p-value < 0.05 was considered significant. Missing 
data were supplemented using multiple imputation14. The basic characteristics were 
analyzed using SPSS (Version 21.0. Armonk, NY: IBM Corp.).
To investigate the capabilities of CEA and AGP to discriminate between controls and pa-
tients with CLM the distinctiveness of serum CEA and urine AGP levels were investigated 
separately (Figure 2a and b). 
Figure 2a en b Distribution of data points based on a) the urine AGP ratios and b) serum CEA levels. AGP cut-
off = 1.223, CEA cut-off = 5 µg/L. HKD = healthy kidney donors; RFC = relapse-free controls; PCC=primary 
colorectal cancer controls.
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Next, a multivariate logistic regression analysis was performed. Potential non-linear 
effects of CEA and AGP in the log odds of having CLM were looked for using restricted 
cubic splines with three internal knots. The p-values for non-linearities were calculated 
based on the Wald test. In a second stage, the discriminative ability of the fitted model 
quantified by the RN2 index of NagelKerke and Somers’ Dxy rank correlation between 
predicted probabilities and observed responses (in other words, the model’s ability to 
distinguish patients with CLM from controls) was investigated15. For both measures, val-
ues close to one indicate good predictive performance16. These measures were validated 
to account for possible over-fitting using the Bootstrap method taking 500 re-samples. 
Results and conclusions are based on the corrected (i.e., validated) RN2 and Dxy indexes. 
The regression analysis and model fitting were performed in the R programming lan-
guage (version 3.1.3).
Since the group sizes were unequal, the Tukey’s contrasts test was used to test for sig-
nificant differences between the four groups. Tukey’s contrasts test was also performed 
in the R programming language (version 3.1.3.).
reSuLtS 
basic Characteristics
The basic characteristics of both patients and controls are presented in Table 2. The me-
dian age and percentage of males was significantly different between the four groups 
(both p<0.001). No difference in BMI was found between the groups (p=0.541). The 
median number of liver lesions was 2 (IQR 1–4), with a median diameter of 2 cm (IQR 
1.8–4.0 cm). The serum creatinine level was > 115 µmol/L for several subjects (CLM n=4, 
HKD n=0, RFC n=2, PCC n=1), indicating impaired renal function. 
table 2: Basic characteristics of patients with colorectal liver metastases (CLM) and controls
CLM (n=98) hkD (n=100) rFC (n=20) PCC (n=18) P-value
anova
Age 64 (57-70) 52 (43-63) 72 (63-81) 73 (69-81) <0.001
Gender, male 71 (72%) 37 (37%) 11 (55%) 13 (72%) <0.001
BMI 26 (25-28) 25 (23-28) 27 (23-29) 26 (23-28) 0.541
No. of lesions 2 (1-4) - - - -
Size of largest lesion, cm 2.7 (1.8-4.0) - - - -
Serum creatinine >115 µM/L 4 (4%) 0 (0%) 2 (10%) 1 (6%) 0.062
HKD = healthy kidney donors; RFC = relapse-free controls; PCC = primary colorectal cancer controls; BMI = 
body mass index.
Data are presented as a median with the interquartile range (25th – 75th percentile) or n(%).
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Cea and agP
A relatively large proportion of patients in the CLM group (34%) had serum CEA levels 
below the cut-off value (5 ng/ml, Table 3). In the control groups, several subjects had 
elevated CEA levels (HKD n=8, RFC n=3, PCC n=6). As shown in Table 4, the serum CEA 
levels in the CLM group significantly differed from the serum CEA levels in all control 
groups individually, whereas the controls did not significantly differ from each other. 
The sensitivity and specificity was 66% (95% CI 56–76%) and 92% (95% CI 85–96%), 
respectively, when comparing the CLM and HKD groups. 
Urine AGP levels were measured in all CLM samples except for two in which no signal 
was observed. In the CLM group, 33% of the urine AGP levels were below the cut-off value 
of 1.223, which was the optimal cut-off point calculated with an ROC curve (Table 2). In the 
control groups, several subjects had elevated urine AGP levels (HKD n=27, RFC n=10, PCC 
n=6). Urine AGP levels in the CLM group significantly differed from the urine AGP levels in 
table 3: Serum CEA levels and urine AGP levels in patients with colorectal liver metastases (CLM) and con-
trols
CLM (n=98) hkD (n=100) rFC (n=20) PCC (n=18)
Serum CEA (ng/ml) 9.05 (3.90-22.93) 2.14 (1.22-3.21) 2.3 (1.48-3.38) 3.3 (2.05-9.63)
Serum CEA >5 ng/ml 65 (66%) 8 (8%) 3 (17%) 6 (33%)
Urine AGP (analyte/IS) 1.96 (1.06-3.23) 0.9 (0.53-1.44) 1.3 (0.71-1.9) 0.78 (0.56-2.04)
Urine AGP >1.223 (analyte/IS) 66 (67%) 27 (27%) 10 (50%) 6 (33%)
Mult. Var. 10.38 (1.73-158.42) 0.19 (0.08-0.47) 0.32 (0.19-0.89) 0.44 (0.12-2.93)
Mult. Var. >0.6278 83 (85%) 16 (16%) 6 (33%) 8 (44%)
HKD = healthy kidney donors; RFC = relapse-free controls; PCC = primary colorectal cancer controls; IS = 
internal standard; CEA: carcinoembryonic antigen; AGP: (AGPP(-OH)GEAGKP(-OH)GDLGAP(-OH)GP).
Urine AGP ratios were used in calculations. The lowest and highest quartile (ratio of 0.53 – 3.23) represents 
a concentration range of 7.4 – 45.2 nmol/L (16 - 98 µg/L).
Data are presented as the median with the interquartile range (25th – 75th percentile) or n(%).
table 4: Univariate and multivariate group comparisons using regression analysis
group comparison agP p-value Cea p-value Mult var p-value
CLM - CRC 0.0283 <0.001 <0.001
HKD - CRC 0.6713 0.127 0.0984
RFC - CRC 1.0000 0.572 0.798
HKD - CLM <0.001 <0.001 <0.001
RFC - CLM 0.0197 <0.001 <0.001
RFC - HKD 0.6397 0.932 0.615
CLM = colorectal liver metastasis; HKD = healthy kidney donors; RFC = relapse-free controls; PCC = primary 
colorectal cancer controls. 
P-values were calculated using Tukey’s contrasts.
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all control groups individually, but the controls did not significantly differ from each other 
(Table 3). The AGP test had a sensitivity and specificity of 68% (95% CI 58–77%) and 69% (95% 
CI 59–78%), respectively. No significant correlations were found between AGP and the size 
of the liver lesion, the number of lesions, or liver enzyme values for alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), and gamma glutamyl transferase (g-GT).
Serum CEA levels and urine AGP levels did not correlate (r2 = 0.08) and, therefore, were 
complementary. 
Multivariate Logistic regression Model
A multivariate logistic regression model was created: 
Odds of being sick = e 3.9090+1.1213 AGP + 1.622 ln(CEA) 
Based on this model, the combined value of serum CEA and urine AGP was significantly 
different for the CLM group compared to all individually tested control groups, whereas 
the combined values in the controls groups did not significantly differ (Table 3). The final 
model produced with an AUC of 0.9139 (95% CI 0.8745-0.9532) resulted in a sensitivity 
of 85% (95% CI 76-91%) and specificity of 84% (95% CI 75-91%) with a corresponding 
optimal cut-off value of 0.6278 (Figure 3).
Figure 3 Distribution of data points based on 
the final multivariate regression analysis com-
bining serum CEA and urine AGP levels. HKD = 
healthy kidney donors; RFC = relapse-free controls; 
PCC=primary colorectal cancer controls
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DiSCuSSion
The current study demonstrates that collagen-derived peptide AGP has a very specific 
hydroxylation pattern that can be reliably measured in urine using mass spectrometry. 
When combined with serum CEA levels, urine AGP demonstrates to be a promising bio-
marker with a sensitivity of 85% (95% CI 76-91%) and specificity of 84% (95% CI 75-91%). 
Clinical proteomics using mass spectrometry has yielded early and positive results in 
different diseases17. These results have the potential to detect patients with a specific 
disease but need to be confirmed in large-scale studies18. Large-scale validation is es-
sential for assessing the value of biomarkers, as large independent validation studies 
have often shown less promising results than small discovery sets17,19. Due to the cost 
and time required for prospective sample collection, preliminary results are often pre-
sented. In a small discovery study consisting of 24 patients, we reported a sensitivity and 
specificity of 88% for AGP13. In the current study with 100 patients, the sensitivity de-
creased to 68% for AGP alone. This decrease may be attributed to the increased variation 
in patients and sampling conditions, since both males and females were included, urine 
was collected randomly during the day and the time to aliquoting and freezing the urine 
varied depending on the routine schedule of the hospital. However, even with these 
more variable conditions, the sensitivity of AGP combined with CEA clearly exceeded 
that of CEA alone (85% vs. 68%), which is similar to the sensitivity of CEA combined with 
liver imaging5.
This study focused on AGP, a naturally occurring hydroxylated peptide that is part 
of collagen type α1(I)13. Collagens are the most abundant proteins in the animal king-
dom. In the human body, 80-90% of the total collagen is collagen type I, II, or III20. In 
our study, not the amino acid sequence, but more the hydroxylation pattern for AGP 
found appears to be very specific since the chance that this specification hydroxylation 
occurs at the specific positions can be estimated to be 0.00072% based on a chance 
process described by Rapaka et al 21. The location from which the AGP peptide with 
the specific hydroxylation pattern found in the urine of patients with CLM is derived 
remains unclear. However, it is tempting to suggest that it is derived from the liver, either 
from the metastasis or the metastasis surrounding tissue. One may reason that it is not 
likely that AGP originates from more central, hypoxic regions of the tumor as the lack of 
oxygen inhibits the hydroxylation of proline by prolyl 4-hydroxylase. This assumption is 
supported by the previously described decrease in hydroxylation of hypoxia-induced 
factors inhibiting degradation in hypoxic regions22 and suggests the formation of col-
lagen with a limited number of hydroxylations in hypoxic tumor regions, whereas AGP 
is fully hydroxylized. A more plausible origin may be the activity at the invasion front, 
including increased tissue remodeling and production of collagen, thus enabling tumor 
progression with enhanced production of matrix metalloproteinase (reference) and an 
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increase in urine AGP levels with a specific hydroxylation pattern, as observed in this 
study.
CEA, the standard biomarker used for CLM, is known for its high specificity. Ten sub-
jects in the control groups (7%) had serum CEA levels > 5 ng/ml. Other factors that have 
been linked to an increase in CEA include smoking, the use of paroxetine (a selective 
serotonin reuptake inhibitor, SSRI), metabolic syndrome, and alcoholic liver disease23-28. 
Of the 10 subjects, four were medium to heavy smokers (15-25 cigarettes per day), three 
used an SSRI at the time of CEA determination, one was diagnosed with metabolic 
syndrome, and one was diagnosed with alcoholic liver disease, leaving only one control 
subject with an unexplained elevation of CEA. 
From a clinical perspective, the main goal of our study was to increase the sensitivity 
of CEA to more accurately identify CLM in patients with a medical history of resected 
CRC. When comparing CEA alone and combined with the urine peptide, the sensitivity 
increased from 68% to 85% and specificity decreased from 91% to 84%.
Further research is needed to evaluate the potential of using the combined biomark-
ers to detect CLM at an earlier stage, possibly resulting in more effective interventions. 
Longitudinal sampling is expected to be of value and may improve the sensitivity, as 
an increase within one patient can be observed. More research should be performed in 
patients with CLM who have a false negative AGP. Whether these false negative patients 
are positive after multiple testing at various time points should be investigated. To 
answer these questions and to validate the added value of the AGP peptide, a large 
follow-up study should be performed in which urine AGP levels are determined in ad-
dition to the regular follow-up tests (CEA and US and/or CT). Ultimately, a test may be 
constructed in which the urine AGP test and serum CEA test are combined and routine 
imaging is needed less frequently. 
In conclusion, the collagen-derived urine AGP peptide with a very specific hydroxyl-
ation pattern can be measured reliably using mass spectrometry and may be a promis-
ing biomarker to reliably identify CLM in combination with serum CEA levels. 
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abStraCt 
background: The increased use of neoadjuvant chemotherapy and minimally invasive 
therapies for recurrence in patients with colorectal liver metastases (CLM), makes 
a surgical strategy to save as much liver volume as possible pivotal. In this study, we 
determined the difference in morbidity and mortality and the patterns of recurrence 
and survival in patients with CLM treated with anatomical (AR) and nonanatomical liver 
resection (NAR).
Methods: From January 2000 to June 2008, patients with CLM who underwent a re-
section were included and divided into two groups: patients who underwent AR and 
patients who underwent NAR. Patients who underwent simultaneous radiofrequency 
ablation in addition to surgery and patients with extrahepatic metastasis were excluded. 
Patient, tumor and treatment data as well as disease-free survival (DFS) and overall 
survival (OS) were compared.
results: Eighty-eight patients (44%) received AR and 113 patients (56%) underwent 
NAR. NAR were performed for significant smaller metastases (3cm vs. 4cm, p<0.001). 
The Clinical Risk Score did not differ between the groups. After NAR, patients received 
significantly less blood transfusions (20% vs. 36%, p=0.012) and the hospital stay was 
significantly shorter (7 vs. 8 days, p<0.001). There were no significant differences in com-
plications, positive resection margins or recurrence. For the total study group, estimated 
5-year DFS and OS was 31% and 44%, respectively, with no difference between the 
groups.
Conclusions: Our study resulted in no significant difference in morbidity, mortality, 
recurrence rate, or survival according to resection type. NAR can be used as a save pro-
cedure to preserve liver parenchyma.
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introDuCtion 
Colorectal cancer is the most common gastrointestinal malignancy worldwide, affecting 
nearly one million people each year1. Half of these patients have or will develop hepatic 
metastases at some point during their life. Liver resection is considered to be the best 
treatment for colorectal liver metastases (CLM) with 5-year survival rates up to 60% in 
highly selected patients2. Until recently, only 10-20% of patients were considered suit-
able for attempted curative resection3,4. Due to improvements in surgical techniques, 
the acceptance of resection margins smaller than 1cm5,6, the introduction of more ef-
fective systemic chemotherapeutics7,8, the use of portal vein embolisation (VPE)9,10, the 
addition of radio frequency ablation (RFA)11,12 and stereotactic body radiation (STBR)13 
to surgery, more patients are eligible for liver surgery. Moreover, the indications for liver 
resection have expanded over the past decade and there are only few limitations left, 
which include unresectable extrahepatic disease and insufficient future remnant liver. 
The question nowadays has shifted from “what can be resected” to “what will be left”.
During this period a change in surgical approach can be observed by an increase 
of non-anatomic resections14. A non-anatomical resection maximizes the amount of 
residual liver parenchyma which is important, in particular for patients who received 
neoadjuvant chemotherapy. While chemotherapy increases resectabilty, it is associated 
with hepatic changes, which might increase the risk of progressive hepatic failure and 
death after resection15,16. Moreover, in case of intra-hepatic recurrences after partial liver 
resection in patients with CLM, a sufficient liver residual can offer the opportunity for 
local treatment17.
Although anatomical hepatic resection has been reported to improve patient survival 
in hepatocellular carcinoma (HCC)18-20, the literature about CLM is conflicting.
The purpose of this study was to investigate the influence of a non-anatomical resec-
tion (NAR) compared to an anatomical resection (AR) on morbidity, mortality, margin 
positivity, disease free survival (DFS) and overall survival (OS).
MethoDS 
All patients undergoing partial hepatic resection for CLM at the Erasmus Medical Center 
from January 2000 to June 2008 were evaluated for inclusion in this study.
Patients who underwent simultaneous AR and NAR or received additional RFA in addi-
tion to surgery as well as patients with extra hepatic metastasis were excluded.
Patients were divided into two groups: patients who underwent an AR and patients 
who underwent a NAR. An AR was defined as resection of two or more hepatic seg-
ments as described by Couinaud21. This includes, bisegmentectomy, (extended) right 
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hemihepatectomy, (extended) left hemihepatectomy or a combination of these22. NAR 
was defined as resection of the CLM including a rim of microscopically normal tissue. 
The choice of resection type was made in a multidisciplinary hepatobiliary working 
group, based on tumor number, location and patient status.
Information collected included demographic details, primary tumor stage (TNM-
classification), maximum size, number and distribution of liver metastases on CT, plasma 
carcinoembryonic antigen (CEA) levels, neoadjuvant chemotherapy, Clinical Risk Score 
(CRS)23, type of liver surgery, transfusion data, overall duration of hospital stay, periop-
erative complications, radicality, site and treatment of recurrence.
OS and DFS were calculated from the date of liver resection. Complications or death 
occurring either within 30 days or before discharge were considered perioperative. 
We defined a positive surgical margin as the presence of vital tumor along the line of 
transection.
After partial hepatic resection, patients routinely underwent a physical examination 
and determination of CEA-level, abdominal/chest CT or ultrasonography every 4 months 
for the first year, every six months the second year and once a year thereafter.
Statistical analyses were conducted using SPSS (version 15, SPSS Inc., Chicago USA). 
Categorical variables are presented as number (percentage). Continuous variables are 
presented as median (range). Categorical variables were compared with the c2 test; 
continuous variables were compared with the Mann-Whitney-U test. Actuarial survival 
was calculated using the Kaplan-Meier method from the date of resection of CLM, and 
differences in survival were examined using the log-rank test. p <0.05 (two-sided) was 
considered significant.
reSuLtS 
Clinicopathological variables
Between January 2000 and June 2008, 308 patients underwent a partial hepatic resec-
tion for CLM; 201 patients met the study inclusion criteria, including 126 men (63%) 
and 75 women (37%). The median age was 65 years (range, 30-86). The primary tumor 
was located in the colon in 114 patients (57%) and rectum in 87 patients (43%). After 
resection of the initial tumor, positive lymph nodes were present in 114 patients (57%); 
synchronous liver metastases were identified in 78 patients (39%). The median disease 
free interval for the remaining 123 patients was 20 months (range, 4-193) from the time 
of resection of the colorectal tumor. The median CEA level was 16 ng/ml (range, 1-1,292) 
at the time of liver resection. In 16 patients (8%) the CEA level exceeded 200 ng/ml. 
The median number of metastases was one (range, 1-8) with a median diameter of the 
largest metastases of 3 (range, 0.5-15) cm. The Clinical Risk Score was ≥3 in 60 patients 
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(30%). Fifty-nine patients (31%) were treated with neoadjuvant chemotherapy. AR was 
performed in 88 patients and a NAR was performed in 113 patients. The clinicopatho-
logical features of the AR and NAR are compared in Table 1.
table 1: Clinicopathological variables
variable anatomical non-anatomical P-value
(n=88) (n=113)
Age 65 (30-82) 65 (36-86) 0.585
Gender (Male) 56 (64) 70 (62) 0.806
Number of tumors 2 (1-7) 1 (1-7) 0.295
Size largest tumor (cm) (a) 4 (1-15) 3 (1-7) <0.001
Bilobar distribution 20 (23) 32 (28) 0.369
CEA (b) 16,4  (1-1292) 15,9 (1-909) 0.078
>200 ng/ml 10 (12) 6 (5) 0.113
Time to resection
Synchronous 35 (40) 43 (38) 0.804
Metachronous 53 (60) 70 (62)
Disease free interval (months) 24 (4-93) 17 (4-193) 0.430
Clinical risk score (a)
1-2 57 (66) 82 (73) 0.241
3-5 30 (34) 30 (27)
Neoadjuvant chemotherapy 31 (35) 28 (25) 0.107
Site primary tumor
Colon 55 (63) 59 (52) 0.144
Rectum 33 (37) 54 (48)
Tumor stage primary tumor
0-2 12 (14) 23 (20) 0.213
3-4 76 (86) 90 (80)
Lymph node primary tumor
Positive 45 (51) 69 (61) 0.159
Negative 43 (49) 44 (39)
Missings: a = 2, B = 4
Data are numbers with percentages in parentheses or medians with ranges in parentheses unless other-
wise indicated
Surgical treatment
A single NAR was performed in 69 of the patients (61%), while 44 (39%) had two or more 
NAR simultaneously. A right hemihepatectomy was the most frequently performed AR 
(47 resections, 43%) followed by left hemihepatectomy (15 resections, 14%). Bisegmen-
tectomies were performed in 18 patients (21%). (Table 2)
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table 2: Type of resection
Liver resection no. of resections
n= 201 (%)
Nonanatomic (n=113)  
Single 69 61
Two 25 22
Three 13 12
Four 4 3
Five 2 2
Anatomical (n=88)
S 2-3 12 14
S 6-7 6 7
Right hemihepatecomy 47 53
Left hemihepatectomy 15 17
Extended right hemihepatectomy 4 5
Extended left hemihepatectomy 1 1
Combination of anatomical resectionsa 3 3
S segment
a seg 2-3 + seg 1 resection, seg 2-3 + seg 6-7 resection
outcome
Table 3 presents the outcome of patients who underwent AR vs. NAR. After AR, 32 pa-
tients (36%) received a blood transfusion. This was significantly lower after a NAR (23 
patients, 20%; p=0.012). The transfused patients in the AR group received a median of 
3 units of erythrocytes (range, 1-6). In the NAR group the median transfusion rate was 
also 3 units of erythrocytes (range, 1-9), but with a larger range. The hospital stay was 
significantly shorter after NAR (7 (range, 1-26) days vs. 8 (range, 4-42) days; p <0.001). 
There was no significant difference in mortality rate between the two groups. Insuf-
table 3: Outcome surgery
variable anatomical non-anatomical P-value
(n=88) (n=113)
Blood transfusion 32 (36) 23 (20) 0.012
Hospital stay 8 (4-42) 7 (1-26) <0.001
Complications 24 (27) 26 (23) 0.488
In-hospital mortality 2 (2) 1 (1) 0.421
Positive resection margins 8 (9) 12 (11) 0.728
Data are numbers with percentages in parentheses or medians with ranges in parentheses unless other-
wise indicated
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fi cient capacity of the liver remnant was the cause of death in the two patients in the 
AR group. One patient in the NAR group died due to aspiration pneumonia. The median 
follow-up was 35 (range, 1-111) months in both groups. With respect to the median 
time to recurrence, the groups were comparable (AR group 9 (range, 1-46) months vs. 
10 (range, 2-55) months in the NAR group; p= 0.802).  The DFS was similar for the AR 
and NAR group, 56%, 38%, 30% and 60%, 39%, 32% at 1, 3, and 5 years respectively (p= 
0.441, p= 0.81, p= 0.599) (Figure 1). The pattern of recurrence did not diff er between the 
two groups (Table 4). The 3-year intra hepatic recurrence rate was 37% in the AR group 
and 33% in the NAR group (p=0.620). Seventeen patients in AR group and 26 patients in 
the NAR group developed liver metastases limited to the liver. These patients received 
similar therapy (Table 4). The OS was 96%, 61%, 49% for the AR group and 97%, 65%, 
39% for the NAR group at 1, 3, and 5 years, respectively (p= 0.715, P= 0.611, p= 0.989; 
Figure 2)
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Figure 1 Disease free survival stratifi ed by surgical procedure. Median DFS was 16.7 months in the AR group 
and 18.7 months in the NAR group. The 5-year DFS rate was 30% and 32%, respectively (p= 0.599)
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table 4: Patterns of recurrence and treatment modality
anatomical non-anatomical P-value
(n=88) (n=113)
Location recurrence
Liver 17 (30) 26 (38) 0.156
Liver + Lung 10 (18) 4 (6)
Liver + elsewhere 2 (2) 5 (7)
Elsewhere 28 (49) 34 (49)
Therapy Liver Metastases
No therapy 1 (6) 2 (8) 0.398
Systemic therapy 9 (53) 8 (32)
Local therapy 7 (41) 15(60)
- Resection 3 10
- RFA 2 3
- STBR 1 2
-Liver perfusion 1 0
RFA= radio frequency ablation, STBR= stereotactic body radiation
Data are numbers with percentages in parentheses or medians with ranges in parentheses unless other-
wise indicated	
No. at risk  AR            88  84             61              41             24             14  
       NAR        113            109           81              52             27             14      
60 48 36 24 12 0 
100 
80 
60 
40 
20 
0 
Follow-up (months) 
O
S
 (
%
) 
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Figure 2 Overall Survival stratifi ed by surgical procedure. Median OS was 49 months in the AR group and 
47.2 months in the NAR group. The 5-year OS rate was 49% and 39%, respectively (p= 0.989)
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DiSCuSSion 
This study demonstrates no significant difference in outcome between patients with 
CLM anatomical or NAR. The 5-year disease free (AR 30% vs. NAR 32%) and OSs (AR 49% 
vs. NAR 39%) in our study is consistent with the literature2,24-28.
The major drawback is the retrospective nature of this study. Randomization would be 
difficult in this patient group, because the technique for liver resection is a tailor-made 
approach based on the size, number, location and distribution of the metastases. In ad-
dition, the consideration between conservation of liver parenchyma, complete surgical 
tumor clearance and complications is of importance in this decision. Although patients 
were not randomized the basic characteristics were similar as shown in Table 1.
Liver parenchymal-sparing surgery is already frequently used for CLM for several 
reasons. Functional hepatic reserve must be considered for any liver resection, its signifi-
cance increases in the context of neoadjuvant chemotherapy, which is used to downsize 
the tumor load, making more patients eligible for surgery29. However, although che-
motherapy increases resectability, it is associated with significant hepatic changes such 
as hepatic sinusoidal obstruction, periportal inflammation and steatohepatitis, which 
can affect patient outcome15. Specifically, chemotherapy-associated steatohepatitis is 
associated with the risk of progressive hepatic failure and death after resection16. There-
fore, maximizing the amount of residual liver parenchyma is of considerable importance 
in patients who have had chemotherapy.Moreover, surgical stress can be reduced by 
non-anatomical resections, which may affect perioperative morbidity and mortality14,25. 
Several studies reported significant shorter operating times and significant less blood 
loss after NAR25,26,28.  This is also seen is our study population. Patients who underwent an 
AR received significant more blood transfusions than the patients after a NAR. (AR 36% 
vs. NAR 20%, p= 0.012). In our series, there were three deaths within 30 days of surgery: 
two in the AR group and one in the NAR, which was not significantly different. There are 
studies suggesting more postoperative deaths in the AR group2,25,26,28. It is important to 
note that postoperative mortality is a rare event and that these studies are not powered 
to compare this.
The possibility to treat recurrent CLM with local therapy, such as repeated hepatecto-
my17, RFA11 or STBR30 is a great benefit of the parenchymal sparing method. In our study, 
disease recurrence in the liver was similar for both AR and NAR (51%). The re-intervention 
rate for CLM was higher in the NAR group (AR  41% vs. NAR  60%) Although this number 
does not reach significance, probably due to the small numbers, our findings suggest 
that local treatment for intra-hepatic recurrences is more often possible in the parenchy-
mal sparing method. Our findings are consisted with the literature which states that re-
interventions for CLM increases the survival after disease recurrence31-33.  For this reason 
close surveillance of patients after NAR is essential. One of the possible disadvantages 
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of NAR  reported in the literature by DeMatteo et al. is the higher incidence of positive 
resection margins24.  In more recently published literature, it is advocated that a resec-
tion margins  <1 cm is no longer a contra-indication for a curative resection. Moreover, 
recent literature suggests that size of surgical margin does not correlate significantly 
with DFS or OS; even the need for R0 resections is being discussed34,35. In a study by de 
Haas et al. the 5 year overall survival was similar for patients after a R0 or a R1 resection 
(61% vs. 57%; p = 0.27) although the recurrence was  higher in the R1 group (28% vs. 
17%; p = 0.004)6.  In our study the R1 resection rate was 9% in the AR group and 11% 
in the NAR group, which is comparable to the literature6,27. The concept of performing 
limited NAR with narrow margins is supported by the fact that micro metastases in the 
liver parenchyma surrounding CLM are rare and are primarily confined to the immediate 
surrounding area of the tumor border36,37.
The second possible drawback of NAR which is postulated in the literature24 is the lack 
of vascular control. This is the opposite of what is published in the past years. Blood loss 
and blood transfusions are reported to be significant less during and after NAR, which is 
also confirmed by our results25,26,28.
In contrast to CLM, some studies report AR to be superior NAR in HCC18-20. This dif-
ference may be explained by the variation in disease biology seen in primary versus 
metastatic liver tumors. Metastatic liver lesions develop from blood-borne tumor cells 
circulating throughout the body. AR may not offer the same advantage for these lesions 
as for HCC, which arise within a segment of the liver and might benefit from the removal 
of the complete functional liver unit.
Multiple studies have been conducted to investigate which resection is favorable for 
patients with CLM: anatomical or a nonanatomical. Most authors similarly conclude that 
there is no significant difference between AR and NAR in DFSs an OSs. A disadvantage 
of the majority of studies is that the patient characteristics are not comparable between 
the two groups regarding tumor size and number, nodal status of the primary tumor, 
disease free interval and CEA blood levels2,14,25,26. Our study contributes to this discussion 
due to the use of the Clinical Risk Score (CRS) in which the previous described character-
istics are incorporated. The CRS is the same for the AR and NAR which indicates that the 
groups are comparable.
Furthermore the use of different neoadjuvant chemotherapy regimens over the years 
makes it difficult to compare the results of the studies2,14,26-28. We started our patient 
selection after 2000, because Irinotecan and Oxaliplatin were added to the chemothera-
peutic arsenal from this year and all patients were treated with effective chemothera-
peutics.
We conclude that with a comparable complication rate, less blood transfusions, a sig-
nificantly shorter hospital and comparable DFS and OS rates, a NAR is a save technique 
for the resection of CLM.
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introDuCtion 
Jiao et al. studied the presence of circulating tumor cells (CTCs) in blood of patients with 
colorectal liver metastases (CRLM) by automated immunomagnetic enrichment and 
image cytometry using the CellSearch system (Veridex, Raritan,NJ)1. They showed CTCs 
to be present in the hepatic macrocirculation in significantly higher numbers than in the 
peripheral circulation (median 187, (range, 0-500) vs. median 1, (range, 0-6)). Despite 
the number of evaluated patients in this study being small, the low number of detected 
CTCs in the peripheral circulation suggest that CTC enumeration and characterization 
plays no role in this specific patient population. 
Enumeration and in particular characterization of CTC holds great promise for patient 
management and research purposes2.  Of several assays enabling CTC detection (re-
viewed by Mosterd et al.3), the CellSearch system has been approved by the US Food 
and Drug Administration for use in metastatic breast, prostate and colorectal cancer. 
According to the manufacturer’s instructions, CTC enumeration should be performed 
in 7.5 ml blood. In the first study of 196 patients with metastatic colorectal cancer 
whose CTCs were measured with the CellSearch system. At least 2 CTCs per 7.5ml blood 
were detected in 30% of patients, whereas only 17% had ≥ 5 CTCs per 7.5 ml blood4. 
In a subsequent publication by Cohen et al. investigating the prognostic role of CTCs 
in advanced colorectal cancer, patients with a CTC count above a threshold of 3 CTCs 
per 7.5ml blood had a worse outcome after systemic therapy compared with patients 
with lower CTC counts. The 430 patients in this study received first-, second- or third-
line chemotherapy, of whom 26% had a CTC count ≥ 3 CTC threshold, whereas 48% of 
the patients had ≥ 1 CTC per 7.5ml blood5. In a third study in 451 metastatic colorectal 
cancer patients, at least 3 CTCs per 7.5 ml blood were detected in 29% of the patients6. 
From these studies we can conclude that the number of detectable CTCs in patients with 
advanced colorectal cancer using the CellSearch System is low to even below detection 
limit, which is in contrast to other tumor types. In metastatic breast and prostate cancer, 
the percentage of patients with a CTC count of ≥5 CTCs per 7.5ml was 66% and 49%, 
respectively7,8. Not surprisingly and in line with the findings of Jiao et al., in nonmetasta-
stic colorectal cancer, the number of patients with detectable CTCs is even lower than in 
advanced disease1. One study revealed ≥ 2 CTCs/7.5 ml in two of 11 patients9, whereas 
in another study CTCs could be identified in only two of 31 patients10.
The inability to detect CTCs in more patients with cancer with the currently available 
methods can have several causes. CTC detection could be limited by technical difficulties, 
such as the absence of marker expression required for CTC detection11, but could also be 
a true reflection of the CTC frequency. The low number of detected CTCs in patients with 
colorectal liver metastases (CLM) compared with overt metastatic disease prompted us 
98
to explore whether analyzing a larger blood volume would improve CellSearch-based 
CTC detection in patients with CLM.
PatientS anD MethoDS 
In 15 patients undergoing liver resection and/or open radio frequency ablation, we 
obtained, before operation, 40 ml blood from a peripheral arterial line. Blood was col-
lected in 10 ml evacuated tubes (CellSave tubes; Veridex) and pooled, stored at room 
temperature and processed within 72 hours of collection according to the standard 
operating procedure4. 
For each patient we compared the number of detected CTCs in 7,5 ml blood to the 
number found in 30 ml blood. We performed a modified Ficoll density gradient separa-
tion to reduce the 30 ml blood to a volume of 7,5 ml enriched blood12.
In short, samples were processed on the semi-automated CellTracks AutoPrep System 
using the CellSearch Epithelial Cell Kit (both Veridex LLC). To immunomagnetically en-
rich epithelial cells from whole blood, magnetic beads coated with anti-epithelial-cell 
adhesion molecule were used. The remaining cells are then stained with the nuclear dye 
4’,6-diamidino-2-phenylindole (DAPI), anti-cytokeratin (CK) 8/18/19 antibodies labelled 
with phyco-erythrin (PE), and anti-CD45 antibodies labelled with allophycocyanin 
(APC). The samples are transferred to a Magnest Cell Presentation Device (Veridex LLC), 
where the cells are scanned by the CellSpotter Analyzer (a four-color semi-automated 
fluorescence microscope). Cell images were evaluated by skilled readers and all cells 
fulfilling all criteria for a CTC - size of ≥4µm, round to oval morphology, positive staining 
for CK-8/18/19, a visible nucleus (DAPI positive), at least 50% overlap between nucleus 
and cytoplasm, and negative staining for CD45- were selected.   
The statistical analyses were carried out using the statistical software package SPSS 
(version 15, SPSS Inc., Chicago USA). Continuous variables are presented as median 
(range). Categorical variables are presented as number (percentage). For comparison of 
continuous data, the independent sample t-test was used. In all analyses the significance 
level was set at p<0.05. 
reSuLtS 
In 7.5 ml blood, the median number of CTCs was 1 (range, 0-4). In 30 ml blood, the 
median number of CTCs was significantly higher (median 2 CTCs; range, 0-9; p = 0.03). 
The median paired CTC difference between 7,5 ml and 30 ml blood was 1 (range, -1 to 7). 
The median CTCs and range of the 7,5 ml, 30 ml samples and the paired difference are 
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shown in figure 1. Analyzing 7,5 ml blood ≥1 CTC was found in 10 patients (67%) and ≥3 
CTCs were found in two patients (13%). In 30 ml blood, ≥1 and ≥3 CTCs were detectable 
in 13 (87%) and seven patients (47%), respectively (figure 2). 
Figure 1  The distribution of the CTC 
counts is shown of the 7,5 ml, 30 ml blood 
samples and paired difference. The hori-
zontal lines across the samples depict the 
median and interquartile range.
Figure 2 Depicted are the categorical 
data of the CTC enumeration in the 7,5 ml 
and 30 ml blood samples.
DiSCuSSion 
In this study we demonstrate that significantly more CTC’s can be recovered in 30ml 
blood compared to 7,5ml blood using an enrichment step, prior to enumeration with 
the CellSearch System in patients with CLM. 
The CellSearch system samples 7.5ml volume of blood, which represents ~0.15% of 
the total blood volume in an average patient. The sensitivity of the Cell Search system is 
thus limited by both statistical considerations and the blood volume that can be tested. 
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Knowing that CTC’s have been observed in the peripheral blood of cancer patients at 
very low concentrations of 10-7- 10-8 of normal peripheral blood cells13, enlarging blood 
volume and adding an enrichment step in the sample preparation is only a logical tactic. 
Ficoll density gradient separation is a commonly used method and reported on since 
the sixties14. This technique is easy applicable, can be used for all tumor types and is 
inexpensive. One of the major advantages is that cells are undamaged after Ficoll den-
sity gradient separation and the nucleus is intact15. Especially in combination with the 
CellSearch system this is of great importance; the images captured by the CellSpotter 
Analyzer, are judged for CTC criteria, including size (≥4µm), morphology (round to oval) 
and visible nucleus presence. 
In our study we did not perform repeated measurement as this Ficoll enrichment 
technique in combination with the Cell Search was previously tested and presented by 
Gross et al.12 . 
The number of CTCs in CRC is relatively low, particularly when compared to breast 
and prostate cancer1,4,5,9,10.  This difference can be explained by tumor biology. Breast 
cancer has been well described as a systemic disease from diagnosis, even in patients 
with localized tumors, micrometastases can be visualized in the bone marrow using 
immunohistochemistry techniques16. Prostate cancer has a similar biology, 25% of men 
with clinically localized disease have micometastases in bone marrow17. Both of these 
diseases are often accompanied by hematogenous metastases to the bone. In CRC the 
most frequent site of metastases is the liver via portal vein drainage. This concept is 
supported by data of Jiao et al.1, who find higher numbers of CTCs in the portosystemic 
circulation than in peripheral blood. The low number of CTCs is also seen in other gas-
trointestinal malignancies, such as gastric and esophageal cancer, probably caused by 
filtration of these cells by the portal circulation9.
Another explanation for the small amount of retrieved CTCs in CRC could be the 
dependence of the Cellsearch System on antibodies to EpCAM. EpCAM, short for 
epithelial cell adhesion molecule, is expressed on the surface of epithelial cells. It has 
been reported that tumor cells that have gained entry to the bloodstream can undergo 
epithelial-mesenchymal transition (EMT). In this process tumor cells lose their epithelial 
traits including cell-cell adhesion, apical-basal polarity, and lack of motility and acquire 
mesenchymal properties such as motility, invasiveness, and a resistance to apoptosis18. 
With the loss of cell-cell adhesion, epithelial cell adhesion molecules such as EpCAM 
are down regulated19. In a study by Rao et al. the EpCAM expression was 10-fold less 
in CTCs compared to primary and metastatic tissues20. By using EpCAM antibodies, the 
CellSearch System is unable to detect the EMT positive CTCs and can give an underesti-
mation of CTCs.  
Though this study is based on a relatively small number of patients, it shows that 
more CTCs can be detected in CRLM patients when using 30 ml instead of 7.5 ml pe-
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ripheral blood. This more frequent CTC detection renders it worthwhile to explore CTC 
enumeration as a prognostic factor in this patient population. In addition, detection of 
CTCs in the majority of patients with CLRM may allow for more widespread molecular 
CTC characterization. Characterization is already possible using a single CTC and might 
contribute to additional individualization of patient management21. We believe that 
future clinical studies in CRLM patients should be performed using 30 ml blood, thereby 
making the potential benefits of CTC detection and characterization available for more 
patients.
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abStraCt 
background: Despite good outcomes for many, a substantial group of patients un-
dergoing metastasectomy for isolated liver metastases from colorectal cancer (CRC) 
experience early recurrence. We have investigated whether circulating tumor cell (CTC) 
detection can identify patients developing disease recurrence within 1 year after liver 
metastasectomy.  
Methods: In CRC patients undergoing liver metastasectomy, 30ml peripheral blood was 
withdrawn preoperatively. CTCs were detected by the CellSearch system after a density 
gradient-based enrichment step.
results: 173 samples from 151 individual patients were analyzed. In 75 samples (43%), 
CTCs were detected, 16% had ≥3 CTCs/7.5ml of blood. Eighty-two patients (47%) expe-
rienced early disease recurrence (<1 year). The 1-year recurrence rate between patients 
with or without detectable CTCs were similar (47% vs. 48%) or with a low or high CTC 
count (<3 or ≥3 CTCs/7.5 ml of blood) (50% vs. 47%). Also disease-free and overall sur-
vival were similar between patients with or without CTCs. 
Conclusion: The presence of CTCs in preoperative peripheral blood samples does not 
identify patients at risk for early disease recurrence after curative resection of colorectal 
liver metastases. Other parameters are needed to better identify patients at high risk to 
relapse after liver metastasectomy for CRC.
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introDuCtion 
In Western countries, colorectal cancer (CRC) represents one of the most common malig-
nant diseases and forms a substantial cause of death, frequently due to liver metastases. 
For patients presenting with isolated colorectal liver metastases (CLM) and disease ame-
nable for complete resection, liver metastasectomy is a potentially curative approach 
yielding 5-year survival rates, of up to 60% in highly selected patients1,2.  The indications 
for liver resection have expanded over the past decade due to improvements in surgical 
techniques, the introduction of more effective systemic chemotherapy and the use of 
portal vein embolization, radio frequency ablation and stereotactic radiation. And in 
carefully selected patients, extra-hepatic disease is even no longer a contra-indication 
for local therapies.3-9. 
However, despite the good outcomes for many patients undergoing this procedure, 
there is still a substantial group of patients encountering early recurrence. In a retrospec-
tive analysis performed in our center, the 1-year recurrence rate of CLM after liver resec-
tion was almost 50%10. Obviously, the identification of patients at high risk of disease 
recurrence after surgery for resectable CLM might lead to better selection of patients 
for this procedure. These patients should either be spared a potentially futile surgery or, 
their condition permitting, additional and more intensified therapy should be explored 
to minimize the risk of early relapse.
Circulating tumor cells (CTCs) are cells present in the peripheral circulation of the ma-
jority of metastatic cancer patients. Several techniques are currently available for their 
measurement, but of these, only the CellSearch technique (Veridex LLC, Raritan, NJ) has 
been approved for use as a prognostic marker in metastatic breast, prostate and CRC 
by the US Food and Drug Administration. Using this method, the presence of CTCs in 
peripheral blood of patients has strong prognostic value in various malignancies includ-
ing metastatic CRC11-15. Most studies on the prognostic value of CTCs in metastatic CRC 
include patients with irresectable disease treated with chemotherapy14,16,17. However, 
concerning patients with isolated CLM undergoing liver metastasectomy, little is known 
about the possible prognostic value for CTCs. 
The objective of this study was to evaluate whether the detection of CTCs by the 
CellSearch System can identify patients with resectable CLM undergoing liver metasta-
sectomy who will develop disease recurrence within 1 year after surgery.
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MethoDS 
Patients
Patients over 18 years of age with an adenocarcinoma of the colon or rectum with 
metastases confined to the liver confirmed by computed tomography (CT) scan or mag-
netic resonance imaging (MRI)) and eligible for liver resection or “open” radio frequency 
ablation therapy (RFA) were included. Patients were excluded if complete resection of 
the liver metastases was not possible in one procedure, the primary tumor was in situ 
(liver-first approach or synchronous resection of primary tumor and liver metastasis), 
extrahepatic metastasis, histological examination of the liver specimen showed no 
CLM, or follow-up after resection was <1 year. Ours is a referral hospital; preoperative 
chemotherapy is not administered as a standard treatment protocol for patients with 
resectable CLM according to the Dutch Guidelines. Most of our patients have already 
received neoadjuvant chemotherapy in the referring hospital. In our center, the indica-
tion for neoadjuvant chemotherapy is  two-fold:  in case of initially difficult/unresect-
able liver metastases, or in case of multiple (>4) synchronous metastases. None of the 
included patients received adjuvant chemotherapy after the curative liver resection. 
Clinical data were collected from the medical records and included demographic details, 
maximum size, number and distribution of liver metastases on CT scan or MRI, plasma 
carcinoembryonic antigen (CEA) levels, pre-operative chemotherapy (chemotherapy 
administration within 6 months prior to resection), Fong Clinical Risk Score (CRS)18, loca-
tion and pathological TNM stage of the primary tumor. 
This study was approved by the Ethical Board of the Erasmus MC (METC 2006-089) and 
all patients gave their written informed consent.
blood sample analyses
Thirty ml of blood was drawn from the peripheral arterial line directly preoperatively, 
before manipulation of the tumor, by the anaesthesiologist in “CellSave” tubes (Veridex 
LLC). Samples were stored at room temperature and analyzed within 96 hours after 
collection. The three blood tubes were pooled and then reduced to a volume of 7.5ml 
by Ficoll density-gradient separation as previously described19,20. CTCs were enumer-
ated using the CellSearch System according to the manufacturer’s instructions21. Briefly, 
samples were processed on the semi-automated CellTracks AutoPrep System using the 
CellSearch Epithelial Cell Kit (both Veridex LLC), which contains magnetic beads coated 
with anti-epithelial-cell adhesion molecule (EpCAM) antibodies to immunomagnetically 
enrich epithelial cells from whole blood. Remaining cells are then stained with the nu-
clear dye 4’,6-diamidino-2-phenylindole (DAPI), anti-cytokeratin (CK) 8/18/19 antibodies 
labelled with phyco-erythrin (PE), and anti-CD45 antibodies labelled with allophyco-
cyanin. After transferral of the sample to a Magnest Cell Presentation Device (Veridex 
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LLC), the cells are scanned by the CellSpotter Analyzer, a four-color semi-automated 
fluorescence microscope. Presented images were assessed by trained readers and all 
cells fulfilling all criteria for a CTC - size of ≥4µm, round to oval morphology, positive 
staining for CK-8/18/19, a visible nucleus (DAPI positive), at least 50% overlap between 
nucleus and cytoplasm, and negative staining for CD45- were selected.   
Follow-up
After hepatic resection, patients routinely underwent a physical examination and deter-
mination of CEA-level, abdominal/chest CT or ultrasonography every 4 months for the 
first year, every 6 months the second year and once a year thereafter.
Statistical analysis
The primary endpoint of this study is disease recurrence within 1 year after hepatic 
resection for CLM. In a pilot study, 50% of a patient group with characteristics similar 
to the population studied here tested positive for the presence of CTCs20. To detect a 
20% difference in 1-year recurrence rate between patients with detectable CTCs vs those 
without detectable CTCs with a power of 80% and a significance level of 5%, knowing 
that the overall 1-year recurrence rate is approximately 50%, 200 patients had to be 
included.
We use the presence of CTCs (≥1 CTC) as well as high CTC count (≥3 CTCs) as a cut-off 
points for analyses in line with Allard et al. and Gazzaniga et al.21,22. Categorical data were 
described as counts with percentages between brackets and continuous data as median 
with the range between brackets. The c2-test was used to compare categorical data, for 
continuous date the independent sample t-test and if data were not equally distributed 
the Mann-Withney U-test  was used. Disease free survival (DFS) was defined as the in-
terval elapsing between the day of surgery to the day of recurrence, death or censoring 
at most recent follow-up. Overall survival (OS) was the time between the day of surgery 
and the day of death or censoring at most recent follow-up. Survival analyses (DFS and 
OS) were executed following the Kaplan-Meier method and comparisons were made 
using the log rank test. A linear regression model was used to evaluate the association 
between CTC count and the time interval from the last dose of chemotherapy until 
the operation. In all analyses the significance level was set at P<0.05. All the statistical 
analyses were two-sided and carried out using the statistical software package SPSS 
(IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY, 
USA)
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Patients
Blood was drawn from all patients (included in the METC 2006-089 trail) undergoing a 
liver metastasectomy for isolated CLM, between 1 June 2008 and 31 May 2012. Out of 
the in total 343 blood samples from 289 individual patients collected, 170 samples were 
excluded (Figure 1). After applying these exclusion criteria, 173 blood sample of 151 
individual patients were left for evaluation. Twenty-two patients underwent a second 
liver resection for recurrent disease confined to the liver following the first resection. 
Also these samples were included and were considered as separate cases. Patients were 
divided into two groups according to disease recurrence <1 year (n=82) and disease 
recurrence ≥1 year or no recurrence (n=91) following hepatic surgery (Table 1). There is 
a significant difference between the groups in the number of metastases (2 (range, 1-10) 
vs. 1 (range, 1-8) p=0.04), as well as the ratio between synchronous, metachronous and 
recurrent liver metastases, with higher percentages of metachronous metastases in the 
group with late or no disease recurrence (42% vs. 60%, p=0.02). Also the distribution of 
the Fong CRS showed significant difference, which was, as expected, higher in the early 
recurrence group (40% score 3-5 vs. 21%, p=0.01). 
	
173 evaluable blood samples 
9 patients: lost to follow-up < 1 
year after surgery 
56 patients: primary tumor in situ 
 
 
343 blood samples 
26 patients: liver resection 
intraoperatively aborted 
43 patients: two stage procedure 
 
21 patients: extrahepatic 
metastases 
9 patients: no diagnosis of CLM 
after histological examination of 
resection specimen 
6 patients: technical failure Cell-
Search System 
Figure 1 Flow chart sample inclusion
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CtC enumeration and primary endpoint
In Table 2 the results of the CTC analyses are shown. CTCs were detected in 43% of the 
blood samples and the median number of CTCs was zero (range, 0-49) in all samples. 
With respect to the primary objective, there was no significant difference in the 1-year 
recurrence rate between patients with (≥1 CTC) or without CTCs (47% vs.48%; p=0.87). 
The 1-year recurrence rate in the group with ≥3 CTCs also showed no significant differ-
ence compared to the <3 CTC group (50% vs. 47%; p=0.76). We performed the analyses 
on a per patient basis as well (151 samples); this showed similar results (data not shown).
table 1: Basic characteristics of the study population divided by recurrence <1 year versus no recurrence 
or later than 1 year
total inclusion n=173
variable recurrence 
< 1 year
(n=82)
no recurrence or 
recurrence > 1 year
(n=91)
P-value
Age (years, median (range)) 63 (36-81) 65 (37-84) 0.26
Gender (male) 52 (63%) 59 (65%) 0.85
Liver metastases
Number of tumors (median (range) § 2 (1-10) 1 (1-8) 0.04
Size largest tumor (cm, median (range))§ 2.8 (0.2-18) 2.6 (0.2-10) 0.24
Bilobar distribution 27 (33%) 28 (31%) 0.76
Time to resection
synchronous
metachronous
recurrence
27 (33%)
34 (42%)
21 (25%)
25 (28%)
55 (60%)
11 (12%)
0.02
Clinical risk score §
0-2
3-5
46 (60%)
31 (40%)
69 (79%)
18 (21%)
<0.01
Preoperative chemotherapy 41 (50%) 39 (43%) 0.35
Primary tumor
Site primary tumor §
colon
rectum
59 (72%)
23 (28%)
66 (73%)
24 (27%)
0.84
Tumor stage primary tumor§
0-2
3-4
11 (14%)
69 (86%)
12 (13%)
78 (87%)
0.94
Lymph node primary tumor§
Positive
Negative
49 (60%)
32 (40%)
45 (50%)
45 (50%)
0.17
§ missing data
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Survival analyses
The median follow-up for all 151 patients was 28 months (range, 12-59 months), and the 
median DFS, calculated for every blood sample (n=173) was 14 months (95% CI 10.9-
17.2 months). Disease recurred in 115 cases (66%), of which 82 (47%) were within 1 year. 
There was no significant difference in DFS between patients with no or ≥1 CTCs (p=0.56) 
or between those with <3 or ≥3 CTCs (p=0.34, Figure 2a and 2b). During the follow-up 
period 40 patients (26%) died. Survival analyses showed no significant difference in OS 
between patients with no or ≥1 CTCs (P=0.96) or between those with <3 or ≥3 CTCs, 
(p=0.17, Figure 3a and 3b). 
table 2: Results CTC enumeration divided by recurrence <1 year versus no recurrence or later than 1 year 
total inclusion n=173
variable recurrence < 1 year
(n=82)
no recurrence or 
recurrence > 1 year
(n=91)
P-value
CtCs
Number (median, range) 0 (0-28) 0 (0-49) 0.70
CTCs present 35 (43%) 40 (44%) 0.87
CTCs ≥3 14 (17%) 14 (15%) 0.76
CTC = circulating tumor cell
Figure 2a Disease-free survival (DFS) stratified 
by CTC presence (≥1 CTC). Median DFS was 13.5 
months (95% CI 5,9-21,1) when CTCs were pres-
ent and 14 months (95% CI 8,8-19,4) when CTCs 
were not present. There is no significant difference 
when the groups are compared (P=0.56).
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Subgroup analyses
A subgroup analysis was performed for the CTC count between patients who did (n=80) 
and did not (n=93) receive preoperative chemotherapy. Patients in the preoperative che-
Figure 2b Disease-free survival (DFS) stratified by 
high CTC count (≥3 CTC). Median DFS was 10.4 
months (95% CI 2,5-18,4) when ≥3 CTCs were pres-
ent and 14.5 months (95% CI 7,8-21,3) when there 
were less than 3 CTCs. There is no significant dif-
ference when the groups are compared (P=0.34).
Figure 3a Overall survival (OS) stratified by CTC 
presence (≥1 CTC). There is no significant differ-
ence in CTC presence in relation to overall survival 
(P=0.96)
Figure 3b Overall survival stratified by high CTC 
count (≥3 CTC). There is no significant difference 
in high CTC count in relation to overall survival 
(P=0.17)
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motherapy group, received a median number of four cycles chemotherapy (range, 2-12). 
The median time interval between the last dose of chemotherapy and the operation was 
8.6 weeks (range, 2.7-38 weeks). The results concerning the CTC count are shown in Table 
3. The median CTC count was lower in patients who received chemotherapy (p=0.05) 
(Figure 4). In 36% of the patients who received preoperative chemotherapy CTCs were 
detected (≥1CTC), compared to 50% of patients who did not receive chemotherapy, this 
difference was not statistically significant (p=0.08). The percentage of patients with a 
high (≥3) or low (<3) CTC count also showed no difference between the groups (p=0.22). 
The 1-year recurrence rate for patient who received preoperative chemotherapy was 
not significantly different between patients with or without CTCs present (48% vs. 53%, 
p=0.69). There was no association between CTC count and the time interval from the 
last dose of chemotherapy until the operation (for each week increase in time interval 
between the last dose of chemotherapy and the operation, the CTC count increases by 
0.067 CTCs (95% CI: -0.008, 0.142; p= 0.08). For patients who did not receive preoperative 
chemotherapy the 1-year recurrence was similar between the group with and without 
CTCs (46% vs. 43%, p=0.76) 
table 3: Results CTC enumeration divided by preoperative chemotherapy  
total inclusion n=173
variable with preoperative 
chemotherapy
(n=80)
without preoperative 
chemotherapy
(n=93)
P-value
CtCs
Number  (median (range)) 0 (0-13) 1 (0-49) 0.05
CTCs present 29 (36%) 46 (50%) 0.08
CTCs ≥3 10 (13%) 18 (19%) 0.22
CTC = circulating tumor cell
Figure 4 CTC counts in patients who received pre-
operative chemotherapy (n=93) and patients who 
did not (n=80), depicted are the medians with the 
interquartile range.
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DiSCuSSion 
This study does not demonstrate a prognostic value for CTC enumeration in patients 
with isolated CLM undergoing a partial liver metastasectomy with a curative intent. 
The power analysis conducted prior to our study indicated that 200 patients had to be 
included to show a 20% difference in the relapse rate at 1 year between patients with vs 
those without CTCs. Of the 343 patient samples, 170 cases had to be excluded for several 
reasons including extra-hepatic disease or residual disease after surgery. We excluded 
these patients as we expected their remnant tumor tissue to influence the course of 
disease. Nevertheless, despite this slightly reduced power, the DFS curves clearly show 
no differences in outcome between patients with vs those without detectable CTCs. We 
therefore feel that further studies using the same technique and similar study design 
and setting are not justified as futility has been adequately demonstrated.
The lack of prognostic value of CTC counts in this patient group with limited meta-
static disease is in contrast to findings in patients with advanced CRC. In these studies 
where the same CTC enumeration technique was used, a CTC count of ≥3 per 7.5ml 
of blood was associated with a worse progression-free and OS among patients with 
advanced CRC treated with first-, second- or third-line chemotherapy14,23. Importantly, 
instead of drawing and analyzing 7.5ml of blood as was done in these previous studies, 
we drew 30ml of blood and then reduced this to a volume of 7.5ml of enriched blood 
by density-gradient separation. We choose this approach as we expected CTC counts to 
be lower in our patient group with limited metastatic tumor load. The potential benefit 
of this method was shown in a pilot study among 15 patients, in which more CTCs were 
detected using 30ml instead of 7.5ml blood (median paired difference 1 (range, −1 to 
7))20. As a consequence, when we compare our CTC counts to other studies detecting 
colorectal CTCs using CellSearch in 7,5ml of blood, the difference in blood volume 
should be taken into account. Despite the higher blood volumes in our study, both the 
number of patients with CTCs present (≥1 CTC) and the number with a high CTC count 
(≥3) is clearly lower in our study population compared to other studies in patients with 
metastatic CRC. In our study CTCs were present in 43% of the patients and 16% had ≥3 
CTCs, in the study of Tol et al. 29% of the patients had ≥3CTCs, Cohen et al. reported 31% 
≥3CTCs and Hiraiwa et al. 41.4% ≥2 CTCs14,16,24. This difference is likely due to the fact that 
our study patients have relatively limited metastatic disease, as they had to be eligible 
for liver surgery with curative intent. This is in stark contrast with the aforementioned 
other studies which included patients treated up to third-line chemotherapy and who 
are therefore likely to have more extended disease. It has been demonstrated that more 
advanced disease is associated with larger amounts of CTCs24. Hiraiwa et al. found a sig-
nificantly higher percentage of patients with ≥2 CTCs among patients with metastases 
confined to the peritoneum compared to patients with metastases to the liver and lung 
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(64 % vs. 26%, p<0.01). Similar results have recently been published by Kaifi et al.; in 
their case series 60% of patients with diffuse metastases had CTCs present, in contrast to 
patients with metastases confined to the lung and the liver (11% and 32% respectively 
(p< 0.01))25. 
Numerous articles report on the impact of chemotherapy on CTCs, and in the vast ma-
jority of patients undergoing chemotherapy, CTC numbers decline during treatment14,26. 
To exclude the possibility of the impact of neo-adjuvant chemotherapy obscuring the 
prognostic value of CTCs in this setting, associations were explored in only the patients 
receiving neo-adjuvant chemotherapy as well as those who were untreated before liver 
metastasectomy. But also in these separate groups, CTC counts had no prognostic value. 
Only recently Seeberg et al. published an article were also the CellSearch was used as 
a method to detect CTCs (in 7.5ml blood) in patients with isolated CLM. The recurrence 
rate was similar to our study group. They reported that CTCs can predict nonresectability 
and impaired survival. CTC positivity was significantly higher in nonresectable (46%) 
than in resectable patients (11.7%), p<0.01. Contrary to our findings, patients who 
underwent resection and with two or more CTCs experienced reduced time to relapse 
or disease progression (p<0.01). As we used 30ml blood, had a different, predefined 
primary end point and used other cutoff values the studies are not fully comparable. A 
major difference between the studies is that they also included patients who were not 
eligible for resection. It is also not clear if the patients who underwent liver surgery had 
extrahepatic disease. Therefore, our group is more homogeneous27.  
Three studies have looked in this population (resectable CLM) using other CTCs enu-
meration tests based on RT-PCR assays. Vlems et al. and Topal et al. could not predict dis-
ease recurrence in patients with resectable CLM using their CTC detection methods28,29. 
A third study by Koch et al. did show that intra-operatively detected CTCs were of 
prognostic value30. It should be noted that these studies concerned only small numbers 
of patients and that the prognostic value found in latter study is yet to be confirmed. In 
general, the nature of RT-PCR based CTC detection assays confers to a higher sensitivity 
compared to the CellSearch technique, due to the fact that the CellSearch System uses 
very stringent criteria by which a CTC is defined. In this way, small tumor fragments, 
apoptotic CTCs or CTCs with low expression of one of the detection markers are not 
counted as CTCs. This idea is supported by our previous findings in which tumor DNA 
and RNA could be detected using RT-PCR, whereas using the CellSearch technique in the 
same blood samples, no CTCs could be detected31. Especially in patients with low tumor 
load, more sensitive CTC detection methods such as RT-PCR based methods should 
be explored for their value as prognostic marker, while remaining aware of concerns 
about test specificity. In addition to RT-PCR based methods, various other techniques to 
enumerate CTCs have recently been described. In contrast to the CellSearch technique, 
which amongst others relies on EpCAM and CK 8/18/19 expression on CTCs to be identi-
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fied, other methods use size-based enrichment methods and/or other antibodies to 
detect CTCs. This may lead to a higher sensitivity to detect CTCs in CRC patients. Also 
these techniques should be explored for their value in this patient setting.
In our study we have used 30ml blood which was reduced to 7.5ml for the CellSearch 
analyses. With the idea that CTC detection is more frequent when sample volume is 
larger. This is shown when we compare the data on CTC presence between Seeberg et al. 
and ours (19,6% vs. 43%). Coumans et al. investigated different methods to increase the 
detection of CTCs and undescribed our method. They state that by statistical analysis 
of the distribution in 7.5ml of blood detected by CellSearch in patients with metastatic 
cancer the sample size should be 5 l of blood for the detection of CTCs32.  Knowing that 
there are organ systems which have the ability to filter CTCs it is also the question if 
peripheral blood sampling alone is sufficient33.      
In conclusion, in this relatively large study no prognostic value for CTC counts as 
determined by the CellSearch technique could be found for outcome following liver 
metastasectomy in patients with resectable isolated CLM. The relatively high relapse 
rate in this group of patients with more than 50% of the patients relapsing within 1 
year again underlines the high need for novel biomarkers to guide treatment in patient 
category.
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Summary of the thesis 
Colorectal cancer (CRC) is one of the most common forms of cancer with annually, 1.36 
million new patients and 694 000 deaths1. The liver is the most common organ affected 
by metastatic disease. Disease staging is performed by the TNM classification system 
and therapeutic strategies are based on this system2. Following international guidelines, 
patients with stage II CRC are not offered adjuvant chemotherapy after surgical resection 
of the primary tumor, while 25-30% of the patients will develop distant metastases3. For 
stage III CRC patients adjuvant chemotherapy is part of the standard care. Unfortunately, 
only a small portion (5-15%) of these patients will benefit from this therapy which is 
accompanied by toxic side effects4. The existing tools for identification of individual 
patients with high risk for disease recurrence are not sufficient, therefore regular follow-
up visits plus blood analyses and liver imaging are necessary5,6. Although this follow-up 
regimen is expensive and time consuming it may be of value if curative treatment can 
be offered when liver metastases are discovered in an early stage. 
Due to improvements in surgical techniques, additional treatment modalities and 
more effective systemic chemotherapy more patients are eligible for curative liver re-
section7-13. Unfortunately, the 1-year recurrence rate after liver resection is up to 50%14. 
When these patients could be identified at forehand, they could be spared an operation 
or treated with systemic chemotherapy to prevent extension of metastatic disease.
This thesis discusses clinical and biomarker approaches to determine the outcome of 
patients with colorectal cancer and patients with colorectal liver metastases.
Currently, information on the course of CRC disease depends on the TNM classifica-
tion, subtracted from the pathology report2. In addition, 5 parameters are reported, 
including pT-stage, tumor differentiation grade, lymphovascular invasion (LVI), tumor 
perforation and lymph node metastasis status. These characteristics are being used to 
identify high risk stage II patients. In this high risk population adjuvant chemotherapy 
may be considered3. However, it’s pivotal to adequately report on these parameters if 
subsequent treatment may depend on the outcome of the staging. in chapter 2, 356 
pathology reports of stage II patients included in the MATCH study cohort are reviewed 
studying the completeness of the description of these 5 factors. In 69.1% of the reports, 
1 or more factors were not described adequately. T- stage and N-stage were reported in 
all cases. Nevertheless, in the 44 Nx patients, the amount of lymph nodes being below 
10, was not mentioned being a risk factor and in 2% of the records tumor differentiation 
was not reported. The presence or absence of LVI was not mentioned in 62.8% of the 
cases. After 2012 the reporting of LVI became mandatory and was reported significantly 
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more (33.5% vs. 87.5%; p < 0.001). Median follow-up of the cohort was 72.4 months (IQR 
62.8-80.8). The 1-, 3- and 5-years survival was 98%, 89.1%, and 80.4% respectively. When 
examining high-risk factors more closely in our cohort of stage II patients we found that 
these risk factors did not seem to have a significant impact on survival. Also, we did 
not find a significant association between the failure to report any of the five factors 
and overall survival. In multivariable analysis, age, moderately- and well differentiated 
tumors were significantly associated with overall survival.
We can conclude that more accurate pathology reports are needed to describe the 
five high-risk factors in stage II colon cancer in order to enable proper patient selection 
for additional treatment. 
in chapter 3, we studied the quality of the collected fresh frozen (colon)tumor sam-
ples within the MATCH study. We randomly selected 10 tissue samples per participating 
hospital, excluding samples of patients who underwent neoadjuvant chemo- and/or 
radiotherapy. The RNA integrity number (RIN) of 70 samples was determined to evalu-
ate the quality (range, 1(low quality) to 10(high quality))15,16. The median RIN value of 
all samples was 7.3 (range, 2.9 to 9.0). A RIN value ≥ 6, which is the cut off value for 
good quality, was present in 91% of the samples. The median RIN value of the university 
hospital (a center with large experience in tissue storage) was 7.7. The RIN value of the 
non-university teaching hospitals ranged from 6.5 to 7.8. The overall median RIN of the 
non-university teaching hospitals did not differ significantly from the median RIN of the 
university hospital (p= 0.39). These data show that the collection of high quality fresh 
frozen samples of CRC is feasible in a multicenter design.
Follow-up of patients after resection of the primary colorectal tumor is indicated to detect 
metastases in an early stage, enabling optimal treatment. However, follow-up programs 
are expensive and time consuming for patients as well as hospitals. The availability of a 
biomarker that would allow an out-of-hospital control of the course of the disease would 
offer a benefit to patients and health care organizations. In search for a marker enabling 
identification of early metastases, we explored the urine proteome of patients with 
colorectal liver metastases (CLM). In chapter 4, the urine sample preparation and urine 
sample analyses by mass spectrometry are described. The urine proteome of 24 patients 
with CLM was compared to that of 25 healthy persons (kidney donors). Seven peptides 
were discovered that could discriminate between the 2 populations with a sensitivity 
of 84.6% and a specificity of 92.3%. Additional analyses showed 2 peptides of the seven 
to be suitable for further research, AGP(-OH)GEAGKP(-OH)GEQGVP(-OH)GDLGAP(-OH)
GP and KGNSGEP(-OH)GAPGSKGDTGAKGEP(-OH)GPVG. These peptides combined had a 
sensitivity and specificity of 69.2% and 84.6% respectively, for discrimination between 
the two study groups. 
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CRC blood biomarker CEA (carcinoembryonic antigen) has a sensitivity of approximately 
64%17, therefore additional liver imaging is necessary. In an attempt to improve the de-
tection of CLM we combined the blood CEA test with the urine AGP biomarker (chapter 
5). We compared the CEA blood levels and AGP urine levels between 100 patients with 
CLM and 100 healthy kidney donors. A multivariate logistic regression model was build 
resulting in a combined sensitivity and specificity of CEA and AGP of respectively 85% 
and 84%. Further research is needed to evaluate this combined biomarker. Ultimately, 
a test may be constructed in which the urine AGP test and serum CEA test is combined 
successfully.
In case of early detection of liver metastases improvement of treatment modalities is an 
important issue to be addressed. The use of neoadjuvant chemotherapy and minimally 
invasive therapies for recurrence of CLM are increasingly incorporated in the surgical 
strategy, allowing proper patient selection, reducing collateral damage and saving 
remnant liver volume7-13.  In chapter 6 we compared two surgical approaches, anatomi-
cal (AR) versus non- anatomical liver resection (NAR). The study included 201 patients, 
113 patients (56.2%) received an AR and 88 patients (43.8%) received a NAR. Analyzing 
the data, we learned NARs were performed for significantly smaller metastases (3cm vs. 
4cm, p=<0.001), received significantly less blood transfusions (20% vs. 36%, p=0.012) 
and had a shorter hospital stay (7 vs. 8 days, p=<0.001) compared to AR. There was no 
significant difference in complications, the rate of positive surgical margins and recur-
rence rate. For the total study group estimated 5-year disease-free and OS was 31% and 
44%, respectively, with no difference between the groups. These results underline NAR 
to be a save procedure to treat CLM and preserve liver parenchyma. 
Unfortunately, liver resection for CLM knows a high recurrence rate14. Identifying pa-
tients at high risk for disease recurrence, could spare them an operation and might be 
offered chemotherapy to prevent extension of disseminated disease. To address this 
problem, we investigated whether the enumeration of circulating tumor cells (CTCs) 
could identify patients developing disease recurrence within 1 year after liver metasta-
sectomy. The Cell Search Technique is the only method approved by the US Food and 
Drug Administration. The standard blood sampling volume is 7.5 ml18. Several studies 
concluded that the amount of CTCs retrieved by the Cell Search system in limited CRC 
disease is very low18-22. Therefore, we conducted a pilot study (chapter 7) comparing the 
number of CTCs detected in 7,5 ml peripheral blood to 30 mL peripheral blood prepared 
by a modified Ficoll density gradient enrichment step in 15 patients. In 7,5 ml blood 
the median number of CTCs was 1 (range 0 to 4). In 30 ml blood, the median number of 
CTCs was significantly higher (median 2; range, 0 to 9; p=0.03). Analyzing 7,5 ml blood, 
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≥ 1 CTC was found in 10 patients (67%) and ≥3 CTCs were found in 2 patients (13%). In 
30 ml ≥ 1 CTC and ≥3 CTCs were detected in 13 (87%) and 7 (47%) patients, respectively. 
This sample preparation method was used in combination with the Cell Search System 
in a large study, including 151 patients with CLM, undergoing liver resection (chapter 
8). One hundred and seventy- three samples were analyzed. In 75 samples (43%) CTCs 
were detected, 16% had ≥ 3 CTCs/7,5 ml blood. Eighty-two patients experienced disease 
recurrence. The 1-year recurrence rate between patients with or without detectable 
CTCs was similar (47% vs. 48%), the presence of a low or high CTC count (<3 or ≥ 3 
CTCs/7,5 ml) (50% vs. 47%) made no difference. Disease-free and overall survival were 
similar between patients with or without CTCs. From this study we concluded, that the 
presence of CTCs in peripheral blood samples does not identify patients at risk for early 
disease recurrence after curative liver resection for CLM. 
In conclusion, the studies presented in this thesis, were conducted with the intention 
to improve identification of patients at high risk for disease recurrence after colorectal 
tumor resection as well as after colorectal liver metastases. 
On a clinical level, we can state that the completeness of pathology reports can be im-
proved to identify high risk stage II patients. It’s an essential step in optimizing patient’s 
prognosis and inclusion for adjuvant chemotherapy. 
In addition to the classical pathology report, molecular analysis of CRC may help to 
identify high risk patient groups. Large cohorts will be needed to unravel the molecular 
subtypes playing a role in tumor progression. We demonstrated the feasibility of us-
ing fresh frozen samples from a multicenter cohort study to allow molecular research, 
including DNA, RNA and proteomic assays.
To date, research on biomarkers identifying patients with progressive disease is mak-
ing great steps forward. Focus on urine and blood analysis may reveal new biomarkers 
within the near future, but large numbers of patients will be needed to allow proper 
discovery and validation research. With the introduction of the Dutch platform for CRC 
this research can be facilitated allowing more successful diagnostics and treatment of 
patients with colorectal cancer. 
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neDerLanDSe SaMenvatting 
Darmkanker is een van de meest voorkomende vormen van kanker. Jaarlijks worden we-
reldwijd 1.36 miljoen mensen gediagnosticeerd met darmkanker en overlijden 694.000 
mensen aan de gevolgen van deze ziekte1. Afstandsmetastasen zijn de belangrijkste 
oorzaak en komen het meest voor in de lever. Voor de bepaling van het ziektestadium 
wordt gebruik gemaakt van het TNM (tumor, lymfklier, metastase) systeem2. Het ziekte-
stadium wordt mede gebruikt om een indruk te krijgen over de prognose en de juiste 
behandelingsstrategie te bepalen. Volgens (inter)nationale richtlijnen worden patiën-
ten met stadium II ziekte (darmkanker zonder lymfkliermetastasen) niet aanvullend 
behandeld met chemotherapie. Toch weten we dat 25-30% van deze groep patiënten 
te maken zal krijgen met metastasen3. Patiënten met stadium III ziekte (darmkanker met 
lymfkliermetastasen) worden wel behandeld met aanvullende chemotherapie. Helaas 
heeft maar een klein gedeelte van deze groep (5-15%) baat bij deze therapie. Jammer 
genoeg krijgt wel de hele groep te maken met de toxische bijwerkingen van deze the-
rapie4. Vooralsnog kunnen we patiënten met een hoog risico op ziekte recidief niet op 
een goede manier identificeren. De enige mogelijkheid die geboden kan worden is een 
regelmatige controle volgens een standaard schema middels bloed- en beeldvormend 
onderzoek van de lever5,6. Deze follow-up is duur en belastend voor patiënten, maar 
waardevol omdat (lever)metastasen in een vroeg stadium ontdekt kunnen worden en 
een curatieve behandeling kan worden aangeboden.
Door verbeteringen in chirurgische technieken, aanvullende modaliteiten, zoals abla-
tie en bestraling, en effectievere vormen van chemotherapie komen meer patiënten in 
aanmerking voor een curatieve leverresectie7-13. Helaas ligt met 50% het 1-jaars recidief 
percentage erg hoog14. Daarom is het belangrijk testen te ontwikkelen die kunnen 
bepalen welke patiënten een hoog risico op ziekte recidief hebben. Bovendien zouden 
we geïnformeerd moeten zijn over de kans op een goede reactie bij behandeling, hetzij 
door operatie, door chemotherapie of een combinatie van behandelingen. 
In dit proefschrift worden onderzoeken gepresenteerd naar klinische factoren en 
biomarkers die de ziekte uitkomsten van individuele patiënten met darmkanker en 
levermetastasen beter kunnen voorspellen.  
Momenteel wordt het TNM-systeem gebruikt om het ziektebeloop van patiënten te 
voorspellen2. De informatie die nodig is voor het vaststellen van het ziektestadium 
wordt verkregen uit het pathologieverslag. In deze verslagen worden 5 factoren vermeld 
(tumor stadium, tumor differentiatie, lymphovasculaire invasie (LVI), tumorperforatie en 
lymfklier metastase) die patiënten met stadium II ziekte en een hoog risico op ziekte 
recidief kunnen identificeren. In deze groep zou chemotherapie overwogen kunnen 
worden3. Het is dus van groot belang dat deze factoren op een juiste manier worden 
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beschreven in de pathologie verslagen, aangezien dit van belang kan zijn voor de 
therapie keuze. In hoofdstuk 2 hebben we 356 pathologie verslagen beoordeeld van 
patiënten met ziektestadium II die deelnamen aan de MATCH-studie. In de verslagen 
hebben we bestudeerd of de 5 factoren op juiste wijze werden beschreven. In 69,1% 
van de verslagen ontbrak een adequate beschrijving van 1 of meer van de factoren. 
Tumorstadium werd in alle verslagen juist beschreven; in 44 verslagen werd door ons 
vastgesteld dat het aantal onderzochte lymfklieren kleiner was dan 10, een aantal dat is 
gedefinieerd als betrouwbare grens om de lymfklierstatus te benoemen, maar dit was 
niet expliciet in het oorspronkelijke verslag vermeld. In 2% van de verslagen werd de tu-
mordifferentiatie niet beschreven. Over de aan- of afwezigheid van LVI werd in 62,8% niet 
gerapporteerd. Vanaf 2012 werd de beschrijving van LVI verplicht gesteld en wij stelden 
vast dat sinds dat moment de LVI-status ook significant vaker beschreven werd (33,5% 
versus 87,5%; p<0,001). De mediane follow-up van het bestudeerde cohort was 72,4 
maanden (interkwartielafstand 62,8 - 80,8 maanden) met een 1-, 3- en 5-jaarsoverleving 
van respectievelijk 98%, 89,1% en 80,4%. Wanneer de hoog risico factoren nader werden 
bekeken, vonden we geen associatie tussen de overleving en het niet beschrijven van 
1 van de factoren. Uit de multivariaat analyse bleek dat leeftijd, goede - en matige dif-
ferentiatie invloed hadden op de overleving. Deze resultaten geven aan dat de 5 hoog 
risico factoren beter beschreven moeten worden in de pathologieverslagen zodat er 
een optimale patiënten selectie gemaakt kan worden voor verdere behandeling. 
In hoofdstuk 3 hebben we de weefselkwaliteit getest van ingevroren tumorsamples die 
zijn verzameld in het kader van de MATCH-studie. Per deelnemend ziekenhuis werden 
willekeurig 10 tumorsamples geselecteerd. Weefsels werden geëxcludeerd indien ze 
blootgesteld waren aan neoadjuvante chemo- en/of radiotherapie. Om de kwaliteit 
te beoordelen werd van 70 weefselsamples het RNA-integriteit nummer (RIN) bepaald 
(schaal 1(lage kwaliteit) tot 10 (hoge kwaliteit)15,16. De mediane RIN van alle weefsel-
samples was 7,3 (uitersten 2,9 -9,0). In 91% van de weefselsamples was de RIN-waarde ≥
 6, een waarde die wordt gebruikt als ondergrens voor een goede kwaliteit. De mediane 
RIN van het universitaire ziekenhuis (een centrum met grote expertise in weefsel opslag) 
was 7,7. De mediane RIN-waarde van de niet-universitaire ziekenhuizen lag tussen de 
6,5 en 7,8. De mediane RIN van alle niet-universitaire ziekenhuis tezamen was 7,3, en 
deze waarde verschilde niet van de mediane RIN-waarde van het universitaire zieken-
huis (p= 0.39). Deze resultaten tonen aan dat binnen een multicentrische studie, waarin 
ook ziekenhuizen participeren waar geen traditie bestaat in weefselopslag, weefsels 
verzameld kunnen worden met een hoge kwaliteit. 
Follow-up van patiënten na resectie van de primaire darmtumor is geïndiceerd om 
afstandsmetastasen in een vroeg stadium op te kunnen sporen zodat een optimale 
behandeling kan worden geboden. Deze follow-up programma’s zijn duur en belastend 
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voor zowel ziekenhuizen als voor de patiënt. Beide groepen zouden baat hebben bij 
biomarkers die ziekte recidief op eenvoudige en betrouwbare wijze zouden kunnen 
detecteren, bij voorkeur in een setting buiten het ziekenhuis. In een zoektocht naar een 
biomarker die levermetastasen (LM) in een vroeg stadium zou kunnen aantonen hebben 
we onderzoek gedaan naar eiwitten in de urine van patiënten met LM. In hoofdstuk 4 
worden de urine preparatie en de massa spectrometrie analyse beschreven van derge-
lijke monsters. We hebben het urine eiwitspectrum van 24 patiënten met LM vergeleken 
met dat van 25 gezonde personen (nierdonoren). Er werden 7 peptiden gevonden die 
de twee groepen van elkaar konden onderscheiden met een sensitiviteit van 84,6% 
en een specificiteit van 92,3%. Aanvullende analyses toonden dat 2 van de 7 peptiden 
geschikt waren voor verder onderzoek, AGP(-OH)GEAGKP(-OH)GEQGVP(-OH)GDLGAP(-
OH)GP and KGNSGEP(-OH)GAPGSKGDTGAKGEP(-OH)GPVG. Samen hebben deze twee 
peptiden een sensitiviteit en specificiteit van respectievelijk 69,2% en 84,6% voor het 
onderscheiden van de twee groepen. 
Darmkanker tumormarker CEA (carcinoembryonic antigen) heeft een sensitiviteit 
van circa 64%17, daarom is het noodzakelijk om naast bloedonderzoek ook afbeel-
dend onderzoek van de lever te verrichten. In een poging om de detectie van LM te 
verbeteren hebben we de bloedtumormarker CEA gecombineerd met de urinemarker 
AGP (hoofdstuk 5). We hebben de CEA-waarde en de AGP-waarde vergeleken van 100 
patiënten met LM met die van 100 nierdonoren. Voor de analyse werd een multivariaat 
logistisch regressie model opgesteld, wat resulteerde in een gecombineerde sensitivi-
teit en specificiteit van CEA en AGP van 85% en 84%. Verder onderzoek is noodzakelijk 
om deze gecombineerde biomaker te evalueren. Het ultieme doel is een combinatietest 
te ontwikkelen, die buiten het ziekenhuis toegepast kan worden. 
Vroege detectie van LM is van groot belang, maar daarnaast is onderzoek naar de 
verbetering van behandelmethoden ook een belangrijk onderwerp. Het gebruik van 
neoadjuvante chemotherapie en minimaal invasieve technieken voor de behandeling 
van recidief LM worden steeds meer geïncorporeerd in de chirurgische behandelstrate-
gie, waardoor er een betere patiënten selectie kan worden gemaakt, minder additionele 
weefselschade wordt aangericht en het volume resterend leverweefsel vergroot kan 
worden7-13. In hoofdstuk 6 hebben we twee chirurgische resectietechnieken met elkaar 
vergeleken, de anatomische leverresectie (AR) met de niet-anatomische leverresectie 
(NAR). In de studie werden 201 patiënten geïncludeerd, 113 (56,2%) patiënten onder-
gingen een AR en 88 (43,8%) patiënten een NAR. De resultaten toonde dat een NAR 
werd uitgevoerd bij significant kleinere metastasen (3cm versus 4cm, p=0,001), deze pa-
tiënten significant minder bloedtransfusies ontvingen (20% versus 36%, p=0,012) en de 
ziekenhuisopname significant korter was (7 versus 8 dagen, p=0,001) in vergelijking met 
een AR. Er was geen significant verschil in complicaties, ook het percentage positieve 
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resectiemarges en het recidiefpercentage was niet verschillend. De 5-jaarsziektevrije 
en algehele overleving voor de totale studiepopulatie was 31% en 44%, er was geen 
verschil tussen de 2 studiegroepen. Wanneer we naar deze resultaten kijken, kunnen 
we stellen dat een NAR een veilige procedure is voor de behandeling van LM waarmee 
leverweefsel kan worden behouden.
Helaas kent de chirurgische resectie van LM een hoog recidiefpercentage14. Wanneer we 
deze patiënten met een grote kans op recidief op voorhand zouden kunnen identifice-
ren, zouden we deze patiënten een operatie kunnen besparen en eventueel met syste-
mische chemotherapie kunnen behandelen. In een poging patiënten met ziekte recidief 
binnen 1 jaar na operatie te identificeren, hebben we onderzocht of de aanwezigheid 
van circulerende tumorcellen (CTCs) hierbij kon helpen. De Cell Search techniek is een 
methode die goedgekeurd is in Amerika door de FDA (food and drug administration). Bij 
deze techniek wordt 7,5ml bloed geanalyseerd. Meerdere studies hebben gerapporteerd 
dat het aantal CTCs in patiënten met beperkte ziekte (alleen aanwezigheid van de darm-
tumor en/of metastasen in de lever) erg laag is wanneer het Cell Search systeem wordt 
gebruikt18-22. Daarom hebben we een pilotstudie uitgevoerd (hoofdstuk 7) waarin we 
van 15 patiënten het aantal CTCs in 7,5ml perifeer bloed hebben vergeleken met 30ml 
perifeer bloed wat voorbewerkt is met een Ficoll dichtheidsgradiënt verrijkingsstap. In 
7,5ml bloed was het mediane aantal CTCs 1 (uitersten 0 tot 4). In 30ml bloed was het 
mediane aantal CTCs significant hoger (mediaan 2; uitersten 0 tot 9; p=0,03). Wanneer 
we naar de 7,5ml bloedsamples kijken, werden er  ≥ 1 CTC gevonden in 10 patiënten 
(67%) en ≥ 3 CTCs in 2 patiënten (13%). In 30 ml bloed werden ≥ 1 en ≥ 3 CTCs gevonden 
in respectievelijk 13 (87%) en 7 (47%) patiënten. Deze sample preparatie methode werd 
in een grote studie gebruikt, waarin 151 patiënten met LM werden geïncludeerd die 
een leverresectie ondergingen. In totaal werden 173 bloedsamples geanalyseerd. In 75 
samples (43%) werden CTCs gedetecteerd,16% bevatte ≥ 3 CTCs. Ziekte recidief werd 
geconstateerd in 82 patiënten. Het 1-jaars recidiefpercentage was gelijk voor patiënten 
mét en zonder detecteerbare CTCs (47% versus 48%), de aanwezigheid van een laag of 
hoog CTC aantal (<3 CTCs or ≥ 3 CTCs) maakte geen verschil (50% versus 47%). Tevens 
was er geen verschil te zien in ziektevrije en algehele overleving tussen patiënten mét 
en zonder CTCs. Kijkend naar deze resultaten kunnen we concluderen dat patiënten 
met een hoog risico op recidief ziekte na resectie van LM niet geïdentificeerd kunnen 
worden aan de hand van CTCs in perifeer bloed.
De studies beschreven in dit proefschrift hadden tot doel om de identificatie van patiën-
ten met een hoog risico op ziekte recidief zowel na resectie van de primaire darmtumor 
als na resectie van LM te verbeteren.
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Ten aanzien van de kliniek kunnen we stellen dat er ruimte is voor verbetering in de 
beschrijving van de pathologie verslagen, zodat hoog risico ziektestadium II patiënten 
beter geïdentificeerd kunnen worden aan de hand van klassieke criteria. Dit is een es-
sentiële stap in het schatten van de prognose van patiënten en voor de selectie van 
patiënten voor aanvullende therapie. Naast het klassieke TNM-systeem, zullen aanvul-
lende moleculaire analyse van darmtumoren nodig zijn om hoog risico patiënten op 
te sporen. Grote cohortstudies, zoals de MATCH-studie, zijn nodig om de verschillende 
moleculaire subtypes en hun rol in ziekteprogressie op te helderen. We hebben aange-
toond dat het mogelijk is om binnen deze grote cohortstudies een weefselbank aan te 
leggen met weefsels van goede kwaliteit die gebruikt kunnen worden voor moleculaire 
experimenten, waaronder DNA, RNA en proteomic analyses.
In de afgelopen tijd zijn er grote stappen gezet in het onderzoek naar biomarkers 
voor de identificatie van patiënten met ziekteprogressie. In de nabije toekomst kunnen 
urine, bloed- en weefselanalyses mogelijk nieuwe biomarkers aantonen. Het is echter 
essentieel dat naast discovery onderzoek validatie plaatsvindt in grote populaties om 
de waarde voor de klinische bruikbaarheid aan te tonen. Na het MATCH-project is er 
met de introductie van het Nederlandse platform voor darmkanker, een organisatie 
gerealiseerd die dergelijke studies kan faciliteren en die de diagnostiek en behandeling 
van patiënten met darmkanker kan verbeteren.   
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Colorectal cancer (CRC) is a heterogeneous and molecularly complex disease. Over the 
years, a clear need has emerged for markers that add clinically relevant prognostic and 
predictive information to the classic TNM (tumor, node, metastases) staging system to 
refine the individual patient outcome. 
This chapter addresses the problem of tumor heterogeneity, one of the major chal-
lenges in cancer research. We also highlight promising research tools and biomarkers 
and discuss new research strategies and the impact of CRC screening.  
tuMor heterogeneity
Tumor heterogeneity represents an ongoing challenge in the field of cancer therapy. 
Heterogeneity is evident among cancers from different patients (inter-tumor heteroge-
neity) and within a single tumor (intra-tumor heterogeneity). 
Inter-tumor heterogeneity is explained in part by differences in disease develop-
ment. The traditional adenoma–carcinoma sequence is believed to be responsible for 
~50–60% of CRCs. Other disease-development routes, such as the serrated pathway 
characterized by serrated adenomatous lesions that frequently display BRAF mutations1 
and colitis-associated CRC development with TP532,3, are thought to account for the 
other CRC portion. Understanding the various developmental routes of CRC is critical 
because the different pathways directly affect the clinical course of the disease.
A tumor is a heterogeneous population of cells, consisting of transformed cancer 
cells, supportive cells, and tumor-infiltrating cells. The nature of this heterogeneity is not 
limited to this malignant cancer cell population because a tumor is a complex system 
containing cancer cells and other types such as endothelial cells, stromal cells, and infil-
trating immune cells and a complex network of extracellular matrix that is accountable 
for variations in the tumor microenvironment4,5.
Two models have been suggested to explain intra-tumor heterogeneity. In the clonal 
evolution model, stochastic mutations in individual tumor cells act as a platform for 
adaptation and selection for the fittest clones of a tumor. This model explains hetero-
geneity within a tumor as a result of natural selection. The clones that obtain growth 
advantage will increase while the clones with less fitness will be outcompeted6-8. The 
second proposed model for explaining intra-tumor heterogeneity is the cancer stem cell 
(CSC) model, which suggests that only a subset of cancer cells has unlimited self-renewal 
ability to initiate and maintain tumor growth9. Therefore, tumors are structured in a 
hierarchical manner, comparable to the normal tissue hierarchy supported by healthy 
stem cells. It is important to realize that this hierarchy in tumor cells is not a one-way 
route but can be reversible or pliable so that the terminally differentiated cells can also 
dedifferentiate and regain CSC properties under specific conditions10,11. 
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next-generation SeQuenCing
Next-generation sequencing (NGS) technology emerged at the beginning of this 
century as an alternative to Sanger sequencing12. It allows massive parallel sequenc-
ing, reduces turnaround time for analysis, and requires a very low input of DNA/RNA, 
all of which are major advantages. This technology has multiple applications: whole-
genome sequencing covers the complete genome of a sample whereas whole-exome 
sequencing is restricted to the coding regions (i.e., all exons). Targeted sequencing uses 
target-enrichment methods to capture and/or amplify regions of interest. RNA sequenc-
ing facilitates the detection of alternative gene-spliced transcripts, posttranscriptional 
modifications, gene fusion, mutations/single nucleotide polymorphisms and changes 
in gene expression. The introduction of NGS technology in daily practice is hampered 
by use of multiple sequencing platforms, high-complexity workflow and results, and 
challenging bioinformatics analysis.
The CRC subtyping consortium used NGS data to investigate inter-tumor heterogene-
ity, identifying four molecular subtypes of CRC13. Data from six independent studies, 
including 4151 patients, were analyzed. These data were produced on different NGS 
platforms, and DNA was extracted from fresh-frozen samples as well as from formalin-
fixed paraffin embedded (FFPE) materials. Consensus molecular subtype (CMS) 1 was 
found in 14% of samples, showed hypermutations, and was microsatellite instable 
and associated with increased expression of genes linked to immune infiltrate. CMS2 
was present in 37% of samples and displayed epithelial differentiation, chromosomal 
instability, and activation of WNT and MYC signaling. CMS3 was discovered in 13% of 
samples and distinguished by epithelial differentiation and metabolic dysregulation. 
Finally, CMS4 was identified in 23% of samples and showed upregulation of genes 
involved in epithelial–mesenchymal transition, prominent transforming growth factor 
b activation, stromal invasion, and angiogenesis. Of the samples analyzed, 13% showed 
mixed features of the four CMS subtypes. The subtypes were also associated with clinical 
and prognostic factors; for instance, CMS1 was frequently diagnosed in women with 
right-sided lesions and high histopathological grade whereas CMS2 tumors were mainly 
left-sided, and CMS4 tumors tended to be diagnosed at a more advanced stage (III-IV). 
Concerning prognosis, CMS4 tumors displayed worse disease-free and overall survival. 
CMS1 patients had very poor survival after relapse, in contrast to CMS2 patients, who 
showed superior survival after relapse.
Furthermore, NGS enables the identification of biomarkers and targets for therapies, 
with more accuracy and specificity than traditional sequencing methods. Thus, NGS is 
a valuable instrument in the unraveling of CRC biology, improving research quality and 
care for CRC patients.
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ProMiSing bioMarkerS
the liquid biopsy
A potent approach for biomarker discovery is the liquid biopsy, a minimally invasive 
process based on a simple venipuncture that has multiple advantages: it is safe, 
implemented on a wide scale, and can be repeated easily. Moreover, through a liquid 
biopsy, the disease course can be monitored, and molecular changes in the tumor can 
be detected over time. Biomarkers that can be a subject of interest in a liquid biopsy 
can be protein-based, such as cancer antigens (carcinoembryonic antigens (CEA)); cell-
based, such as circulating tumor cells (CTCs) and disseminated tumor cells; or nucleic 
acid–based, such as circulating free DNA (cfDNA) and microRNAs (miRNAs).  
Circulating tumor cells
Primary tumors begin shedding neoplastic cells into the circulation at an early stage14,15, 
and approximately 106 cells are shed daily per gram of tumor16. CTCs constitute a hetero-
geneous population of cells with different biological characteristics and are often differ-
ent from the primary tumor. Because CTCs are usually present in very low frequencies in 
peripheral blood, tumor cell enrichment techniques are used before applying detection 
methods, including density gradient centrifugation (Ficoll-Hypaque separation) and 
immunomagnetic or size filtration procedures17,18. Different detection methodologies 
are in use, such as the more labor-intensive PCR techniques, the less time-consuming 
semi-automated CellSearch Technique (Veridex LLC, Raritan NJ, USA), membrane arrays, 
and weighted enzymatic chip array. The large majority of these techniques depend on 
monoclonal antibodies targeting epithelial cell adhesion molecule (EpCAM) for the 
isolation of CTCs. It has been reported that in tumor cells that have gained entry to 
the bloodstream, EpCAM expression is 10-fold less compared to primary and metastatic 
tissues19. This difference is due to the microenvironment and to EMT. During EMT, tumor 
cells lose their epithelial traits including cell–cell adhesion, apical–basal polarity, and 
lack of motility and acquire mesenchymal properties such as motility, invasiveness, 
and a resistance to apoptosis20. Therefore, alternative isolation methods are now being 
developed that avoid the use of antibody-based enrichment. In spite of different detec-
tion methods, CTCs have proved to be of prognostic and predictive value. Investigations 
by Uen et al. and Lu et al. demonstrated that the persistent presence of postoperative 
CTCs is a poor prognostic factor for patients with CRC after curative resection21,22. The 
CellSearch Technique has been approved by the US Food and Drug Administration to 
evaluate chemotherapy response by CTC counting in patients with metastatic CRC23. 
Likewise, the KRAS mutation status of CTCs can be used to predict therapy response in 
patients treated with cetuximab and FOLFOX4 or FOLFIRI24,25.  
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Circulating free tumor Dna (cfDna)
cfDNA may originate from normal or tumor tissue and be present in increased levels 
in noncancerous conditions such as inflammatory processes and infections26. DNA 
fragments can be passively released by necrotic and apoptotic cells, depending on the 
tumor load, growth kinetics, and the effect of antitumor treatment. It has also been 
reported that tumors actively release cfDNA that can transform cells at distant sites27. 
Finally, CTCs and micrometastases may also be a source of cfDNA. The short half-life 
of cfDNA (~2 hours) makes cfDNA a useful dynamic marker of tumor bulk28. Unfortu-
nately, because of a lack of standardized techniques and low concentrations of cfDNA, 
identification, amplification, and quantification are challenging. Moreover, selection of 
the proper mutation markers for cfDNA analysis is a difficult issue29. In spite of these 
obstacles, multiple studies have been conducted to investigate if cfDNA can be used as 
a biomarker in CRC.
The presence of minimally residual and invasive disease can be identified by cfDNA. In 
a study by Reinert et al.30, the quantification of plasma cfDNA had almost 100% sensitiv-
ity and specificity for the prediction of relapse after surgery, with a mean lead time of 10 
months. Tie et al.31 demonstrated that stage II colon cancer patients who were cfDNA-
positive postoperatively were at extremely high risk of recurrence (hazard ratio=18; 95% 
confidence interval, 7.9–40; p≤0.001). cfDNA has also been shown to be useful in the 
early detection of relapse after metastasectomy of liver metastases, significantly outper-
forming both CEA and imaging32. For the prediction33,34 and monitoring35,36 of therapy, as 
well as the detection of therapy resistance37-39, cfDNA is under investigation.
Micrornas (mirna)
miRNAs are a group of noncoding RNAs containing approximately 18–25 nucleotides 
that affect posttranslational gene expression and can be detected in serum, plasma, and 
tissue samples. Hundreds of genes in the human genome encode these RNAs 40-42, and 
an estimated ~30% of protein expression is controlled by miRNAs43,44. Numerous studies 
have revealed several important roles in many biological functions for miRNAs, includ-
ing in proliferation, differentiation, development, and metabolism. 
A large number of miRNAs have been described as correlated with CRC. For the most 
part, these miRNAs influence the main signaling pathways in CRC, such as the WNT45-49, 
EGFR50-55, TP5356-59, and transforming growth factor beta (TGF-b) pathways60-62. 
The detection of miRNA in plasma can enable early detection of CRC. miR-92a is 
reported to differentiate CRC and advanced adenomas from other colorectal-related 
disease63. Furthermore, stool could be a source of CRC-specific miRNA. Higher levels of 
miR-21 and miR-106a have been detected in feces of patients with CRC and advanced 
adenomas compared to healthy individuals64. miRNAs also can be of use for monitoring 
minimal residual disease and recurrence. Plasma levels of miR 17-3p and miR 92a are 
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raised in patients with CRC and decrease after surgical removal of the primary tumor63. 
Monitoring of treatment response by means of miRNAs has been investigated, and 
Let-7g and miR-181b expression levels are strongly associated with the drug chemore-
sponse on S-1,5-fluorouracil–based antimetabolite65.   
the CLiniCaL aPProaCh
Cohort studies and biobanking
Because of the increasing subclassification, availability, and need for validation of new 
promising biomarkers, and the new technologies and interventions for CRC, there is a 
need for novel clinical trial designs, methods for data acquisition, and patient recruit-
ment. Cohort multiple (cm) randomized controlled trials (RCTs) are an innovative 
alternative to the classic RCT, combining features of a prospective cohort study with the 
possibility of including patients from the cohort in multiple non-conflicting cohort stud-
ies66. The purposes of this design are to facilitate research, include more patients in RCTs, 
enable easy selection of subgroups, and generate results that can be extrapolated to the 
general population. Because of its small size, excellent infrastructure, and high-quality 
health care system, the Netherlands is a country that can excel in this study approach.  
The Dutch Colorectal Cancer Group has launched a cmRCT called the “prospective 
Dutch ColoRectal cancer cohort” [Dutch: “Prospectief Landelijk ColoRectaal kanker Co-
hort” (PLCRC)]. In this project, extensive observational clinical data are collected as well 
as patient-reported outcomes. For each included patient, fresh-frozen and FFPE samples 
from tumor and normal colon tissue are stored. Additionally, the collection of blood 
samples is also approved in this national initiative. With this research approach, we hope 
to improve treatment outcomes in CRC patients67.
CrC screening
Probably the most powerful instrument for improvement of CRC outcomes is the early 
detection of CRC and advanced adenomas. Multiple strategies are available for CRC 
screening, including fecal occult blood testing (with the use of guaiac-based or immu-
nochemical tests)68-73, alone or in combination with stool DNA examination 74, endos-
copy (flexible sigmoidoscopy or colonoscopy)75-77, radiologic examination (computed 
tomographic colonography)78, and testing for blood-based molecular markers, such 
as circulating methylated septin 9 gene DNA79. Multiple high-quality studies support a 
strategy of fecal occult blood testing every year or every 2 years, with colonoscopy used 
as a follow-up to a positive test to screen for CRC. Several RCTs have reported mortality 
reduction even up to 32% with a follow-up69-73.
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In 2014, a screening program for CRC was introduced in the Netherlands for persons 
ages 55 to 75 years. Biannually, immunohistochemical fecal occult blood testing (iFOBT) 
is performed, followed by a colonoscopy when the test is positive. With a hypothesized 
response rate of 60%, it is estimated that 1400 CRC deaths could be prevented80. In 2014, 
a total of 703,626 persons were invited; the response rate was 71.3%, and the test was 
positive in 40,842 cases (7.8%). In this group, colonoscopy identified 2483 individuals 
with CRC and 12,030 with advanced adenomas81. The detection and treatment of the 
advanced adenomas may result in a decrease in CRC incidence in the near future, and 
the identification of asymptomatic CRC patients with lower tumor stages is expected to 
improve disease-free and overall survival. 
the Future
Implementation of screening programs is of utmost importance and the most effec-
tive strategy to reduce CRC incidence and improve CRC survival rates. Once patients 
are diagnosed with CRC, they should be included in cmRCTs because more patients are 
eligible for participation in RCTs, which may offer enhanced survival. The availability of 
biomaterials in this study design facilitates biomarker research, discovery studies, and 
validation studies. These biomarkers can be identified in different levels of the cancer 
genome; as discussed above, CTCs, miRNAs, and cfDNA are promising biomarkers and 
should be investigated in more depth. NGS may help in this mission because it is more 
accurate, less labor intensive, and faster than other methods. Adding this information to 
the classical TNM staging system may help refine prognosis, guide treatment strategies 
for individual patients, and improve CRC outcomes.
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DankwoorD
Toen ik aan dit promotietraject begon had ik nooit voor mogelijk gehouden dat het zo’n 
interessante, verrassende, hobbelige en lange weg zou zijn, waarin ik heel veel nieuwe 
mensen heb leren kennen en waar ik met heel veel mensen heb samengewerkt, die 
allemaal op hun eigen wijze hebben bijgedragen aan dit proefschrift. 
Ik wil beginnen om de belangrijkste personen, de patiënten die hebben deelgenomen 
aan de verschillende studies, te bedanken. Doordat zij weefsels, bloed en urine hebben 
afgestaan hadden wij de mogelijkheid de studies beschreven in dit proefschrift uit te 
voeren. 
Lieve Oom Roy, patiënt van het eerste uur. Helaas heb jij de strijd tegen darmkanker 
verloren. Toch denk ik dat jij vanuit een andere plaats nog stiekem aan de touwtjes trekt. 
De subsidie aanvraag bij KWF die ik indiende op de dag van je crematie, waar jij niet om 
bloemen vroeg maar een donatie voor KWF, hebben we gekregen. Met het geld hebben 
we een grote landelijke studie kunnen opzetten. Dank je wel!
Prof.dr. J.N.M IJzermans, beste Jan, hartelijk dank dat jij mij als jonge arts in 2007 de kans 
hebt geboden om dit promotietraject in te stapen. Wat een avontuur is het geweest, 
begonnen met micro-arrays en nu aanbeland bij next generation sequencing. Maar 
daarnaast hebben we nu ook ruime kennis over databases, urines, nurse practitioners 
en weten we hoe we een internetstrijd moeten leveren om subsidie te krijgen! Bedankt 
voor je heldere analyses, goede adviezen, vertrouwen en de vrijheid die je me hebt 
gegeven de afgelopen jaren. Het was me een voorrecht…
Prof.dr. C. Verhoef, beste Kees, het is dan toch af! Eerst waren er de beenmergpuncties, 
toen het stuk over de leverresecties, later CTC’s en uiteindelijk ook mijn promotor. Dank 
voor je enthousiasme, hulp en luisterend oor de aflopen jaren. Het was me een eer en 
genoegen om met jou te werken.
John Martens, mijn co-promotor, wat een hoop last minute subsidie aanvragen hebben 
we toch samen in elkaar gezet. Ik ben blij dat jullie met het lab van de interne oncologie 
zo betrokken zijn geraakt bij de MATCH-studie. Lieve Anieta bedankt voor al je harde 
werk. John Foekens, wat heb jij toch een scherpe blik, het was fijn om met je samen te 
werken. 
De leescommissie, Prof.dr. S. Sleijfer, Prof.dr. H.W. de Wilt en Prof. dr. F.J. van Kemenade, 
dank voor het beoordelen van mijn proefschrift en de deelname aan de oppositie. 
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Prof.dr. S. Sleijfer, beste Stefan, CTC’s stonden in eerste instantie niet op de planning 
voor mijn promotieonderzoek, maar zijn gaandeweg toch een substantieel deel ervan 
geworden. Dank voor je kritische blik bij het schrijven van de artikelen.
Prof.dr. H.W. de Wilt, beste Hans, de eerste stappen van mijn onderzoekscarrière heb 
jij mogen meemaken. Ik weet nou niet meer wie beter was in het afnemen van de been-
mergpuncties, jij of Kees? 
Leden van de grote commissie, Prof.dr. L.P.S. Stassen, dr. E de Graaf en dr. T.M. Luider 
Prof.dr. L.P.S. Stassen, beste Laurents, als eerste MATCH-studie chirurg uit het RdGG 
hebben we heel wat contact gehad om de studie van de grond te krijgen. Dank daar-
voor, het loopt nog steeds als een trein!
Dr. E. de Graaf, beste Eelco, begonnen als co-assistent bij jullie in het YSL. Daarna heel 
veel uren samen op OK gestaan om alle coloncarcinoombiopten in te kunnen vriezen. Jij 
vertegenwoordigt de chirurgen, die voor de MATCH-studie zo belangrijk zijn geweest.
Dr. T.M. Luider, wat een hoop werk is er gaan zitten in de urinestudies. Ondanks alles 
ging je altijd met een positieve instelling verder, ook al zonk mij de moed af en toe in de 
schoenen. Theo fijn dat je deel wilt nemen aan de oppositie. Nick jij bent onvermoeibaar, 
nieuwsgierig en secuur. Zonder jou waren de analyses niet gelukt. 
Peter Riegman, jij was er vanaf het begin bij! Monique en Shazia bedankt voor de fijne 
samenwerking. Is er nog ruimte in de weefselbank??
Alle chirurgen, nurse practitioners en pathologen die zich hebben ingezet voor de inclu-
sie van patiënten en verzameling van klinische data en weefsels voor de MATCH-studie. 
Ik kan jullie niet genoeg bedanken.  
Lieve Conny en Carola jullie ondersteuning de afgelopen jaren was goud waard. 
Suzanne van Rossum en Maaike Kleistra superfijn dat jullie de MATCH-studie hebben 
ondersteund, tijdens mijn opleidingsperiode in het Erasmus MC.
Mijn mede onderzoekers en co-auteurs, Mirelle, wie had gedacht dat we zoveel over 
urines en peptides zouden kunnen leren en dat we zo dicht op elkaar zouden pro-
moveren. Ik wens je alle succes en geluk!  Stefan Büttner, super student! Succes met 
jouw promotie.  Anne van der Pool, Ninos Ayez, Bianca Mostert en Wendy Onstenk, dank!
Lieve Nienke, Tamara, Brechtje, Tessa, Sanne, Carlijn, Stephanie en Marjolein…. Meisjes 
van de Heelkunde, dan zijn we toch allemaal gepromoveerd. Ik hoop dat we nog heel 
veel gezellige momenten samen mogen delen met nu een hele schare lieve kinderen 
erbij. 
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Bedankt alle Z-flat bewoners en heelkunde onderzoekers met wie ik zoveel gezellige 
momenten heb gedeeld, Martin (mijn oudste onderzoeks- en skiciemaatje!), Joost, Olaf, 
Karel, An, Joël, Eelke, Shiromani, Kirstin, Jeff, Lucas, Niels, Max, Eva en Juliëtte.
Chirurgen en assistenten uit het Franciscus, bedankt voor alle hulp en steun de afgelo-
pen jaren.
Lieve MC, wat ben ik blij dat ik met jou mag samen werken. Ik hoop dat we nog lang 
lief en leed mogen delen. VIC, je wordt een geweldige moeder. Guy, Ralph, Sander, Eefje, 
Michiel jullie worden TOP-chirurgen.
Lieve Lindsay, mijn oudste en liefste vriendinnetje. We zien elkaar te weinig, maar ge-
lukkig is onze vriendschap daar niet van afhankelijk. Ik verheug me op je huwelijk en 
hopelijk snel een kleine Lindsay of Diederik….
Geertje wat een leuke studententijd hebben we gehad! Ik wens je heel veel succes 
met je “tweede” carrière, je wordt een geweldige huisarts.
Mijn Paranimfen: 
Lieve Pieter, wat heb ik gelachen met jou aan mijn zijde. Uit kamer Z-836 kwam altijd 
de beste muziek (ons nummertje van de dag). De BBQ’s met geweldige situatieschets, 
openstaande bruggen en ontploffende satésaus. En dan natuurlijk het cabaret, daar 
draaien wij onze hand niet voor om, groot of klein, maar mijn mooiste herinnering 
is toch wel dat ik jou mocht omtoveren tot Judeska. Verder natuurlijk de biertjes, de 
feestjes en de opleidingsborrel waarbij ik je plechtig beloofde, dat jij mijn paranimf zou 
zijn. Pieter heel veel geluk met Dee en de kids.
Lieve Robert, mijn opvolger, wat heb jij het goed gedaan. Promotiedatum geprikt, 
een van de trekkers van het landelijk cohort en dan ook nog mij tussendoor helpen. Het 
promotietraject gaat niet altijd over rozen, maar uiteindelijk is het ‘t waard. Je wordt vast 
een hele goede chirurg, maar eerst wordt je vader, geniet ervan!
Lieve familie dank voor jullie hulp, steun en interesse de afgelopen jaren, het was een 
lange weg, maar het is af. Radjnish, het MATCH-logo was een begrip in Rotterdam en 
omstreken.
Een speciaal woord van dank aan mijn schoonouders. Jullie zijn er altijd voor ons en 
we hebben met plezier (weer) bij jullie gewoond, maar ik beloof, dat we dit keer niet 
meer terugkomen;) Lieve Janice, heel fijn dat jij mijn schoonzusje bent, bedankt voor de 
leuke vakanties.
Lieve Rahiela, mijn kleine zusje…. Ik bewonder je moed en de manier hoe jij je eigen 
plan trekt. Succes met het afronden van je Master, jij komt er wel. Hopelijk hebben we 
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daarna meer tijd om samen (en met de kleintjes) leuke dingen te doen. Lieve Terence en 
Omari heel fijn dat jullie er zijn.
Lieve Mama, mijn grote steun en toeverlaat. Wat moet ik zonder jou. Dank je wel dat je 
altijd achter me hebt gestaan. Ik ben trots dat jij mijn lieve, actieve en onvermoeibare 
moeder bent. Lieve Pa, mijn interesse in de geneeskunde/chirurgie werd door jou 
gewekt. Vroeger keken we samen naar alle medische programma’s op TV. Maar ook sa-
men klussen gaat ons goed af. Geen klus schrikt ons af (lees Lindelaan 6)! Ik beloof dat 
we voorlopig niet zullen verhuizen. 
Lieve Ronny, wat kennen we elkaar al lang. Dank voor je hulp, adviezen, opbouwende 
kritiek en steun de afgelopen jaren. Eindelijk is die promotie af. Dan is het nu tijd om 
samen met onze grote/kleine liefde, Viyan, in ons nieuwe huis te gaan genieten. Ik hou 
van je.
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nonphysician clinicians in the follow up of resected patients with colorectal cancer. 
ZS Lalmahomed, RR Coebergh van den Braak, S Büttner, BE Hansen, JN IJzermans
(Accepted for publication Digestive Diseases)
a Systematic analysis of oncogenic gene Fusion in Primary Colon Cancer.
WP Kloosterman, RR Coebergh van den Braak, M Pieterse, MJ van Roosmalen, AM Sieu-
werts, C Stangl, R Brunekreef, ZS Lalmahomed, S Ooft, A van Galen, M Smid, A Lefebvre, 
F Zwartkruis, JW Martens, JA Foekens, K Biermann, MJ Koudijs, JNM Ijzermans, EE Voest.
Cancer Res 2017;77(14):3814-3822.
Completeness of pathology reports in Stage ii Colorectal Cancer. 
ZS Lalmahomed, S Buttner, RR Coebergh van den Braak, BE Hansen, PP Coene, JW Dekker, 
DD Zimmerman, GW Tetteroo, WJ Vles, WW Vrijland, RE Fleischeuer, AA van der Wurff, M 
Kliffen, R Torenbeek, JH Meijers, M Doukas, JN IJzermans.
Acta Chirurgica Belgica 2017;117(3):181-187
Colorectal tissue sampling in dedicated, non-university surgical programs:  “Does
the quality meet criteria for highly specific (bio)marker research. 
ZS Lalmahomed, RR Coebergh van den Braak, MH Oomen, SP Arshad, PH Riegman, JN 
IJzermans, on behalf of the MATCH study working group.
Cell Tissue Bank 2017 (in press) 
Molecular characteristics of circulating tumor cells resemble the liver metastasis 
more closely than the primary tumor in metastatic colorectal cancer. 
W Onstenk, AM Sieuwerts, B Mostert, ZS Lalmahomed, JB Bolt-de Vries, A van Galen, M 
Smid, J Kraan, M Van, V de Weerd, R Ramírez-Moreno, K Biermann, C Verhoef, DJ Grünha-
gen, JN IJzermans, JW Gratama, JW Martens, JA Foekens, S Sleijfer. 
Oncotarget 2016;7(37): 59058-59069
hydroxylated collagen peptide in urine improves the detection of colorectal liver 
metastases. 
ZS Lalmahomed, ME Broker, NA van Huizen, RR Coebergh van den Braak, LJ Dekker, D 
Rizopoulos, C Verhoef, EW Steyerberg, TM Luider, JN IJzermans. 
Am J Cancer Res 2016;6(2): 321-330
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mrna expression profiles in circulating tumor cells of metastatic colorectal cancer 
patients. 
B Mostert, AM Sieuwerts, J Bolt-de Vries, J Kraan, ZS Lalmahomed, A van Galen, P van der 
Spoel, V de Weerd, R Ramírez-Moreno, M Smid, C Verhoef, JN IJzermans, JW Gratama, S 
Sleijfer, JA Foekens, JW Martens. 
Mol Oncol. 2015;9(4):920-32.
Prognostic value of circulating tumor cells for early recurrence after resection of 
colorectal liver metastases. 
ZS Lalmahomed, B Mostert, W Onstenk, J Kraan, N Ayez, JW Gratama, DJ Grünhagen, C 
Verhoef, S Sleijfer. 
Br J Cancer. 2015;112(3):556-61
Collagen peptides in urine: a new promising biomarker for the detection of 
colorectal liver metastases. 
ZS Lalmahomed, ME Bröker, HP Roest, NA van Huizen, LJ Dekker , W Calame, C Verhoef, 
JN Ijzermans, TM Luider. 
PLoS One. 2013;8(8):e70918.
kraS and braF mutation status in circulating colorectal tumor cells and their cor-
relation with primary and metastastic tumor tissue. 
B Mostert, Y Jiang, A Sieuwerts, H Wang, J Bolt- de Vries, K Biermann, J Kraan, Z Lalma-
homed, A van Galen, V de Weerd, P van der Spoel, R Ramirez- Moreno, C Verhoef, J 
IJzermans, Y Wang, J Gratama, J Foekens, S Sleijfer, J Martens 
Int J Cancer. 2013;133(1):130-41. 
outcome of microscopic incomplete resection (r1) of colorectal liver metastases in 
the era of neoadjuvant chemotherapy. 
N Ayez, ZS Lalmahomed, AM Eggermont, JN IJzermans, J de Jonge, K van Montfort, C 
Verhoef
Ann. Surg Oncol 2012;19(5); 1618-27
is the clinical risk score for patients with colorectal liver metastases still useable in 
the era of effective neoadjuvant chemotherapy? 
N Ayez, ZS Lalmahomed, AE van der Pool, Y Vergouwe, K van Montfort, J de Jonge, AM 
Eggermont, JN IJzermans, C Verhoef
Ann Surg Oncol 2011;18(10): 2757-63  
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anatomical versus non-anatomical resection of colorectal liver metastases: is 
there a difference? 
ZS Lalmahomed, N Ayez, AE van der Pool, LF Dols, J Verheij, JN IJzermans, C Verhoef 
World J Surg 2011;35(3) 656-61
trends in treatment for synchronous colorectal liver metastases: Differences in 
outcome before and after 2000. 
AE van der Pool, ZS Lalmahomed, JH de Wilt, AM Eggermont, JN IJzermans, C Verhoef. 
J. Surg Oncol 2010;102(5):413-18
Circulating tumor cells and sample size: the more, the better. 
ZS Lalmahomed, J Kraan, JW Gratama, B Mostert, S Sleijfer, C Verhoef. 
J Clin Oncol 2010;28:288-89
optimizing the outcome of surgery in patients with rectal cancer and synchronous 
liver metastases. 
AE van der Pool, JH de Wilt, ZS Lalmahomed, AM Eggermont, JN IJzermans, C Verhoef. Br 
J Surg 2010;97(3):383-90
“Staged” liver resection in synchronous and metachronous colorectal hepatic 
metastases; differences in clinopathological features and outcome. 
AE van der Pool, ZS Lalmahomed, Y Ozbay, JH de Wilt, AM Eggermont, JN IJzermans, C 
Verhoef. 
Colorectal Dis 2010;12(10) e229-35
after-hours colorectal surgery: a risk factor for anastomotic leakage. 
N Komen, JW Dijk, ZS Lalmahomed, K Klop, W Hop, GJ Kleinrensink, H Jeekel, RW 
Schouten, JF Lange. 
Int J Colorectal Dis 2009;42(7):789-95
Local treatment for recurrent colorectal hepatic metastases after partial hepatec-
tomy. 
AE van der Pool, ZS Lalmahomed, JH de Wilt, AM Eggermont, JN IJzermans, C Verhoef. 
J Gastrointest Surg 2009;13(5):890-95.
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PhD PortFoLio
name PhD student:   Zarina Shehnaaz Lalmahomed
erasmus MC Department:  Surgery
PhD period:    January 2007- March 2017
Promotors:     Prof. dr. J.N.M. IJzermans
    Prof. dr. C. Verhoef
Year Workload 
(ECTS)
PhD trianing
general Courses
Classical methods for data analysis 2009 5.7
Good clinical practice 2009 1.0
English writing course 2009 0.3
Introduction to clinical research 2008 0.9
Biostatistics for clinicians 2008 1.0
in-depth courses
Course Biomedical Research Techniques 2009 1.0
Basic and Translational Oncology 2007 1.8
national conferences
Najaarsvergadering (2 oral presentations) 2009, 2014 2.0
Chirurgendagen (oral and poster presentation) 2007, 2014 2.0
SEOHS (oral presentation) 2010, 2013 2.0
international conferences
ESSR (oral presentation) 2010 2.0
ESMO (2 poster presentations) 2010,2013 2.0
other
Presentation/interview MLDS 2012 0.3
Presentation kick-off meeting CONNECTION 2014 0.5
teaChing aCtivitieS
Lecturing
MATCH-study introduction presentations 2007-2008 2.0
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Supervising practicals and excursions
Examination of Basic Life Support for medical students 
(coordinator instructors 2008/2009/2010)
2007-2013 2.0
Supervising Master’s theses
D. Koole en B. Zegers 2007-2008 2.0
K. Woltman 2008 2.0
M. Bröker en J. Bekken 2008-2009 2.0
D. van Zanten 2009 2.0
Y. Özbay 2009 2.0
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CurriCuLuM vitae 
Zarina Shehnaaz Lalmahomed werd geboren op 13 februari 1982 te ’s Gravenhage. Na 
het eindexamen Gymnasium, aan het Interconfessioneel Makeblijde College (IMC) te 
Rijswijk Z-H in 2000, startte zij met de opleiding Geneeskunde aan de Erasmus Univer-
siteit Rotterdam. De laatste fase van haar coschappen heeft zij voltooid op de afdeling 
Heelkunde van het IJssellandziekenhuis in Capelle aan de IJssel (opleider: Dr. I. Dawson). 
Voor haar keuze coschap is zij naar Suriname geweest en heeft gewerkt op de afdeling 
Heelkunde van het Diakonessen Ziekenhuis in Paramaribo (begeleider: drs. A. Bergen 
en drs. R. Does). In november 2006 behaalde zij haar artsenbul. In januari 2007 begon zij 
als arts-onderzoeker op de afdeling Heelkunde van het Erasmus MC onder de begelei-
ding van Prof. dr. J.N.M IJzermans en Prof. dr. C. Verhoef. Het onderzoek wat gedurende 
deze aanstelling heeft plaatsgevonden vormt de basis van dit proefschrift. Tijdens deze 
periode schreef zij meerdere subsidieaanvragen en deze werden gehonoreerd door 
Fonds NutsOhra, de Maag Lever Darm Stichting, Stichting Coolsingel, Erasmus MC 
Doelmatigheidsonderzoek en het Koningin Wilhelmina Fonds. In januari 2011 begon zij 
aan de opleiding tot chirurg in het Erasmus MC (opleider: Prof. dr. J.N.M. IJzermans/ Dr. 
B.P.L. Wijnhoven). In 2013 onderbrak zij de opleiding om de lopende studies waaraan zij 
begonnen was tijdens haar onderzoeksperiode af te ronden. In januari 2014 hervatte 
zij de opleiding in het Franciscus te Rotterdam (opleider: Dr. T.M.A.L. Klem). Zarina is 
getrouwd met Ronny Kalloe en samen hebben zij een prachtige zoon, Viyan. 
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